COVID-19, SARS-CoV-2
Conditions
Brief summary
The purpose of this study is to learn more about infection with and recovery from the virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Some people know this virus by the name coronavirus. It can cause the disease called COVID-19. The information gained from the study will be used to help develop better tests for SARS-CoV-2 infection and COVID-19 disease and may help in developing future vaccines and treatments by allowing researchers to determine the difference between the body's immune response to natural SARS-CoV-2 infection and immunization with a SARS-CoV-2 vaccine.
Detailed description
This study aims to characterize the SARS-CoV-2-specific immunity in convalescent individuals. The observational cohort study will include 3 groups, as described in the table below. Participants will complete a minimum of one visit (1-8 weeks post resolution of COVID-19 OR 2-10 weeks post most recent positive SARS-CoV-2 test, if asymptomatic) and optional visits approximately 2 months, 4 months, and 1 year later. Participants diagnosed with SARS-CoV-2 infection at an optional follow-up visit may be contacted more frequently. Additional follow up visit(s) may be added over time in response to evolving information regarding SARS-CoV-2 infection and COVID-19. Study visits may include physical examinations, medical history, questionnaires, pregnancy tests (for participants assigned female at birth), blood draws, optional nasal samples, and optional HIV testing.
Interventions
OTHERSample collection
* Optional nasal specimen(s) * Blood collection
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Prevention Trials Network
HIV Vaccine Trials Network
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 or older. * Reports having had a positive test for SARS-CoV-2. * Reports resolution of COVID-19 within 1-8 weeks of enrollment OR, if asymptomatic infection, reports positive SARS-CoV-2 test within 2-10 weeks of enrollment. Not excluded: individuals with symptoms consistent with residual sequelae of resolved COVID-19, in the clinical judgement of the investigator. * Access to a participating HVTN or HPTN CRS and willingness to be followed for the planned duration of the study. * Ability and willingness to provide informed consent. * Assessment of understanding: volunteer demonstrates understanding of this study. * Volunteers who were assigned female sex at birth: negative urine or serum beta human chorionic gonadotropin (β-HCG) pregnancy test within 4 days of enrollment visit (ie, prior to enrollment blood draw or nasal collections). Persons who are NOT of reproductive potential due to having undergone hysterectomy or bilateral oophorectomy (verified by medical records) or having reached menopause (no menses for ≥ 1 year ), are not required to undergo pregnancy testing.
Exclusion criteria
* Reports current COVID-19. * Pregnant. * Receipt of SARS-CoV-2 specific antibodies (eg, convalescent plasma or sera, monoclonal antibodies, hyperimmune globulin). Not excluded: antibody therapy without SARS-CoV-2 specificity (eg, IL-6 pathway inhibitors for COVID-19). * SARS-CoV-2 vaccine(s) received in a prior vaccine trial. * Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence or a volunteer's ability to give informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Measured at Months 0 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , overall and by region |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Measured at Months 0 | Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and comorbidity group among America Cohort |
| SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | Measured at Months 0 | Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1, overall and by region and comorbidity group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | Measured at Months 0, 2, 4 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and enrollment group |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | Measured at Months 0, 2, 4 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and enrollment group |
| SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarizedSARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and enrollment group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarizedSARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and enrollment group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and enrollment group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and enrollment group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and enrollment group among America Cohort (USA and Peru only) |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3,4, overall and by region and enrollment group among America Cohort (USA and Peru only) |
| SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and enrollment group among Africa Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and enrollment group among Africa Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Measured at Months 0 | Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and enrollment group among America Cohort (USA and Peru only) |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Measured at Months 0 | Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and enrollment group among America Cohort |
| SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | Measured at Months 0 | Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1 , overall and by region and enrollment group among America Cohort (USA and Peru only) |
| SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | Measured at Months 0 | Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and enrollment group among America Cohort positive responders (USA and Peru) |
| SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | Measured at Months 0. | SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). There is no positivity call for B cell phenotypic data. The magnitude is B cell subset frequency. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and enrollment group among America Cohort (USA and Peru only) |
| SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0, 2, 4 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3 , overall and by region and COVID-19 severity among America Cohort (USA and Peru) |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0, 2, 4 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and COVID-19 severity among America Cohort (USA and Peru) |
| SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru) |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point.SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru) |
| SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru) |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru) |
| SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and COVID-19 severity |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3,4, overall and by region and COVID-19 severity among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and COVID-19 severity |
| SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | Measured at Months 0 | SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). The sample will be included in the analysis only if the number of IgD- B cells is equal or greater than 1000 for that sample. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and comorbidity group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and COVID-19 severity among Africa Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0 | Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru) |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0 | Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru) |
| SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0 | Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru) |
| SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0 | Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and COVID-19 severity among America Cohort |
| SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | Measured at Months 0 | SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). The sample will be included in the analysis only if the number of IgD- B cells is equal or greater than 1000 for that sample. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru) |
| SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0, 2, 4 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0, 2, 4 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by BAMA IgG1 at Visit 1, 2, 3, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0 | Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort (USA and Peru) |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among Africa Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among Africa Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0 | Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort |
| SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0 | Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort |
| SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0 | Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort |
| SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Measured at Months 0 | SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). The sample will be included in the analysis only if the number of IgD- B cells is equal or greater than 1000 for that sample. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | Measured at Months 0, 2, 4 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3 , overall and by region and comorbidity group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | Measured at Months 0, 2, 4 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and comorbidity group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and comorbidity group among America Cohort |
| SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | Measured at Months 0 | Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and Comorbidity Group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and comorbidity group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and comorbidity group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | Measured at Months 0, 2 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and comorbidity group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and comorbidity group among America Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3,4, overall and by region and comorbidity group among America Cohort |
| SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Measured at Months 0 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , overall and by region |
| SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and comorbidity group among Africa Cohort |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | Measured at Months 0, 2, 4, 12 | Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and comorbidity group among Africa Cohort |
| SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Measured at Months 0 | Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and comorbidity group among America Cohort |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | Measured at Months 0, Month 2, Month 4, Month 12 | This outcome measures the detection rate of viral RNA in nasopharyngeal or nasal swab samples collected at Visits 1, 2, 3, 4 using RT-PCR. Participation was optional, and not all participants provided samples. Results presented in this table include only participants from the Africa cohort (South Africa and other African countries), whose samples were tested using the RT-RNA Fisher TaqPath assay and Americas cohort (Peru and the United States), samples were tested using the RT-RNA Panther assay. |
| SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | Measured at Months 0, 2, 5 | BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA nasal sample) at Visit 1, 2, 3, overall and by region and enrollment group among America Cohort |
Countries
Malawi, Peru, South Africa, United States, Zambia, Zimbabwe
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Group 1A 1A: Asymptomatic, 18 - 55 | 129 |
| Group 1B 1B: Asymptomatic, \> 55 | 51 |
| Group 1C 1C: Symptomatic, 18 - 55 | 182 |
| Group 1D 1D: Symptomatic, \> 55 | 77 |
| Group 2A 2A: Hospitalized, 18 - 55 | 122 |
| Group 2B 2B: Hospitalized, \> 55 | 74 |
| Group 3 3: Clinical spectrums | 125 |
| Total | 760 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 |
|---|---|---|---|---|---|---|---|---|
| Overall Study | Death | 1 | 0 | 2 | 0 | 0 | 0 | 0 |
| Overall Study | Lost to Follow-up | 4 | 3 | 8 | 7 | 8 | 1 | 8 |
| Overall Study | Other | 18 | 9 | 14 | 10 | 11 | 12 | 15 |
| Overall Study | Participant Unable to Adhere to Visit Schedule | 6 | 5 | 12 | 2 | 8 | 1 | 2 |
| Overall Study | Participant Unable to Comply with Study Procedure | 7 | 1 | 7 | 9 | 8 | 8 | 19 |
| Overall Study | Physician Decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Overall Study | Pregnancy | 2 | 0 | 5 | 0 | 1 | 0 | 1 |
| Overall Study | Sponsor Decision | 2 | 0 | 14 | 1 | 1 | 0 | 2 |
| Overall Study | Withdrawal by Subject | 8 | 9 | 22 | 16 | 16 | 8 | 11 |
Baseline characteristics
| Characteristic | Group 1C | Group 1B | Group 1D | Group 2A | Group 1A | Group 2B | Group 3 | Total |
|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 35 years | 62 years | 61 years | 41 years | 33 years | 62 years | 43 years | 44 years |
| Age, Customized 18 - 25 years | 21 Participants | 0 Participants | 0 Participants | 10 Participants | 26 Participants | 0 Participants | 6 Participants | 63 Participants |
| Age, Customized 26 - 35 years | 74 Participants | 0 Participants | 0 Participants | 34 Participants | 54 Participants | 0 Participants | 26 Participants | 188 Participants |
| Age, Customized 36 - 45 years | 52 Participants | 0 Participants | 0 Participants | 36 Participants | 28 Participants | 0 Participants | 39 Participants | 155 Participants |
| Age, Customized 46 - 55 years | 35 Participants | 0 Participants | 0 Participants | 42 Participants | 21 Participants | 0 Participants | 27 Participants | 125 Participants |
| Age, Customized 56 - 65 years | 0 Participants | 35 Participants | 59 Participants | 0 Participants | 0 Participants | 54 Participants | 23 Participants | 171 Participants |
| Age, Customized 66 - 75 years | 0 Participants | 11 Participants | 13 Participants | 0 Participants | 0 Participants | 13 Participants | 4 Participants | 41 Participants |
| Age, Customized Over 75 years | 0 Participants | 5 Participants | 5 Participants | 0 Participants | 0 Participants | 7 Participants | 0 Participants | 17 Participants |
| Age, Customized Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 28 Participants | 19 Participants | 28 Participants | 30 Participants | 28 Participants | 27 Participants | 52 Participants | 212 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 153 Participants | 32 Participants | 49 Participants | 92 Participants | 101 Participants | 47 Participants | 73 Participants | 547 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 8 Participants | 1 Participants | 1 Participants | 5 Participants | 2 Participants | 0 Participants | 5 Participants | 22 Participants |
| Race (NIH/OMB) Black or African American | 87 Participants | 17 Participants | 20 Participants | 68 Participants | 83 Participants | 27 Participants | 27 Participants | 329 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 6 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 60 Participants | 23 Participants | 30 Participants | 42 Participants | 36 Participants | 26 Participants | 56 Participants | 273 Participants |
| Race (NIH/OMB) White | 25 Participants | 8 Participants | 26 Participants | 6 Participants | 7 Participants | 21 Participants | 36 Participants | 129 Participants |
| Region of Enrollment Non-RSA | 31 Participants | 3 Participants | 5 Participants | 16 Participants | 15 Participants | 5 Participants | 10 Participants | 85 Participants |
| Region of Enrollment Peru | 25 Participants | 16 Participants | 25 Participants | 25 Participants | 25 Participants | 25 Participants | 50 Participants | 191 Participants |
| Region of Enrollment South Africa | 98 Participants | 14 Participants | 21 Participants | 57 Participants | 64 Participants | 19 Participants | 14 Participants | 287 Participants |
| Region of Enrollment United States | 28 Participants | 18 Participants | 26 Participants | 24 Participants | 25 Participants | 25 Participants | 51 Participants | 197 Participants |
| Sex: Female, Male Female | 129 Participants | 21 Participants | 42 Participants | 70 Participants | 59 Participants | 33 Participants | 54 Participants | 408 Participants |
| Sex: Female, Male Male | 53 Participants | 30 Participants | 35 Participants | 52 Participants | 70 Participants | 41 Participants | 71 Participants | 352 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 6 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 4.2 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 8.2 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 6.7 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 5 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 6.1 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 6.9 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 6 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 6.4 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 10 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 4.9 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 13 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 5.9 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 5.1 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 7.5 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 8 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 4.3 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 6.6 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 1.8 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 8 Percent CD107a+ NK Cells |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 6.6 Percent CD107a+ NK Cells |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 4.5 Percent CD107a+ NK Cells |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 5.7 Percent CD107a+ NK Cells |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 8.6 Percent CD107a+ NK Cells |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Time frame: Measured at Months 0
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 1.6 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 1.1 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 0.7 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 4.8 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 3.8 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 1.6 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 6 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 5.2 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 7.7 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 3.4 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 8.6 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 4.6 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 12.9 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 12 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 11.3 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 9.5 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 10.8 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 7 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 15.9 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 13.3 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 10.8 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 9.4 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 13.1 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 13.6 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 9.5 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 17.5 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 17.6 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 5.9 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 11.8 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 17.9 Percent CD107a+ NK Cells |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Time frame: Measured at Months 0
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 4.1 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 6.5 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 9.7 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 7.2 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 5.6 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 6.9 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 6.3 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 5.8 Percent CD107a+ NK Cells |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by antibody-dependent cellular cytotoxicity assay (ADCC) Visit 1, overall and by region and enrollment group among America Cohort
Time frame: Measured at Months 0
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 1.4 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 1.5 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 1.2 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 1 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 3.4 Percent CD107a+ NK Cells |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 4.5 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 0.3 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 3.7 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 8.3 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 1.4 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 0.8 Percent CD107a+ NK Cells |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 2.8 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 6.7 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 1.4 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 3.4 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 8 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 5.6 Percent CD107a+ NK Cells |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 5 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 6.8 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 8.8 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 6.5 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 4.6 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 8.6 Percent CD107a+ NK Cells |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 5.8 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 13.1 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 10.8 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 9.4 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 12.6 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 15.7 Percent CD107a+ NK Cells |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 7.7 Percent CD107a+ NK Cells |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 15.3 Percent CD107a+ NK Cells |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 15.2 Percent CD107a+ NK Cells |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 14.1 Percent CD107a+ NK Cells |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 12.5 Percent CD107a+ NK Cells |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 13.6 Percent CD107a+ NK Cells |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 7.7 Percent CD107a+ NK Cells |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 9.8 Percent CD107a+ NK Cells |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 6.8 Percent CD107a+ NK Cells |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 8.9 Percent CD107a+ NK Cells |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 3.3 Percent CD107a+ NK Cells |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 4.5 Percent CD107a+ NK Cells |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 6.3 Percent CD107a+ NK Cells |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 16.5 Percent CD107a+ NK Cells |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 6.7 Percent CD107a+ NK Cells |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 5.8 Percent CD107a+ NK Cells |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 8.8 Percent CD107a+ NK Cells |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 15.5 Percent CD107a+ NK Cells |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 10.8 Percent CD107a+ NK Cells |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and enrollment group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-USA | 1405.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Total | 94.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 809.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-USA | 504.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 151.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 1917.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 1902.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 2649.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 2534.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 481.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 587 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 2649.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Total | 92 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 2012.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Peru | 16 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Peru | 421.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 713 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 16.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-USA | 46.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 481.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-USA | 906.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-USA | 24.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 2534.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 147.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-USA | 82.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Peru | 451.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 906.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 26.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 140.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 147.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Peru | 1386.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-USA | 26.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 307.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 3158.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 58 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 2696.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 96.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-USA | 189.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 73 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 6468.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-USA | 518.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 732 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 651.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-USA | 89 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 414.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Peru | 940.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 299.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 214.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Total | 94.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 299.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 46.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 3765.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Peru | 97.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 1250.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 1962.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-USA | 194.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-USA | 140.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-USA | 651.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 3765.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Peru | 365.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 3461.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 663 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Peru | 510.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 655.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 410.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 596.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 859.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 3461.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 4666 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 1579.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 2082.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 1043.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-USA | 83 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-USA | 105.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 1043.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 2120.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 214.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 1355.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Peru | 543 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 826.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 524.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 303.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1067.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 2032.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-USA | 149.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Peru | 125.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 1405.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 256.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 1669.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 280.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-USA | 92 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 264.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 3373.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-USA | 1902.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-USA | 280.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 340.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-USA | 832.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-USA | 429.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 2304.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 6468.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-USA | 663 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 832.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-USA | 16.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 620.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 587 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-USA | 54.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Total | 83 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 656.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Peru | 219.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 373.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 375.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 153.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Peru | 149 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 278.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 278.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 465.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 5119.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 5119.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 713 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 115.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 383.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 357.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 542.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 1028.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-USA | 162.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 162.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-USA | 109.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 981 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 472.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 343.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-USA | 84.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-USA | 237.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 128.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Total | 237.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Peru | 234.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 1194.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-USA | 146.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Total | 108 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 65.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 82.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Peru | 89 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 1194.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 712.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 712.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 877.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-USA | 65.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Peru | 130 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 1133 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 1297.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-USA | 176 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Total | 176 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-USA | 213.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 579.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 83.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Total | 262.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Peru | 334 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 432.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 432.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 620 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 487.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 453 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Peru | 328.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 121.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-USA | 103.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 126.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-USA | 126.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 1333 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 548.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 493 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 448.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 448.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 328.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 514.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 871.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 324.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 324.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Peru | 481.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Total | 406.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-USA | 406.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Total | 192 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-USA | 192 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 1837.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 1747.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 1747.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 774.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 774.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Peru | 431.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Total | 182.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-USA | 163.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 6779.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 6779.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Peru | 457.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 86.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Total | 55.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-USA | 55.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-USA | 81.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 2130.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 793.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 348.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-USA | 348.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 2256.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 395.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 352.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1427.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 9059.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 9059.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Peru | 166.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 30.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-USA | 43.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 981.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 136.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 94.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-USA | 2368.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-USA | 954 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 258.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 882.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 117.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-USA | 448.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 1936.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 2143 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 6144.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Total | 145 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 218.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 2490 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 495.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 3540 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4734.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Total | 83.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 884.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-USA | 26.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 947 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-USA | 3036 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Total | 105 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Peru | 507.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 9878 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 3682.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 2148 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 947 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 2428 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 1679 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1054.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 506.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Peru | 571.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 242.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Peru | 15.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 1705.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-USA | 180.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 2490 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-USA | 639.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-USA | 1324.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-USA | 105 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 25.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 11144 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-USA | 83.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 578.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 1559 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 36.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-USA | 363.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-USA | 32.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 671.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 176.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 2148 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Peru | 812.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 1324.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-USA | 361.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 483.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-USA | 134.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 3051.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 36.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 4086.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 6.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-USA | 106.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 2364.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 639.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 1150.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Peru | 834.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Peru | 450 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-USA | 6.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Peru | 1661.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 1732.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 150.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 3538 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-USA | 352.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 225.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 71.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 3215.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 1427.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 462.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 2320.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 106.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 3772.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 176.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 2368.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-USA | 115.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 225.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 517.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 11144 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 1423.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 3036 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 612.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 9878 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 2161.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Peru | 1380.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 583.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-USA | 3051.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 382.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-USA | 612.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Total | 120.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Peru | 910.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 43.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 815.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 5532.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 382.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 4734.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Peru | 124.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Peru | 208.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-USA | 242.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-USA | 179.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-USA | 4086.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 595.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 5187.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 3735.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 430 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-USA | 370.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 5461.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Peru | 119.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 417 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 238.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 8446.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-USA | 277.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 3899.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-USA | 712 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1916.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 1471.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 642.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 593 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 988.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 297.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Peru | 457.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-USA | 999.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Peru | 2782.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 265.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 1493 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Peru | 1504.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 321 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 282.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 3106 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 2989 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-USA | 186.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Peru | 37.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Peru | 142 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 210.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 2830.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 329.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 276.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 1066.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 3250.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 328.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-USA | 868.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 387.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Peru | 1318.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-USA | 69.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 1443.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 588 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 510.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-USA | 440 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Peru | 161.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Peru | 341.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 260 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Peru | 119.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-USA | 682 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-USA | 290 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Peru | 90.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-USA | 240.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-USA | 299.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 802.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 802.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 412 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 882.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 649.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Total | 94.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Peru | 883.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 844.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 3802.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 933.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 254.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Peru | 19 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-USA | 769.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 12.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 1039.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-USA | 9.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 709.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Peru | 15.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 20.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-USA | 76 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Peru | 346 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-USA | 21.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-USA | 621.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 78.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 65.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 733.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 41.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 2949.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 74.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Peru | 68.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Peru | 850.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 81.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 92.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 610.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Peru | 621.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 541 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 544 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-USA | 509.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Peru | 346 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 429.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 606.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Total | 66.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 1481.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-USA | 700.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 2410.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 58.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 1713.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 2171.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 1986.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 3981.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 3205.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 1234.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 2316.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-USA | 162.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 2475.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-USA | 66.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 4670 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Peru | 99 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 119.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Total | 64.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 1068.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-USA | 54 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Peru | 52.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 2749.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Total | 53.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-USA | 55.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 487 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 2494.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 337.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 433.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 1324.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Peru | 1166.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-USA | 80.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Total | 180.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 243.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Total | 73.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Peru | 73.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 109 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 642 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 766 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-USA | 166.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 447 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-USA | 62.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 1289.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 659.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 862 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 144.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 698 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-USA | 71.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 1098.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 178.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 2792.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 431.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 329 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 236 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 311 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2231.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 434 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 653 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 1095.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 86.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 692 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Peru | 248.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 239.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 200.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 1603.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 326.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 2052 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 2037.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Peru | 200.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Peru | 157.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Peru | 266.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 1672.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-USA | 111.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 109.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 680.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 593.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 189 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Total | 232.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 260.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-USA | 43.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 323.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Peru | 108.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-USA | 253.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-USA | 98.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-USA | 163.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 273.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 335.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Total | 83.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Peru | 194.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Peru | 57.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Peru | 301.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 172.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Peru | 506 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 1302.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 1055.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 1022.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 128.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 3225.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 686.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 1991.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 491.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 917 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 549 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 561.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 1909.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 656.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Peru | 735 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Peru | 276.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Total | 300 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-USA | 355.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Peru | 312 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Total | 375 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-USA | 405.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-USA | 137 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 1158.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 1160.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 1478 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 1186.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1368.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-USA | 330.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 1467.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 163.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Peru | 103.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Total | 142.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-USA | 162.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 2117.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 2325.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Peru | 238.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Peru | 1170.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Peru | 123.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 3766.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Total | 173.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 769 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-USA | 239 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-USA | 483.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-USA | 104.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 413 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Peru | 651 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 344.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 1853.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-USA | 323.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 4512.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 3119.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 1966 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 2536.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 518.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1435.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 579.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 5186.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Peru | 147 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 445.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 843.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 5510.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 642.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 614.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 680.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 552.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 568 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-USA | 1868.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-USA | 2208 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 970.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 424.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 1005.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 2346.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Peru | 220.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 2467 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Peru | 1272.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 1652.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-USA | 1333.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-USA | 401.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 1380 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 1748.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Total | 155.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 1977.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Peru | 194.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-USA | 1002.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-USA | 1591.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 2688.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-USA | 2575.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Total | 143.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 809.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 2875.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Peru | 983 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Peru | 617.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 6919.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 4462.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 2267.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 3689 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-USA | 630.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 1791.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 1140.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 7723.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 5032.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 7053.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Peru | 1897.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 5855.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 914.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-USA | 1886.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-USA | 157.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 7532.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Peru | 1742.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 6235.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 2359 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 4311.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 639.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 745.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 477.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-USA | 800.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 5355.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 698.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-USA | 2761.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 5426.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 524.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-USA | 1146 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 749 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 4557.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 2952 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 678.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 7931.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 8326.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-USA | 157.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 410.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Peru | 135.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 4758 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-USA | 135 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-USA | 744.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 564.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4578.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Peru | 165.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Peru | 598 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 772.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Peru | 113.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 4780.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 1083.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 2715.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 248.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 527.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 9177.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Total | 150.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 1357.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 1427 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 3951.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 67.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 5716.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 700 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 1045.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 61.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-USA | 159.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Peru | 2827.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 72 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 2831 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-USA | 18.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Peru | 1633.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Peru | 556 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 82 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-USA | 186.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Peru | 3824.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-USA | 1116 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 18.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Peru | 900.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 643.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 80 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Peru | 179 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Peru | 18.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 2212 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-USA | 16.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 1549.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 6952.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 78 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 18 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-USA | 559.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 3087.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Peru | 21.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-USA | 1958.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Peru | 112.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Peru | 1187.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 4018.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Total | 177 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 1655.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 2519.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 6633.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Peru | 328.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 1386.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 405 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 1299 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Peru | 1819.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 2800.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 2643.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 1510.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 1118.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 704.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 3228.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Peru | 161.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Total | 152.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-USA | 139 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Peru | 75.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Total | 90.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-USA | 177.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 599.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 598 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 464.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 295.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 332.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Peru | 357.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 483.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-USA | 650.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Peru | 342.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 605 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 786.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 299 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 552.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 653.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Peru | 3860.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 1701.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-USA | 1050.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Peru | 1100.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 994.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-USA | 654 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 379.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-USA | 530.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 1471.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 1848.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 2481.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 1766.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 1766.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 1723.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Peru | 24.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 31.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-USA | 51.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Peru | 16 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 18.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-USA | 49.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 88.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 133.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 198.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 67.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 87.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 163.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Peru | 989.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 1181 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-USA | 1362.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Peru | 717 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 921 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-USA | 1412.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 3525.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 4103.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 5224.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 1990 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 3481 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 4800.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 8992.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Peru | 169 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Total | 156.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-USA | 135.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Peru | 95.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Total | 112.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-USA | 132.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 629 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 971.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 965.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Peru | 3140.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 1764.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-USA | 910.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Peru | 1057.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 846.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-USA | 347.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 8338.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 4588.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 3400.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 3117.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 2881.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Peru | 734.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Peru | 8149.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 3937.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-USA | 2831.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Peru | 2037.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 1765 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-USA | 1148.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 17476.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 11991.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 8299.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 6588 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 6300 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 4303.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 1429.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 496.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-USA | 288 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 9250.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 4361.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 2609.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 2455.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 1840.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 1178.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Peru | 2386.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 1636.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-USA | 1168 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Peru | 1152 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 1152 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-USA | 1008.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Peru | 3305.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 1273.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-USA | 612 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 8764.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-USA | 2092.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Peru | 1913 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 1777.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-USA | 1139 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 6353.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 5069.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 4357.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4357.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 3620.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Peru | 5367.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 11580.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 9034.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 6613.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 5526.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 825.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-USA | 275.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Peru | 355.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 248.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 452.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-USA | 105.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 971.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 2289 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 3021.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-USA | 634.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 555 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 440.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 3996.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 510 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 5091.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 699.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 2308.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 1155 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Peru | 138.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 469.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 942.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 3545.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Total | 402.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Peru | 1408 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Peru | 256.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 364.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 105.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-USA | 265.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Peru | 340.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-USA | 171.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 424.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 256.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Peru | 232.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 5402.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 421.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 3509.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Peru | 1406.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 2868 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 685.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Peru | 76.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-USA | 204 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Total | 161.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 1706.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 3837.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 1256.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 1375.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Total | 332.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 6168.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 5463 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 397.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Total | 139.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-USA | 359.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Peru | 104.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-USA | 747.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 3611.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 387 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 166.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Peru | 128 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 3929.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-USA | 189.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1185.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 1041 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-USA | 1064.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-USA | 652.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-USA | 91.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 1399.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Total | 160.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Peru | 379.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 723.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-USA | 100.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 3749 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 2219.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Peru | 424.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-USA | 123.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 559.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Peru | 476.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Peru | 3855.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 418.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Total | 311.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-USA | 116.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 542.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 9308.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Peru | 2562 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-USA | 309.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 2402 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-USA | 1066.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Total | 419.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 327.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 776.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Peru | 1382.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Peru | 399 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 809.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 126.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-USA | 339.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 12226 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 529.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 3956.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 8303.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 4295.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 3912.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 3870.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Peru | 157.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 731.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 771.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 5477.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 6261.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 1765.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 659.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 1543 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 1683.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 1590.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 6267.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 395.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 2510.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-USA | 197.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 1347.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 135.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 466.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 959.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 735 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 782.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Total | 300.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Peru | 223.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 4108.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 2405.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 4198.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Peru | 308.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 1327 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 1364.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 2385.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-USA | 1391.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-USA | 325.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Total | 204.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 1302.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-USA | 334.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 1553 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 400.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 3018.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 10069.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 1728.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 2145.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-USA | 543.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Peru | 244.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 1104 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Peru | 1213.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-USA | 1435.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 1759.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 40.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Peru | 2382.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 3049.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Peru | 3588.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Peru | 346.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 1573 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-USA | 637.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-USA | 309.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 1595.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-USA | 331 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 2252.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 99.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 8970 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Peru | 4564.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 594.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 1226.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 2501.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 1226.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Total | 236.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-USA | 1236.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Peru | 2742.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 2104.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 4073 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Peru | 6622 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 6586.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 186 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 476 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 4939.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 606.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 123.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-USA | 116.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 5087.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 7566.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Peru | 540.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 3434.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 12948.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 1672.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 11542.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-USA | 875.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 21.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 634.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Peru | 1065.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4247.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Total | 160.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Peru | 599.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-USA | 16.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 5020.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 786.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 8850.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 3844.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-USA | 1290 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-USA | 144.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 1148.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 25.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 476 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 421 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 5101.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Total | 258.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 831.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Peru | 5372.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-USA | 119.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 3256.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Peru | 98 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Peru | 9913.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 4292.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Peru | 1439.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-USA | 39.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 1119.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-USA | 2407.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Peru | 223.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 2239.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 164.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 1364.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Peru | 4681.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-USA | 451.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 6224.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 29.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 1804 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 776.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 17681.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 1630.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Peru | 15.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 4657.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 583.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 12204.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 993.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-USA | 920.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-USA | 1239.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 5126.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-USA | 371.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 1364.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 628.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 497.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 1364.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 1475.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Peru | 2268.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 1904.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-USA | 536 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 12474.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-USA | 221.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 9468.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Peru | 805.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 1754.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Peru | 4220.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Peru | 4241.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 12178.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 3168.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 590.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 4570 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 684.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 19584.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-USA | 108.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Total | 122.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 2111.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 2-Peru | 157.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-USA | 98.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Total | 130 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-250 at Month 0-Peru | 134.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 6778.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 6193.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Peru | 113.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 115.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 841.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 3977.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 4846.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 9763 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-USA | 104.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 3052.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 2708.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-USA | 103.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 5657.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 2568.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-USA | 1055.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 2317.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 1088.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Peru | 4030.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 3687.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 1080 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-USA | 772.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 6491 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 735.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Peru | 591.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 3418.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 541.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 122.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 98 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Total | 132.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 519.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 90.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Peru | 1843.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 81.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 70.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 2002.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 1109.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-USA | 39.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 36.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-USA | 439.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Peru | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 0-Peru | 175.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Peru | 3516.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-USA | 19.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 19.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 1102 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Peru | 19.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 888.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-USA | 1041.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 1057.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 6969 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 1310 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 479 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Peru | 1587 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 1280.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 1273.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 644.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-USA | 254 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 269.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 2093.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-USA | 276.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 6459.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-USA | 211.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 245.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Peru | 4030.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-USA | 949.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Peru | 1853.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 41.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Peru | 12174 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-USA | 425.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 868.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 473.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Peru | 2018.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 600.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 594.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-USA | 182.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 588 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 388 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 4322.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 431.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Peru | 2519 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 139.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 1926 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 9814.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-USA | 319.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 304.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 3859.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Peru | 129.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 362.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Peru | 774.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 3751.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 268.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 409.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-USA | 409.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 504 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Peru | 3818.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 654.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 2177.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Peru | 1564.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 850.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 0-USA | 1292.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 14234.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 141.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Peru | 8920.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 1629.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 3352.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 465 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 6274.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-USA | 169.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 11726.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-250 at Month 2-USA | 460.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 176 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Peru | 5367.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-USA | 99.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 11884.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-USA | 435 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 1069.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 7086 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Peru | 1891.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-250 at Month 2-Total | 99.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 5188.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Peru | 1141.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 1310.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 423.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 361.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 1932.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Peru | 150.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Total | 151.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 527 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 405.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 445 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Peru | 165.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-Total | 431.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2042.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 1991.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 836.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-USA | 38.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-USA | 83.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1793.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 955.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Peru | 569 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 2-USA | 455 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 7420.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 376.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-Peru | 166.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 884.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 1166.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 99.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 364.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 164.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 420 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 482.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Peru | 224.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 480.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 106.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Peru | 17 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-USA | 129.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Peru | 303.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 571 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 427.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Peru | 289.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 447.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-USA | 433.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 2402 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 82.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 1751.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 2-USA | 135.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 2882.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | NL63-RBD-250 at Month 0-Total | 285.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-Total | 108.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 1466.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-USA | 239.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 2181.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 1591.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | OC43-RBD-250 at Month 0-USA | 100.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-USA | 111.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 858.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 1033.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 424.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgA) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 333.5 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and enrollment group
Time frame: Measured at Months 0, 2, 4
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 4748.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 16886.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 18049.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 2414.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 2985.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Peru | 1456.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-USA | 13.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 4491 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 16187.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 13251.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-USA | 162.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1370.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Peru | 614.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 2449 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Peru | 1450.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 15439 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Total | 16414.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Peru | 44.7 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 2431.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Peru | 10735 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-USA | 236.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Total | 3976.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 17290.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 1456.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 2241 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 4511.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 7790.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-USA | 14.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 19899 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Peru | 1696.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 2171 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 4680.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 3937.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-USA | 958.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 380 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-USA | 345 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 2676.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-USA | 11432.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Peru | 1226.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 10297.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Peru | 2149 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 792.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-USA | 214.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-USA | 1367.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 8894.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 1172.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-USA | 34.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 2090.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Peru | 2329.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 22000 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 587.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-USA | 419 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 10629 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-USA | 272.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-USA | 2032.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-USA | 19733.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 44.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Peru | 876 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Peru | 4390.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 7752.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 14484 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Peru | 1159.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 15490 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-USA | 292.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Peru | 5674.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 10373.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-USA | 16102.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 1159.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 92.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Peru | 8176.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 11668.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 4032 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 12764.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-USA | 3782.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-USA | 1182.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 5480.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 373.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Peru | 16414.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-USA | 6045.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 3685.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-USA | 2439.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 6075 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Total | 4769.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 22000 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 11552 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 10593.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 1884 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 301.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 4321.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 448 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Peru | 2272.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 885 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Peru | 12664 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-USA | 3915.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Peru | 489.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 2664.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-USA | 1347.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Peru | 3639.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 7194.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 2935.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Peru | 705 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-USA | 2245 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 3673.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Total | 3609.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 3474.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Peru | 330.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Peru | 8894.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-USA | 362.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 434.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 1310.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 12036.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-USA | 242.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1652.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Peru | 607.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 185.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Peru | 179.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-USA | 371.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Peru | 102.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 3289.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-USA | 9.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 473.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Peru | 1418.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-USA | 107.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 2468.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 21654.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Peru | 2497.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-USA | 716.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 21228.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 15608.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-USA | 240.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 290.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 20290.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Peru | 306.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Peru | 494 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Peru | 17605 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-USA | 223.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-USA | 155.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 1280 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 252.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Peru | 330.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 634.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Peru | 401.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 938.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Peru | 7273.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 676.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-USA | 3998.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Peru | 2714.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Total | 4994.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 14067.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 8870.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Peru | 4673.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 2873.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 7070.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 118.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Peru | 13223.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-USA | 219.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Peru | 5505.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Peru | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 20565.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 751.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 654.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-USA | 578.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 807.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-USA | 3377.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Peru | 7622.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-USA | 292.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 4605.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 647.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-USA | 129.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 904 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Peru | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Peru | 1295.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-USA | 470.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-USA | 282.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 15556 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Peru | 7824.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 527.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-USA | 85.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 1111.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-USA | 654.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-USA | 8.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Peru | 7358.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 140.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 2398.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 256.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 7437.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 7710.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Peru | 782 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Peru | 21475.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 21984.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 9305.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 3607.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Total | 16318 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 7937 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-USA | 741.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 10204.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 8322.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 5538.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Peru | 12305.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 14867.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 967.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 4896 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-USA | 2603.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 20167.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-USA | 5549.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Peru | 12835.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 741.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Total | 7684.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-USA | 1141.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 455 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 656.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 6665.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Peru | 11985.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Peru | 1503.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-USA | 63.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-USA | 185.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Total | 6590.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Peru | 10406.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 223.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 1082.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Peru | 4613.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Peru | 13067 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Peru | 2067.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-USA | 144.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Peru | 8367.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 13696.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-USA | 13144.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-USA | 454.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 9490.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Peru | 998.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 162.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-USA | 694.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 9414.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-USA | 839.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 6679.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 307 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 19538.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-USA | 220 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-USA | 8271.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1894.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Peru | 2351 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 15246.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1134 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 14859.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Peru | 5225.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Peru | 3533.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 5477.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 2740.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 3413.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 694.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 904 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-USA | 3013 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-USA | 10165.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 5882.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-USA | 227 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Peru | 14129.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 16623.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-USA | 102 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 3946.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Peru | 2720.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 20287.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-USA | 1315.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 743 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 10792.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 5071.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Peru | 12284.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 527.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 11830.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 2888 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 15622.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 1027.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-USA | 1.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Peru | 5839.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-USA | 206.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-USA | 12529.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 230.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 8687.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Peru | 3001.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 19506.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 2462.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 3656.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Peru | 21957.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-USA | 101.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Peru | 3486.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 3887.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Peru | 1474.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Peru | 16831.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 1524.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-USA | 2272.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 609.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Peru | 11742 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 10723.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-USA | 8299.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-USA | 3812.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Peru | 1741.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Peru | 5064.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Peru | 8985.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 1741.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-USA | 2163.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 13275.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 12702.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-USA | 18198.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 12460.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Peru | 5647.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 16900.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 15328.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 11465.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Peru | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 13862.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-USA | 8418 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-USA | 427.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Peru | 7039 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 4182 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 6997.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-USA | 5189.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Peru | 2039.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 1917.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 384.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-USA | 1867.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 4655.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 4164 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 4182 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 3365.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Peru | 18752.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-USA | 2803.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Total | 16138.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 5184.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 4630.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 3227.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 4038.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Peru | 6628.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 3937.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Total | 5758 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-USA | 3770.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 21138.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 19071.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Peru | 4992.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 13781.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 4049.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 12450.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 8613.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Peru | 12504.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 16831.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 9961.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-USA | 443.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-USA | 7846.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 20251.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 20251.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 3940.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 1485.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 20279.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 3162 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 11187 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Peru | 10096.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 10398.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 183.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-USA | 10398.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 2484.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Peru | 938.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 3263.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 3725.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 3319.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 2083.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-USA | 13724.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 3186.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-USA | 2242.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-USA | 15998 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Peru | 544.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Peru | 4000.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 425.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 13842 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-USA | 415.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 3332 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Peru | 2662 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Peru | 8110.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 4689.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-USA | 3478.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Peru | 1056.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 819.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Total | 3957.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-USA | 413.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-USA | 521.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-USA | 299.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Peru | 224.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 12295.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 13642.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 1773.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 2163.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 4343.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Peru | 2002.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-USA | 842.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 2889 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 3561 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 3520.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Total | 2662 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-USA | 2509 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Peru | 1634.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 1088.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Peru | 585.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 332.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-USA | 4259.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Peru | 457.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 475 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-USA | 581.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-USA | 10606.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Peru | 5731.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 6221.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 2349 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-USA | 788 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Peru | 685.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-USA | 3212.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Peru | 316 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 341 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Peru | 1177.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 1330.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-USA | 1483.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Peru | 353 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 3900.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-USA | 3034.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 11627.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-USA | 6620 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 21400.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-USA | 6872.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Peru | 2770.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Peru | 2838.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1109 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 3168.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 3245.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Peru | 7468 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Peru | 1731.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 6385 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 2359 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-USA | 1922.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Peru | 5485.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 1779.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Peru | 3683 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 12119.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-USA | 1288 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 5100.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Total | 7003 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Peru | 3506 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 2125.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 5347.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-USA | 2889.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-USA | 9666.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-USA | 5231.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 685.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 771.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 3341.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 14119.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Peru | 12088.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 10721.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-USA | 1600.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-USA | 3362.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Peru | 4116.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Peru | 1314 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 8602.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-USA | 8169.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-USA | 18560 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-USA | 3806.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 14351.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Peru | 20468.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-USA | 2158 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 458.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Peru | 14945.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 12310.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Peru | 4938.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 5276 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 11096.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Peru | 14945 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 1884.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 10680.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Peru | 15417.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 16420.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Peru | 1209 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 2153.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-USA | 2799.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-USA | 432.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Peru | 5299.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Peru | 12227.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Peru | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-USA | 9064.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 6640.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-USA | 11051 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Peru | 3231 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-USA | 489 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 6299.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 18167.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 7205 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Peru | 15238.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-USA | 1024.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 918.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Peru | 4508 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Peru | 5357.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 17539.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-USA | 6620.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 3248.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-USA | 2524 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Total | 8742.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 2048 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-USA | 2586.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 18757 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Peru | 10900.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 8441.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-USA | 764.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-USA | 6330 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-USA | 245.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Peru | 12070.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 5982 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-USA | 9651.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Peru | 13619.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 1329.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 14711 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Peru | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 11990 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Peru | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 7680.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 3972.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1474.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 15478.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 9766.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 9299.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Peru | 11573.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 14482.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Total | 16900.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Peru | 10768.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 16298 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 8399.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 12649.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Peru | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Peru | 17525 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-USA | 6295.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Total | 5989.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 15861.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 6339.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 3874.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-USA | 1472.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1526 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 5345.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 4221.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 10741.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-USA | 8462.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 4465.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-USA | 3557.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-USA | 13457.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 6920.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 6026.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 9110.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 2854.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 1359.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 13423.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-USA | 18645.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 12133.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 6486.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 18858.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-USA | 705 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-USA | 8241.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Peru | 11718 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 7667.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 15706.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 11396 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-USA | 5671.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-USA | 10991.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 8064.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 5411.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Peru | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 17805.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-USA | 344.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Peru | 11351.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 14465 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 2078 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 3908 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 5722.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-USA | 7162 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Peru | 21820.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 13855.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Peru | 2275.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 13478.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-USA | 887.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 14461.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 4755.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Peru | 15596.3 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Peru | 21771.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 15129 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Peru | 5677.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-USA | 19159.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 13772.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 3091.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-USA | 1042.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-USA | 994.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Peru | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 3793.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Peru | 1372 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 2501.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 13769.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-USA | 21096.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1561.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 12332 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-USA | 17576.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-USA | 12634.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-USA | 7541.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 6529.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 4335.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 12491 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-USA | 740.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-USA | 3185.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Peru | 7757.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 11885.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Peru | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 10645 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 21747.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-USA | 6531.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Peru | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 14161.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-USA | 5373 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 18282 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 8435.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Peru | 10770.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Peru | 3738.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 2361.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Total | 5765.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Peru | 11834.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Peru | 14651.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Total | 6800.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 3224 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Peru | 7793 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-USA | 6125 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 4185.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 12012 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 4738.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-USA | 880.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 21350.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 795.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Peru | 18083.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 6259.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Peru | 6637.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 15729 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Total | 17029.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 11982.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Peru | 16948.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 12104.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-USA | 5952.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 5078.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 3852.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 10419.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 14499.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 3977.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Peru | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 9798 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 5606.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 5609 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-USA | 1554.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Peru | 21598.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-USA | 5568.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 1122.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 5122.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Peru | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Peru | 3952.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 14027.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 19478.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Peru | 1442.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 4030.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-USA | 8365.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Peru | 7015 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 13228.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 8948.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1688.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Peru | 6996.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 576.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 1777.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-USA | 4223.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1825.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-USA | 1465.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 4323.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 11095 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 3926 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 4034.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Total | 6118 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-USA | 7229.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 20708.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-USA | 2130.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 4251.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-USA | 11546.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 3188.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Peru | 3457.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-USA | 1453.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 21717.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Peru | 2815.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 1877 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-USA | 7256.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Peru | 7619.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Peru | 8686.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 21985.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-USA | 18665 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Peru | 7362.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-USA | 4840.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Peru | 14203.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 6804.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-USA | 4590 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-USA | 3858.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 12770.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 5922.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 5370.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 20107.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 21808.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-USA | 12049 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-USA | 6990.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Peru | 5575.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 6120 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-USA | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-USA | 482.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 201 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 20787.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-USA | 5221 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 710.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Peru | 16491.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 8853.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 936.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 21639 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-USA | 7731.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Peru | 2589.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 1776.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Peru | 15530.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-USA | 12100.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 9842.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 7340 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-USA | 11397 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 5495.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Peru | 8543.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Total | 7069.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 3015.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-USA | 6559.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-USA | 14427.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Peru | 19485.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-USA | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 6905.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 5831.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 3987.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 8100.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 5169 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 1491 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Peru | 8563.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Total | 6267 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-USA | 1736.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 11912.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 11120.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 8861.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 14408.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 11789.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-USA | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-USA | 16418.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Peru | 20226.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 16315.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-USA | 11730.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 8987 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 7848.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 5114.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 7331.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Peru | 15513.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Total | 14393.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 9592.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 7152.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 4205.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Peru | 11288.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Total | 9087.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-USA | 6074.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 14855.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 14555.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 11300 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 13485.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 10632 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 6805.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Peru | 11386.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 11556.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-USA | 11764.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 19896.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 19475.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 17473.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Peru | 17215.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 16627.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Peru | 1213.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-USA | 12415 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 6453.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1099.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 21857.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Peru | 5318.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 4971.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-USA | 1522.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 2695.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 21909.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Peru | 16795.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 8501.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-USA | 1989 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 9353.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-USA | 6323.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-USA | 18872.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Peru | 18837.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 15269 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-USA | 11779.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 7602.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-USA | 2081.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-USA | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Peru | 9158.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-USA | 833.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 16904.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-USA | 10463.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Peru | 7131.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 5453.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-USA | 3039 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Peru | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Peru | 4180.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 2540.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-USA | 1035 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Peru | 1242 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-USA | 163.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 4607.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Peru | 12744.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Peru | 5364.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Peru | 8798.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-USA | 3969.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 3108.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 1322.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Peru | 2636.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 21939.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1570 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-USA | 15684.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 3182 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-USA | 4664.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Peru | 971.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 658.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 1460.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1302.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 12564.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 3674.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Peru | 3019.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Peru | 15132.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 13830.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 14566.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 15293.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-USA | 7501.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 7501.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Peru | 7465.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 6789.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 4642.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-USA | 422.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 6951 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 7754 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 10404 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 10404 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 10342.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 4159.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Peru | 14558.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-USA | 4619.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Total | 5392 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 4-Peru | 6895.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 3671.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 4715.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-USA | 93.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 3888 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 6666.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Total | 16313.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 4-Peru | 17003.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 4339.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 13760 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 371.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-USA | 1830 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 4889.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 4299 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Peru | 3884.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 5536.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-USA | 1706.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 4329.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Peru | 11395.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-USA | 3124.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 4614.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 997.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 7604.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Peru | 17594.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-USA | 8637 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 16428.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Peru | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-USA | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-USA | 382.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 14403 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 15272.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 10617.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 12568.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 14069.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Peru | 16546 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-USA | 5670 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 4-Total | 5670 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-USA | 2181.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 4275.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Peru | 9704 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-USA | 3458 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 7608.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Peru | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-USA | 468.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 2243.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Peru | 5311.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Peru | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 794.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Peru | 13939.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-USA | 349.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 1748.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Peru | 5463.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 1694 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Peru | 14899.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 3453.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 556.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-USA | 1301.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-USA | 2024.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-USA | 5977.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 13306.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 14302.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-USA | 476.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Peru | 4801.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-USA | 12463.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-USA | 652.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 1178 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Peru | 2745.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Peru | 4075.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 1820 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-USA | 686.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 11295.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 4977.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Total | 5000.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-USA | 1919.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-USA | 536.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-USA | 1044.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 5338.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-USA | 657.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 4046 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 1062.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 4057.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 4586.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 1755.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 6321.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 4-Peru | 5337 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-USA | 1301.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Peru | 3668.7 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 4251 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1041.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-USA | 1799.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 4985.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Peru | 2819.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Peru | 698.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 1885.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 920.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 14260.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Peru | 17893.5 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarizedSARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and enrollment group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 406.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 300.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 21.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 4540 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 1190.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 488.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 610.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 268.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 4377 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 28.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 2775.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 202.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 147.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 610.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 19.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 110.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 147.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 1045.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 33.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 167 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 71.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 122.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 3074.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 122.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 3345.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 290 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 154.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 250.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 6430.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 764.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 288.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 2129 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 131.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 393 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 489.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 207.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 1013.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 16.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 131.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 121.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 741.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 1247.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 514.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 146 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 214.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 577.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 343 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 1902.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1482.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 514.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 577.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 618.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 553.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 16.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 331 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 1482.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 4.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2345.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 489.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 4.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 3472.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 799.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 2903.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 393 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 2345.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 7.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 2903.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 499.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 81.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 5.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 206.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 4.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3472.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 4036.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 128.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 406.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 1367.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 644.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 2121.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 346.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 346.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 8121.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 3968.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 10084.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 2257.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 2438.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 4475.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 7057.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 7057.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 2001.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 6061.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 76.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 335.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 61 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 58.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 42 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 13.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 991.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 4066.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 134 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 4066.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 742.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 217 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 91.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 134 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 2553.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 171.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 8733.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 7774.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 4262.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 260.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 195.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 8733.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 11872.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 73.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 107.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 19.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 4631.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 19.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 3743.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 3743.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 11872.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 4631.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 28.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 519.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 921.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 932.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 357.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 312.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 1220.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 39 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 20 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 28.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 49 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 497.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 14.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 5450.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 240 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 101.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 100 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 260.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 2987.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 108.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 96 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 2885.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 1595.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 132.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 410.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 721.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4254.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 149 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 5864 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 262.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 581 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 41.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 3877.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 6731.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 481.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 1480.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 1089.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 6749.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 244.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 547.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 124.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 45.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 7385.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1269.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 697.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 124.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 1406 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 156.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 1896.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 171.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 205 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 132.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 21.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 288.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 262.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 3970.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 160.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 212.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 431.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 157 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 2059.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 1621.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 2059.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 2001.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3146.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 2346.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 6082.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1421.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 68.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 21.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 2205 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 181 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 243 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 20.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 273.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 6265.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 1896.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 463.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 175.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 3757.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 1523.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 1883.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 75 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 313 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 6036.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 397.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 46.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 622.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 1728.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 112.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 7544.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 7088.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 435.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 178.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 47.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 843.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 205.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 6082.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 3563.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 73.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 5091.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 918.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 7904.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 3125.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 2077.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 18.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 136.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 1709.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 2211 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 2088.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 1439.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3713 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 1.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 1568.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 205.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2320.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 1893.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 3691 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 3037.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 825.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 8299 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 121.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 3415 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 259.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 5159.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 3317.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4811.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 787 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 5985.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 4713.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 4660 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 93.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 204.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 5818.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 176.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 10450.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 188 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 1788.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 4657 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 2111.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 7420 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 8299 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 157.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 224.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 616 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 8291.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 216.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 4377.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 279.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 2111.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 5331.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 3266.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 2984.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 2262.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 132.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 16.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 1470.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 1562 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 4610 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 980.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 7411.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 312.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 3125.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 183 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 6652.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 132.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 959 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 340.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 268.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 645.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 441.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 257 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 256.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 103 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 781.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 1932.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 1468.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 179.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 1891 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 7271.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 2848.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 594.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 20010.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 3284.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 32 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 21.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4119.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 14250.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 10606.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 1845.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 149.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 2880 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 9226 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 14983.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 3871.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 494.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 9396.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 100.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 22.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 7868.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 4387.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 180.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 323.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 272.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 2566.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 1506 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 3197 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 188.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 233.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 13650.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 190.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 686.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 6749.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 203.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 9181.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 7018.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 9034.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 3902.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 3030 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 441.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 747.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 1351 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 10695.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 781.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 1264.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 5908.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 3152.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 2597 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 12102.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 1350.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 1355.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 887 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 822.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 8.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1506 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 1699.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 370.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 4810.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 22.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 275.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 360.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 5785.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 3347.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 12261.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 11434 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 9738.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 2632.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3717.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 4109.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 221 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 245 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 336.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 304.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 3179.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 672.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 869 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 232 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 869 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 273 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 557.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 612.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 4704.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 102.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 4140.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 32 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 3513.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 1147.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 113.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 359.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 616 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 177.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 204 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 255.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 936.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 243.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 263 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 159.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 189 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 223.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 18159 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 3438.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 3438.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 3307 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 465.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 17.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 936.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 12610.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 13097.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 13518.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 757.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 2865.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 4707.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 4569 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 4066.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 16390 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 9598.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 6808.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 6705 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 6207.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 8264.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 7882 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 6215.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 1634.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2551.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 2993.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 9611.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 7521.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 4729.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 1202.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 1269.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 1269.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 849.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 16761 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 872.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 1580 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 2317.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-Peru | 64.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Peru | 181 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 3609.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-USA | 147 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 154.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 2-USA | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | OC43-RBD-50 at Month 0-Peru | 156 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-USA | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-USA | 230.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 3503.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 2-Peru | 81.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-USA | 246.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 203.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | NL63-RBD-50 at Month 0-Peru | 194.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 273.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 6218.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-USA | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 197.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 2-Peru | 103 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-USA | 207.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 0-Peru | 322.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 4350 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 230.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HKU1-RBD-50 at Month 0-Peru | 278 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-USA | 549.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 534.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Peru | 519.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 1737.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 3454 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-USA | 967 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 485.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Peru | 364.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 126.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 3405.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 1553.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 886 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 130.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 1573.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-USA | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Peru | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 1960.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-USA | 403.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 1836.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 1415.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 453.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 2987.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Peru | 562.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-USA | 546.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 500.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 4400.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 3746.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 143.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 173 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Peru | 403.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-USA | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 5248 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 2698.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 1590 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Peru | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-USA | 9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 780.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 5657.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 630.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Peru | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-USA | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 10162.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1472.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 2606.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 1135 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1260.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 8674.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 2547.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 4659 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 6348.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 177 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 8297.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 6745.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 7004.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 9.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 15.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 496.8 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 1340.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 485.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 419.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 1780.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 1211.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 90.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 3285.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 2914.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 859.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 484.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 1792.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 2540 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 5887.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 402.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 1629.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1627.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 1048.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 1281.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1173.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 507.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 589.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 1744.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 458.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 3073.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 463.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 524.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 2970.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1625.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 359.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 83.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 2630.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 3082.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1096.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 2068.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 2394.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 465.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 726.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 1619 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 65.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 403.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 143.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3782 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 2216.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 407.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 1485.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 1898 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 603.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 475.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 1470.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 339.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3795.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 4301.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 822.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 94 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 7557.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 570.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 1310 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 3141.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 3165.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 728.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 520.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 494.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 1381 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 571.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 3430.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 4204.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 698 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 1844 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 2914.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 1246.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 90.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 471 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 2609.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 1266.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1982.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 84.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 459.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 1416.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 685.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 5632.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 708.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 1634.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 460.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 1191.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 1398.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 521.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 556.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 2167.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6875.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 403.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 4067 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 321 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 1351.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 3008.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 2155.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 5649.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 1467.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 510.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 7904.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1048.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 5561.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 382.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3754.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 835.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1467.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 2467 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 342 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 2872.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 429.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 876.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 532.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 2799.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 2691.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 80.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 447 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 457.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 3462.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 4113.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 3958.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 1275.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 1740 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 85.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 588.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 2869.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3154.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 404.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 1296.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 1351.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 409 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 699.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 457.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 1170.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1126.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 492 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 497.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 1923.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 1690.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 533.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2278.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 341 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 1798 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 320.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 6100.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 445 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 145.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 3058.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 469.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 3754.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 533.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 1028.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 303.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 286.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3765.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 4301.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 1451.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3758 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 233.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 398 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 1462.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 86.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 806.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 2510.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 809.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 7658 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 91.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 1038.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 847.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 3285.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 739.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 390.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 69.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 1574.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 3168.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 33.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 1491.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 2895.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 835.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 2578.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 416.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 1993.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 2402.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 1643.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 403.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 651.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 473.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 1828.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 583.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 481 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 3017.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 362.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1186.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 1224.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 1009.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 2203.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 405.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 91.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 3754.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 492 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 321 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 3177.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 94.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 2436 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 1596 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 773.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1269.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2519.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 1159.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 524.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 409.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 467.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 3528.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 825 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 546.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 1288.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 2149.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 552.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 5132.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 2701 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 1916.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 436.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 454.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 482.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 870.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3154.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 1739.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 1005.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1765.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 8354.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3951.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 445 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 942.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 80.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 489.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 3085.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 1582 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 3524.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 1310 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 7121.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1189 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 214.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 403.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 486.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 1076.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 484.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 88.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 2637 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 466.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 3158.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 1115.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 639.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3765.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 3695.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 3157 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 1417.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 5034.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 1211.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 2453.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 1266.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 492.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 383.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 2926.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 1724 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 4939.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 3567.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 86 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3751.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 603.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 483 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 3351.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 1241 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 3327.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 782.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 4024.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 80.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 439.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 3087.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 2625.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 870.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 1213.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 382.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 3274.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 1358 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 487 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 491.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 492 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 6966.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 4603.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 283 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 321 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 443.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 414.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 2701 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 1909.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 1634.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 442.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 556.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 497.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2807 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 8285 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 2041.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 527 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3227.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 5966 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3758 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 806.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1289.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 83.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 1582 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 1245.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 2897.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1594 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 1350.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 1948.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1067.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 93.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 1306.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 469.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 692 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 1433.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 2043 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 1828.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 7325.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3301.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 7152 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3832.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 487.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 299.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 582.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 480.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 451.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 402 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 670.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 472.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 1240 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 76.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 1296.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 1563.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 84.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 1266.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 2708.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 92.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 93.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 3008.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 3515.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 476.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 2467 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 358.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 447.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 442.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 1191.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1128.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 1282.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1186.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 423.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 477.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 510.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 699.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 1360.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 2997.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 2737.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 1929 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 1905.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 654.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 1427.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 3151.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 1177 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 2536.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 2319.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 1578.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1974.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 683.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 1005.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3751.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 4170.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 3883.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 3765.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 2834.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 5866 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 5388.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 3087.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 286.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 1547.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 1593.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 552.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 2658.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 3041.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 2905.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 86.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 3089 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 7542.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 2408 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1185.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 533.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 1480.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 806.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 1646.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 254.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 80.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1538.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 1226.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 1309.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 567.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 920.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1532.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 406.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 376.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 1433.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2816.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 1192.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 517.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 5715.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 482.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 3981.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 338.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 5832.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 1964.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 5874.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 525.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 471 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 448.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 4889.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 1708.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 3003.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 1308.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 445 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 2625.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 4663.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 849.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 463.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 1828.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 98 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 3819 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 567.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 483 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 598 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 4166.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1566.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 3168.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3754.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 786 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 128.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 3002.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 567.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 536.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 1341.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3758 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 2051.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 587 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 2332.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 5076.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 1561.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 1309.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 3706.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 2583 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 86.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 2728.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 1754 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 453 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 1266.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1048.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 3801.1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 685.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1943.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 1771 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 9327.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 482.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 2486.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 1360.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 725.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 1132 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 2872.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 86.1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 4003.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 614.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 3069.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3751.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 3375.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1225.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 1296.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6569.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 480.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 514.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 5377.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 286.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 6300 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 673 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 393 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 491 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 2701 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 4335.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 1197.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 1582.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 5988.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 1988.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3227.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 773.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 3183.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 2649.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 467.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 506.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 5140.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 484.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 1773.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 536.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 10308.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 121.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 1315 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 6570.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 341 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 497.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 465.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 73 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 1126.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 1235 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 756.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 577.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 1824.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 2923.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 547.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 395.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 4969 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1765.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 1143 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 2419.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 842.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 3356.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 449.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 2015.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 2952.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 79 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 978.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 3141.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 105 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3618 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 3061.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 90.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 1527.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 2043 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 1348 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 2338.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 1088.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 79.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 1478.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 783.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1236.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 811.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 1398.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 387.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 381.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 4313.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 508.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 608.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3782 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 484.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 2637 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 465.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 1297 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 3758.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 394.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 3031 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 624.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 339.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 4522 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 6004.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 513 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 7557.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2629.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 2329.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 385 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 867.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 917.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 1593.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 484.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 479.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1206 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 576 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3751.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 1433.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 311.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 5840.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 1667.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 1899.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 520.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 1217 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 4072.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 5596.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 483 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 708.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 2436 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 2579.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 561 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6934.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 459.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 477.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 553 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 2495.6 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 500 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 5119.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 2895.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 6300 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1186.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 404.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 1256.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 89.9 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 3213.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 3001 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 2882.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 1462.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 453.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 2299.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 2604.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 1427.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 2486.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 83.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 387.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 520 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 683.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1995.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 1258 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 1929 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3136.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 1255.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 86.9 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 4747.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 778.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 313.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 1351.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1185.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 2627.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 1440.9 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 469.6 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 403.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 1275.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 7639.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 1988.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 3097.1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 481.6 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 480.1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 88.6 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 3988.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 1865.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 4304 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 94.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 791.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 89 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 3151.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 560.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3882.9 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 482.9 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 1075.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 3316.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 95 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 465.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 1406 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 3270.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 352.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 577.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 1553.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 756.9 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3839.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 3625 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 490.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 510.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 582.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 2952.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 1994 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 484.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 3073.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 780.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 329.9 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 1329.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1186.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 7548.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 2747.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 453 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 4577 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 504 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 1361.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 1592 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 6126.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 2749.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 2419.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 2082.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 1241 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2399.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 388.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 484.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 3038.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 6037.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 2385.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 1379.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 1118 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 520 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1542.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 963.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 799.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1402.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 78.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 2188.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 1418.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 1576.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 605.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 456.9 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 1297.5 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 744.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 3985.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 410.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-250 at Month 2-Total | 87.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-250 at Month 0-Total | 98 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 1952.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-250 at Month 0-Total | 104 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 2964.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 2260 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 736.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 22.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 46.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 535.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 119.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 89 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 23.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 1499.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 991.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 352.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-250 at Month 2-Total | 84.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 3018.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 1346.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 826.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 323 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 460.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 212.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 151.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 3078.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1065.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 332.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 51 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 875.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 256.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1070.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 118 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 7089.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 542.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 255.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 121.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 95.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 2660 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 2107.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 1296.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 2994.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 498.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 8806.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 712.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 521.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 309 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 363.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 229.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 644.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 531.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-250 at Month 2-Total | 152.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 178.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 2228.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-250 at Month 0-Total | 126.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 743.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 1208.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 484.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 647 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-250 at Month 2-Total | 184 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-250 at Month 0-Total | 307.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 378.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 21.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 5220.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 2630 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-250 at Month 0-Total | 115 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-250 at Month 2-Total | 85.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 443.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 334.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 99.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 110.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 408.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 464.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 320.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 278 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 1302.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 1115.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 18 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 650.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 76.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 85.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 800.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 745.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 3069.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 2630.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-250 at Month 0-Total | 102 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-250 at Month 2-Total | 88.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 389.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 376.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-250 at Month 0-Total | 276.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-250 at Month 2-Total | 328.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 1093.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 1279.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-250 at Month 0-Total | 100.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-250 at Month 2-Total | 105.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 405 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 442.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 569 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 324.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 1591.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 2033.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 1126.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 348.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 163.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 1537 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 654.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 532.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 254.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1990.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 1027.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 408.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 142.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 1619 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 652.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 765.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 885.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 3341.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 3409 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 1215.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 622.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 4547.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2410 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 180.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 59.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 846.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 255.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 8428.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 364.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 1390 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 156.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-250 at Month 0-Total | 411 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 5008.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 1185.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 924.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 1963.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 2644.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 1093.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 3915.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 644.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4357.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 6934.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 470.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 516.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 4093.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 116.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 2653.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 4777.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-250 at Month 0-Total | 139.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 4846 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 1466.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 1378.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1543 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 589.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 308 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 897.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 13988.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 1957.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 1031.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 2011.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-250 at Month 2-Total | 69.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 650.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 25.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-250 at Month 2-Total | 95.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 219.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 502 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-250 at Month 2-Total | 374.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 96.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 585.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 27 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 262.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 6049.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 6263.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-250 at Month 0-Total | 173.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 1287.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 2676.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-250 at Month 0-Total | 159.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 1606.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 3230 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 10962.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 1810.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 7052 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 1686 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 6170 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 4612.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 466.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 2569.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 353.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-250 at Month 2-Total | 87.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 2676.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 6613.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 1183.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 605 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 362.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 3062.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-250 at Month 0-Total | 366 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-250 at Month 2-Total | 332.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 1405.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 533 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 4312 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-250 at Month 0-Total | 168 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 1266.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-250 at Month 2-Total | 154.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 681.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 664.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 668 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 1974.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 575 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 657.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 9146.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 3396.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 174.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 5319.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 10462 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 2415 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 1485.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 135.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 192.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 3716.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 5562.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 843.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 452.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 1807.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 495.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 5485 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 642.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 994.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 1839.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 1399 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 392.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-250 at Month 2-Total | 129 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 4902.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 1502.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 202.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 1695.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-250 at Month 0-Total | 170.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 989.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 1280.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 20.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 6482.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 136.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 32.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 77.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 1124.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 825.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 876.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 1755 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 4348 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4217.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 3524.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-250 at Month 0-Total | 173.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 2137.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 4473.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-250 at Month 2-Total | 144.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 618.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-250 at Month 0-Total | 3914.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 2-Total | 345 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 869.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 2455.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-250 at Month 0-Total | 162.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 445.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-250 at Month 0-Total | 1454.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 536.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 0-Total | 2312.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 3272.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 2-Total | 774.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 3966.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 1192.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-250 at Month 2-Total | 1465.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 401.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 0-Total | 3139 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 708.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 11893.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 0-Total | 482 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 2-Total | 22.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-250 at Month 0-Total | 15.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-250 at Month 2-Total | 379.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 534.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 2436 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 70.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 1911.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 7607.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-250 at Month 2-Total | 1792.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4748.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 31.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-250 at Month 2-Total | 202.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 6588 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 0-Total | 1579.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1432 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 2855.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 5988.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 913 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-250 at Month 2-Total | 961.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 603.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 938 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 2238.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-250 at Month 2-Total | 226.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 5390.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 0-Total | 879.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 1009.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 2-Total | 352.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-250 at Month 2-Total | 157.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 3416.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-250 at Month 0-Total | 569 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-250 at Month 0-Total | 1004.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-250 at Month 0-Total | 107.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-250 at Month 0-Total | 143.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 0-Total | 1221.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-250 at Month 2-Total | 305.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-250 at Month 2-Total | 2037.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 3611.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-250 at Month 0-Total | 132.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-250 at Month 2-Total | 734.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-250 at Month 2-Total | 1083 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 5062.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 10017.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-250 at Month 0-Total | 302.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 4784.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-250 at Month 2-Total | 1577.5 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 73.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 11670.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 481.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 299.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 508.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 278.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 791.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 2649.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 8344.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 251.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 2960.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 4475.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 515.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 293.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 1086.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 604 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 463.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 245 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 3886.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 630.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 2037.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 209.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 3866.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 3622.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 3496.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 342.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 4231.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4205.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 7566.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 12725.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 1366.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 214.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 1977.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 486 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 387 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 3721.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 7185.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 299 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 1005.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 849.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 1773.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 4630.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 49.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 3087.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 3927.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 1916.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 422.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 579.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 2209.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 448 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 74.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 250.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4024.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 358.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 1293.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 585.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 947 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 1097.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 3252.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 4340.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 3516.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 774.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 5244.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 8379.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 1690.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 89.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 90.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 3988.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 2649 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 2548 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 490.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 376.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 3322.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 1582.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1395.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 431.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 477.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 6511.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 3334 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 1949.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 2168.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 641.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 3058.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 3279.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 1578.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 256.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 8258.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3227.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 3014.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 625.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 306.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 465.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 575.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 760.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 1414.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 1010 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 3493 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1269.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 692 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 5754.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 3798.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 1166.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 614.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 2781.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 86.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 447.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 92 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 459.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 1579.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 436.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 1714.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 508.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 1634.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 4671.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 1249.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 1297.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 2041.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 708.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 3401.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 908.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 1510.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 547 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 450 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 2026.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2807 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 342 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 3924.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 1245.8 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0, 2, 4
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 0-Total | 21989.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total | 4467.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 5227.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 4-Total | 16049.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 4186.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 2299.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total | 6729.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 4-Total | 6282.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 21827.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total | 427.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 4366.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 2-Total | 9624.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 21122.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 4-Total | 5278.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total | 8793 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 4-Total | 10361.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total | 743 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 5174.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1217.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total | 2446.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 2889 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total | 2590 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 4-Total | 4279 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total | 21542 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total | 14710.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total | 517.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total | 554 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 2733.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total | 6277.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total | 2712.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total | 245.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 4417.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total | 12799.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 0-Total | 4569.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total | 2182.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 5540 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 4-Total | 3639.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 0-Total | 6112.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 15344 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 4-Total | 226.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 2-Total | 2192 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 9586.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 2-Total | 588 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 4-Total | 958.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 2-Total | 2711.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total | 10934.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 4-Total | 969 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 0-Total | 1174.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 13900.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 4-Total | 223.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 4034.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total | 1363.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 2-Total | 324 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 4-Total | 5357.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 9540.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total | 1020 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total | 1058.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 4014.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total | 21.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 0-Total | 1047.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total | 4139.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 22000 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 4-Total | 781 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 14162.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 3012.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 2-Total | 1735.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total | 5490.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 9758 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 3942.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 4-Total | 5655.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 4-Total | 6172.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22000 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 0-Total | 5749.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 11600.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 4-Total | 9386.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total | 249 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 14274.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total | 1003.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 10845.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 4083.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total | 22000 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total | 13428.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total | 464.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 4-Total | 16414.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1679.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total | 1027.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 13903.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 10434.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total | 338.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total | 2059.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 15792.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total | 92.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total | 948.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total | 292.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total | 1046.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total | 2060.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1510 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total | 1333 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1679.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 15952.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total | 4785.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1260.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total | 12053.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 14306 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 12312 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 13251.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total | 13633.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total | 1147 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total | 11566.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total | 2470 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total | 5957.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total | 7004 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total | 252.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 4-Total | 502.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 2-Total | 1460.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 0-Total | 3491.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total | 2475.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 4-Total | 776.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 2-Total | 1719.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total | 5184.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 0-Total | 5840.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total | 435.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total | 986.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total | 692.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total | 1530.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total | 3242.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total | 1037.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total | 368.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total | 2018.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 0-Total | 21924.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total | 6397.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total | 409.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 2-Total | 9478 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total | 1519 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total | 8591 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total | 645.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 4-Total | 4413 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total | 8316.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total | 3177.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total | 13604.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 0-Total | 16577.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 4-Total | 648.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 2-Total | 1592.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 2-Total | 6956.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 0-Total | 4122.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 4-Total | 1020.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 2-Total | 2048.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 4-Total | 2272.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total | 4697.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 0-Total | 6626 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 4-Total | 4980 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 5035.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 4774.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 4563.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 4738.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 4-Total | 5197.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 4089.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 4-Total | 6242.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total | 573.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 4099.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 4-Total | 16792.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 14215.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 5877 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 12877.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 4-Total | 16306.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 5584.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 14453.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 11438.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 4-Total | 6873 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total | 2524.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 4-Total | 4234.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 3638.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 4322.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 14355 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 4-Total | 5541.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 4248.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 9248.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total | 4330.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 4383.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 4-Total | 9486 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 21722.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total | 21328.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 12464.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total | 14693.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 9870.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total | 1934.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 2125.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 4-Total | 12195 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total | 173 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 14352.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1197.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 0-Total | 21849.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total | 1821.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 3361.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total | 2016 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total | 324 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 13636.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total | 21915.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total | 843.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 4-Total | 16447.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 4362.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total | 278 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total | 986.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total | 945.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 3677.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total | 411.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 14451 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total | 340.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total | 218.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 11798.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 13250.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total | 351.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 4-Total | 3042.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 0-Total | 5270.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 15079 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 4-Total | 5991.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total | 12463.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total | 39 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 2232.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 2677.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total | 5305.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 3121.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 10994 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 2-Total | 1718.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 13899 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 4-Total | 741.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total | 1830 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 4-Total | 5383.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1675.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 0-Total | 434.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 4042.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 11412.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 2-Total | 175.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total | 1718.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 13531.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total | 14647.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 4-Total | 836.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 9590.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 2-Total | 759 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 2-Total | 2039.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total | 1394.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 0-Total | 390.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 4546.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 4-Total | 2031.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 8755.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 2-Total | 418.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 0-Total | 5654.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 4-Total | 404.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 4-Total | 595.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 4-Total | 5997.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total | 8364.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 0-Total | 1313.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total | 17832.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 5623.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total | 12849 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 4265.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total | 5957.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total | 2496 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 4-Total | 3677.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 2867.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total | 519.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total | 474.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total | 2552.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 5268.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total | 479.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 4-Total | 5084.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total | 3604.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 2-Total | 9065.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 4240 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 4-Total | 10086.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total | 705.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 4223.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total | 506.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total | 3959.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 4-Total | 6289 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 4-Total | 12681.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total | 172.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total | 6116 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 4-Total | 16101.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 3976.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total | 17197.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total | 8985.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total | 4351 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total | 9321.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total | 5330.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total | 2116.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total | 6094.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total | 1344 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total | 371.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 0-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 2-Total | 10137.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 4-Total | 4408.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 0-Total | 10749.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 2-Total | 5077.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 4-Total | 1777 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 5836.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 5494 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 4-Total | 6379.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 4230.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 4425.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 4-Total | 5991.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 14104.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 9633 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 4-Total | 10455.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 13181 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 9129.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 4-Total | 9651.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 15229.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 13900.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total | 12836.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 14726.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 13072.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total | 12901.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1104.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1527.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total | 1363.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1957.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 3182.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total | 2059.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total | 21542 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 4850.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 4372 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 4-Total | 5495.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 3371 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 2740.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 4-Total | 3923.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 11690 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 14451 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 4-Total | 16602.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 12419.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 14352.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 4-Total | 15638.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 4186.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 4196.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 4-Total | 5180.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 4748.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 4-Total | 4952.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 0-Total | 7577.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 2-Total | 2409.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 4-Total | 958.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 0-Total | 2841.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 2-Total | 1164.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 4-Total | 517.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total | 13088.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total | 2949.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total | 515.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total | 7330.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total | 1769.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total | 531.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total | 8441.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total | 2361 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total | 987.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total | 2650.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total | 857 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total | 329.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 0-Total | 6567 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 2-Total | 1913.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 4-Total | 795.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 0-Total | 2149.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 2-Total | 776.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 4-Total | 400.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total | 6797.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total | 2753.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total | 1046.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total | 3834.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total | 1542 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total | 577.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total | 1493.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total | 355 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total | 171 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 4-Total | 1001.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total | 1177.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total | 1396.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 4-Total | 16491.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total | 1917.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total | 12901.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total | 3143.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total | 454.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total | 21215.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 12258.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total | 1192 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 5522.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total | 383.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total | 1148.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 14201.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 4-Total | 10725.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 9817.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total | 2397.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 0-Total | 14683.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 4-Total | 16153.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total | 1572.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total | 8630.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 0-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 4-Total | 6274 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 15612.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 4116.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total | 189.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 4-Total | 4980 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total | 427.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 4790.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 4069.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 4-Total | 9645.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total | 1746.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 2-Total | 10664.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total | 2573.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 4801.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 4-Total | 2265 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 4-Total | 5197.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 13072.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total | 8591 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total | 684.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 4318.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 13900.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 4-Total | 4763.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total | 10636 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 5609 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total | 3634 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total | 9365.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 2-Total | 2440.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1645.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total | 6667.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total | 17197.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 2-Total | 1388.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 9108.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 4692.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total | 3231.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total | 1411 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 4-Total | 429 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total | 5994.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 2-Total | 995.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 4358.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 4-Total | 648.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 0-Total | 4012 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1088.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 4-Total | 1157.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 4-Total | 5584.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 0-Total | 3311.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total | 2238.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 14305.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 3816.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total | 14063.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 2-Total | 6829.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 2-Total | 2054.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 14590.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total | 4569.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 3377.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total | 5145 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 0-Total | 7419.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 4-Total | 6451.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total | 7176 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 4-Total | 4078 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 2238.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total | 369.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 11552.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1478.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 0-Total | 8402.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total | 12836.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 13155.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 5078.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total | 619.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 14572.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 3808.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 4986.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total | 883.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total | 5303.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total | 793.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total | 3484 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total | 3930.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total | 985.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total | 7429.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 4-Total | 16491.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1120.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 2-Total | 9271.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total | 21072.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 2-Total | 1574.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 13272.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 0-Total | 6269.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 5418.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 4-Total | 8857.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 14590.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 11313 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 4374.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 2-Total | 1464.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total | 884.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total | 828.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total | 13838 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 11154.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 8861.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 4-Total | 771.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 13960.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total | 688.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 5022.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total | 1742.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total | 1552.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total | 379.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total | 275.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total | 2753.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 3904.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total | 12621.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 4-Total | 16189.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 0-Total | 16814.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1820 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total | 8091.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total | 8793 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total | 13531.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 4-Total | 6289 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 2-Total | 1748.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 0-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1452.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 4-Total | 3660 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 4630 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 4139.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total | 1301 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 0-Total | 4669.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total | 515.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1323 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 4-Total | 870.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total | 3119.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total | 1726.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 4-Total | 10725.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 0-Total | 4992 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 4187.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total | 7229 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 14208.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 4-Total | 6235.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total | 1984 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 2-Total | 7601 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 16171.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 5268.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 0-Total | 4395.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 12737 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 4-Total | 5370.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 4-Total | 5014.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 4-Total | 796.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 15373.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total | 11080.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 11441.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 22000 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 4-Total | 5359.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total | 520.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 14715 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total | 5896.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total | 3469.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 3843 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 2-Total | 2390.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 4-Total | 5343.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 4-Total | 718 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total | 12048.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total | 2042.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total | 14039.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 5818.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total | 3983.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 4-Total | 3382.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total | 3486.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 3227.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 4-Total | 4158 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total | 11886.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total | 1559.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 4-Total | 638.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 4-Total | 4119.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 13385.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 16454 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 4-Total | 2125.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 0-Total | 5736.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 0-Total | 9277.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 2-Total | 1520.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 2-Total | 2033 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 0-Total | 3328.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 2-Total | 8553.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 4-Total | 969 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1741.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 12464.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total | 99.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total | 12836.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total | 3991.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total | 945.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 4-Total | 10408.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total | 2510.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total | 2286 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 22000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1273.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total | 11599 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total | 5731 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total | 20669.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1393.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 4-Total | 392 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 9652.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 4383.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 2-Total | 979.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 4112.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total | 14620.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total | 7004 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 0-Total | 3026.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 14013.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 4-Total | 5373 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 4-Total | 775.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 3781.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 14854.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total | 2599.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 2-Total | 1646.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total | 13150 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 4-Total | 4989 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 3206.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 0-Total | 5146.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total | 8293.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 4-Total | 4047 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total | 5216.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total | 459.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1430 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 11934.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total | 1545.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total | 313.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total | 1470.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 4654.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 14500.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total | 2550.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 4-Total | 16381 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total | 986.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total | 5444.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 5256 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total | 707.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 10177 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 8364.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total | 889.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total | 2000 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 13571.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total | 371.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 14306 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 4-Total | 6334.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total | 5885.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 4-Total | 16206 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 0-Total | 21664.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 4232 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total | 398.9 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total | 1171.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 4-Total | 9061.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 4389.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 5279 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total | 11964.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 4-Total | 5172.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 2-Total | 8898.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total | 530.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 3117.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total | 2276.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 5574.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 4-Total | 7908 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total | 1562.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 127.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 9246 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 762.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total | 717.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 22000 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 10571.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22000 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total | 22000 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 4-Total | 10458.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 21957 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 22000 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 9613.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total | 2875 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total | 19283 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 4653.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 4050.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 14355 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 4-Total | 5055.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 3517.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 4-Total | 6878 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total | 7503.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 3692.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 4-Total | 5655.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 5982 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total | 1242 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 12039.9 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 14500.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 4-Total | 16491.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 5786.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 11280.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total | 1651 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 13393.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 4-Total | 6275 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 4-Total | 15900.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 4132 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 4890.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total | 258.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 4231.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 4-Total | 5074.1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 5444.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 4143.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 4783 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 4-Total | 6604 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 4-Total | 8224.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 0-Total | 4846.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 2-Total | 1626.9 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 2-Total | 12426.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 4-Total | 691 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 0-Total | 10169.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 0-Total | 22000 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 2-Total | 2760.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 4-Total | 1931.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total | 11614.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 4-Total | 3196.9 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total | 8441 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total | 2042.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total | 471.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 2-Total | 7601 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total | 18448.9 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total | 4889.4 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 0-Total | 20217 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total | 962.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total | 4892.4 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total | 12577.9 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total | 1595.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total | 636.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total | 665.9 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total | 6608.9 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total | 2944.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total | 4557 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total | 2427 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total | 1859.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 0-Total | 4258.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 2-Total | 1455.4 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total | 7803.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 4-Total | 597.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 0-Total | 9263.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total | 11160.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 2-Total | 4179.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 4-Total | 1766.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total | 19488.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total | 5030.1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total | 2272.1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total | 884.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total | 3081.1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total | 13915 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 13674.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 12192.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 11415.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total | 8077.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 15364.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total | 9464 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1356.9 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1897 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total | 2880.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 5511.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total | 2578.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 4958 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total | 2025.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 5766.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 10813 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total | 562.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 2-Total | 9065.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 4-Total | 5068.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total | 358.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total | 5702.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 4187.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 5057.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total | 1078.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 0-Total | 21972.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 3974.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 15128.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total | 416.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total | 14418.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 4-Total | 17928.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total | 685.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total | 7081 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 4-Total | 6289 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 15355.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 3515 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total | 1984 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 13838.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 9662.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total | 852 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total | 1003.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1664.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 4-Total | 16171.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 5288 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total | 12795.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total | 2706 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 14233.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total | 1153 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total | 5490.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 11325 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 4939.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total | 444.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 4-Total | 6419.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 3929.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 0-Total | 5061.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total | 2206.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total | 361.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 4-Total | 5978.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 2-Total | 1571.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 4487.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total | 8299.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1949 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 4-Total | 752.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 4-Total | 5228.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 0-Total | 3529.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total | 5687 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 4-Total | 12775.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 4042.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 14162.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1242.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 2-Total | 1180.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 4315 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total | 1364.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 4-Total | 425.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total | 12534.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total | 22000 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 9574.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total | 5896.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 22000 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total | 2573.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total | 3935.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 22000 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 4-Total | 9838 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total | 1004.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total | 3761 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total | 21464.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22000 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total | 12878 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 13636.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 22000 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total | 1335.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 13531.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 4-Total | 870.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total | 152.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 2-Total | 4956.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 11550.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 0-Total | 4199 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 0-Total | 13720.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 2-Total | 1742.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 2-Total | 1211.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 0-Total | 5605.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 4-Total | 6917.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 4-Total | 509.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 4-Total | 3695.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 4-Total | 2586.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total | 13518.9 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total | 7081 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 14537.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 4-Total | 5267.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 12258.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total | 13440.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total | 12795.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total | 2174 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total | 5190.6 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 13289.4 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total | 1123 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 5106.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1830.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total | 1552.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total | 1209 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 4-Total | 4933.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 9195.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 3819.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 22000 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 0-Total | 4639.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total | 5903.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total | 7492.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 4810.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 3514.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 14860.1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 2-Total | 1464.6 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1010.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total | 1046 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 4-Total | 6014.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 4-Total | 764.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 4-Total | 1160.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 4-Total | 683.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 4-Total | 5383.4 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total | 9950.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 0-Total | 7261 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 4042.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total | 3353.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 4-Total | 3414.9 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 14355 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total | 12524.4 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 0-Total | 4847.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 2-Total | 2153.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 4788.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 0-Total | 22000 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1319.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 4-Total | 1073 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total | 15897.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 11759.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total | 21188.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 2-Total | 1655.6 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 4-Total | 4913.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 9677.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total | 299.4 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 3533.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total | 7128.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 2-Total | 11437.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total | 2235.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total | 4911.9 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 2-Total | 7577 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 5536.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 22000 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total | 497.9 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 16129.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total | 4045.6 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 4-Total | 5076.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 21481.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total | 10451.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 4086.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 4936.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total | 1912.4 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total | 2712.6 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 0-Total | 20312 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 15053.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total | 12974.4 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 4412.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total | 3145.1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total | 573.9 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total | 1212.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 2-Total | 2616.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 4-Total | 16009.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total | 22000 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total | 5452.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 4-Total | 10489 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1267.1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 13876.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 4-Total | 6439.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total | 876 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total | 1653.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total | 805.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total | 324 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 9958.9 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 0-Total | 5408.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 4-Total | 10148.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total | 651 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 4-Total | 16547.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22000 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 5449.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 4-Total | 834.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 0-Total | 2931.9 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 5284.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 14315.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 0-Total | 5783 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 8986 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 2-Total | 7791 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 11577 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 4-Total | 3382.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 4471.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 2-Total | 1928.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 4-Total | 442 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 2-Total | 1835.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 4-Total | 6282.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 4-Total | 12878 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 4-Total | 12795.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 5174.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 2-Total | 2188.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 4-Total | 16867 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 4-Total | 5759.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 2-Total | 8894.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 2-Total | 979 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 0-Total | 5892.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-Y at Month 4-Total | 636.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 22000 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 22000 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 4693.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 13599 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 3929.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 5775.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 2-Total | 2056.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1741.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-N at Month 4-Total | 328 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 2-Total | 7388.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 0-Total | 5023.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 4-Total | 3783 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 4-Total | 21464.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 4-Total | 554 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 4-Total | 2445.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 4-Total | 259.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 4487.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1864.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1727.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 4-Total | 4994.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 4-Total | 10458.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 2-Total | 1557.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 12831.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 13531.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 4-Total | 845.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 9798 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 22000 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 4-Total | 6198 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 4-Total | 5277.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 12770.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000-N at Month 0-Total | 7897.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 4-Total | 893.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-N at Month 4-Total | 741.9 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 0-Total | 10848.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 2-Total | 8293.9 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 4086.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 2-Total | 437.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-Y at Month 0-Total | 13720.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 2-Total | 2411.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 4042.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-Y at Month 0-Total | 5030.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 4-Total | 789.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 4-Total | 16171.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 0-Total | 3837.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 0-Total | 13901.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 4-Total | 3660 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-1000-N at Month 0-Total | 22000 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 2-Total | 1712 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000-Y at Month 0-Total | 2676.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 4-Total | 8486.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 11550.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 14499.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 15128.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 4-Total | 1335.9 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 2-Total | 1527 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 14321.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 4315 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-Y at Month 0-Total | 14175.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 5194 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-Y at Month 0-Total | 4638.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-Y at Month 2-Total | 3296.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 4-Total | 22000 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-1000-N at Month 0-Total | 5630.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000-N at Month 0-Total | 12249.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 2-Total | 2470 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-1000-Y at Month 4-Total | 607.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22000 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 4-Total | 7069.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1261.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 4099.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000-N at Month 4-Total | 945.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000-N at Month 4-Total | 3495.2 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Time frame: Measured at Months 0, 2, 4
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 363.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 99.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 375.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 14002.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 228 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 839.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 325.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 402 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 290.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 2430 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 4511.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 10239.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 1456.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 2497.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 21718.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1328.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 18483.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 1159.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 3326.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 3843 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 9754 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 4-Total | 3976.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 11577 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 15942.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 4100.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 12434.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 4-Total | 16414.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 3364.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 4004.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 5989.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 11218.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 4-Total | 3639.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1370.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 1172.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 4701.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 676.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 10870.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 1591.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 2149 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 614.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 218.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 4-Total | 5162.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 838.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 44.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 434.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 292 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 837.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 14045 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 2124.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 4-Total | 6192.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 3808 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 879.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 1910.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 4-Total | 4933.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 3224.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 6736.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 383.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 465 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 14944.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 2031.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 9447.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 3872.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 4-Total | 16559.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 9586.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 472 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 1196 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 1496.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 5351.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 11935.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 3835.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 4057.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 710.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 4487.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 4798 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 2203.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 1093.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 10463.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 12831.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 15650.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 526.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 436.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 5993.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 4138.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 2032.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 165 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1990.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1890.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 3318.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 4-Total | 4952.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 12646.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 13201.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 10582 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 16653.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 21513.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 15596.3 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 4-Total | 8425.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 5480.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 5927.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 7015.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 3360.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 4-Total | 7185.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 14461.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 6201.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 10709.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1430 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 16062.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 583.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 4-Total | 17690.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 18108.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 1442.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 3836.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 6758.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 6048 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 1634.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 4-Total | 6118 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 13555.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 11755.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 3926.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 13049.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 5595.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 1493.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 10200 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 18253.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 6103.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 16940.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 7099.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 5149 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 1147 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 21026.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 11397 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 1479.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 787.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 7490.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 20677.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 15170.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 21644.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1411 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 4634.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1123 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 19418 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 11395.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 7487.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 5405.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 4-Total | 7296.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 13857.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 21907.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 5309.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 4881.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 4-Total | 6354.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 12869.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 13088.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 4-Total | 15559.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 4979.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 4726.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 4-Total | 7069.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 20453.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 5809 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 2783 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 6099.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 1442.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 15429.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 6504.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 2848 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 20747.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 5654.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 2603.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 15822 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 6823.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 3203.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 17261.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 11311.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 22000 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 4301 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 1914.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 8577.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 9325.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 17008.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 16030 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 16039.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 128.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 863 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 18275.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 3884.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 4875 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 10321.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 3229.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 14558.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 801.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 4573.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 4-Total | 6106.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 1798.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 16037.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 3621 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 5567.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 6796.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 4720 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 15945.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 4-Total | 6074.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 9645.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 4209.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 3653.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 4-Total | 15900.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 196 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 14307.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 11879.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 10772.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 4-Total | 5575.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 5035.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 14744.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 3902.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 3714.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 13465.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 12057.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 947.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 17681.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 22000 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 4619.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 8218.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 15764.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 11779.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 14078.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 3391.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 4787.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 384.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 15796.8 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by BAMA IgG1 at Visit 1, 2, 3, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Time frame: Measured at Months 0, 2, 4
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 11484.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1310.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 2241 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 2414.3 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 22000 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 22000 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 5172.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 4731.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 5544.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 2156 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 5759.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 6586 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 4-Total | 5714 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 18341.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 13942 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 11015.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 18176.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 17001.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 16352.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 4-Total | 5317.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 14352.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 16886.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 4-Total | 16381 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 5351.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 6109.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 4-Total | 4053.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 3903.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 1660.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 463.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 2736.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 808.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 321.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 2008.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 1337.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 511.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 3073.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 1460.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 427 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 3146.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 1136.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 701 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 9507.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 4872.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 2363.7 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 1747 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 415.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 96.3 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 9341 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 4108.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 6349 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 7604.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 19343.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 4069.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 4175 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 512 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 2766.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 4-Total | 5068.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 14720.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 1627 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 2169.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 8110.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 5035.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 9659.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 7105 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 2814.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 4688 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 760.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 9217.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 1509.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 15357.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 2651.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 16950.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 13506.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 4770.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 14488 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 11097.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 2109.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 1863.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 4-Total | 5189.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 1459.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 2099.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 12258.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 9134.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 12005 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 4-Total | 6275.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 15328.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 22000 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1363.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1799.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 4-Total | 15586.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 5076 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1197.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1315.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 5212.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 4-Total | 6810.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 7640.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 13943.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 8646.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 332 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 10458.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 16978.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 2739.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 13674.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 11621.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 4-Total | 5507.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 10779.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 1144.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 14236.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 4-Total | 16318.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 685.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 4605 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 4491.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 14710.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 4-Total | 5437 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 6366.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 1729.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 1116.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 8247.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 13011.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 2231.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 509.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 9512.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 3783 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 1999.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 834.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1319.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 5603.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1653.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 1499 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 20646.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 4923.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 8313.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 4311.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 22000 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 9271.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 741.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 3660 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 5897.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 4055.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 3927.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 4-Total | 16580.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 9715.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1318.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 4-Total | 3067.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 4-Total | 923.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 0-Total | 14553.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1478.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 0-Total | 3894.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 13644.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 0-Total | 3940.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 4-Total | 1513.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 11885.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 4-Total | 5373 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 0-Total | 5985 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 21808.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 4-Total | 12100.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-1000 at Month 2-Total | 2470 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 12162.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 21969 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 4-Total | 771.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 12047.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-1000 at Month 2-Total | 8335.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 4-Total | 20511.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-1000 at Month 2-Total | 1481.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 14320 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 0-Total | 12524.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 2-Total | 7916.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 4-Total | 853.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 4738.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 2-Total | 2878 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 4-Total | 279.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 2-Total | 1609 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 4291.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-1000 at Month 4-Total | 556.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-1000 at Month 2-Total | 872.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-1000 at Month 0-Total | 4628.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 4-Total | 6235.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 0-Total | 3997.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 4-Total | 10425.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 0-Total | 13203.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 5698 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 2-Total | 1759.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-1000 at Month 4-Total | 2925.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 4-Total | 5267.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 3500.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-1000 at Month 4-Total | 636.5 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 1770.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 123.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 778.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 41.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 131.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 219.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 207 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 5257.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3302.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 719.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 3164 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 2095.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 5043.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 4718.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 657.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 1840 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 983.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 7626.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1957.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 8735.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 250.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 75 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 4900 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 846 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 295.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 1930 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 441.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 116.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 394.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 43.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 12.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 923 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 769.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 312 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 6368 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6714.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 154.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 167.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 397.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 164.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 2803.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 519.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 668.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 2900.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 13.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 389.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 152.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 2880 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1804 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 2071.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 3715.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 396.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3307 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 123 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6505.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 274.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 112.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 1917.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 523.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 11.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 346.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 1957.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 480.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 2824.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 1748.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 662 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 8827 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 4366.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 4662.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 8549.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 5013.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 349.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 186.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 175.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 224.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 2.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 193.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 17.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 200.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 228.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1623.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 252.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 7312.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 1827 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 6335.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 7812.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 349 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 1404.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 207.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 1617.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 2698.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 441.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 650.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 267.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1828.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 4119.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 1827 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 3630 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 1047.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 2512.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 2865.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 3931.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 131.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 7395.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 150.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 203.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 156.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 514.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 218.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 1326.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 277.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 846 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 12.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 370.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 251.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 8445.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 8681.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2177 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 7626.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 259.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 603.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1870.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 616 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 73.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6657.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 205.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 1739.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 2048 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 764 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 422 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3146.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 151.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 4.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 476 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 4645 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 650.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3467.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 967 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 143.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 1346.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 59.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 227.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 1917.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 10 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 160.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 2.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 24 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 150.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1163.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 136.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 825.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 1963.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 781.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 1781 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 441.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 410.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 1366.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 246.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 414.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 7.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 4753 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 1910 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 3896 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2177 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 809.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 371 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3002.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3467.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 115.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 220.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 179.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 5487.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 200.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 1502.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 603 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 1404.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 233.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 2177 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 8765.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 203.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1960.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 5013.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 133.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 6568.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 7043.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 246.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 3243.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6717.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 450.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1392.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 2.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 341.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 258.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 7569.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 4254.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 346.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 7683 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 202.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 4.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 177.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 1634.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 158.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 8.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 127 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 208.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 2080 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 251.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 3017.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 171.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1563.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 277.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 7366.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 8713.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 6175.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 4781.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 1506 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 4119.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6796.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 1787.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 2556 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 1670.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1954.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 8258.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 219.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 359 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 634 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 221 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 161.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2071.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 489.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 267.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 441.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 419.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 5.6 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 581 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 164.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 610.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 616 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3240 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 432.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1649.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 18.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3079.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 4964.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 2048 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 4330.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 1731 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 220.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 235.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 519.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2211 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 419.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 241.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 957 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 2815.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 4522.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 475.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 150 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 22.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 35.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 337.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 686.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 192.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 3503.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1754.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 1815.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 6524.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 7442 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3467.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 8805.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 174 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 1617.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 8430.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 581 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 514.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1936.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 158.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 252.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 208.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1859.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 23.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 2733.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 217.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6335.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 7369.9 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 5260.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 207.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 4504.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 1482.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 130 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 1827 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 595 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 2839.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 1801.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 1184 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 204 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 219.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 170 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 146.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 138.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1617 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 419.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 7378.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 1827 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 7799 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 924.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 340.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 610.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1859.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 6527 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 4609 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2385.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 2890 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 603.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6576.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 5381.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3472.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 192.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 13.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 8650 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 1034.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 1888.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 205.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 1670.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 489.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 4368.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 8172 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 2048 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 3506 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 1047 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 581.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3146.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 252.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 369 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 164.5 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 478.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 150 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 492.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 10.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 513.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1365.8 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 167.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 4254.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 159.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 4505 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 15769.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 1757.4 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 1891 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 6569.9 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 224.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 246.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 10.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 205.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 2579.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 480.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 369 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 2437.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 1542.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3002.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 771.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 1672.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 63 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 352.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 490.9 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 5847.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 985.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3838.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 186.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 1506 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 7378.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 9506.1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 7990.9 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 4964.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 214.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 2222.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 2906.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 629.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1737.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 303 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 191.6 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 521.2 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 245.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2739 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 13.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 4350 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 2177 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 142.8 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 333 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 1200.5 MFI |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 8540.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 15.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1859.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2192.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 1478.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 382.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 222.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 1703.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 1184.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 4657.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 861.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6703 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 2007.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 7790.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 5317.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 9101.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3273.6 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 576.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 5.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 218.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 138.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 9.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 284.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 201.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 160.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 371.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 681.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 193 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 4645 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 1979 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 5613.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 345.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 376.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 225 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3193.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 644.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1446 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 651.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 2308.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 603.1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 2839.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 3914.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 5506.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 4311.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 14 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 552.9 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 405.8 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 448.5 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1696.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 211.2 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 1866.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 213.4 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 26 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 170.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 595 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 844 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 303 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 2880 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 500.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1738.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 133.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 395.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 157.9 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 161.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 11.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 1859.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 241.4 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 121.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 2733.1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 2852.4 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1960.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 202.4 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 8827 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 581 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 4119.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 352.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 4549.4 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 1917.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6254.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 5013.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 246 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 2183 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1788 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 7442 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 156 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 6800 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 205.1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 202.6 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 21.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 354.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 1404.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2254.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3562 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 427.8 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 1781.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 7179.2 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 476 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 4473 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 8273.5 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 1590.4 MFI |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 690.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 130.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 1848.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 2-Total | 29.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 6703 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 4650.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 2-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 1117.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 9262.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-Y at Month 0-Total | 158.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 2-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | OC43-RBD-50-N at Month 0-Total | 145.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 1836.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 5919 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 0-Total | 296.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 1358.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 6101.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 2-Total | 222.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 2-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-Y at Month 0-Total | 618.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 592.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 1660.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-N at Month 0-Total | 195.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 1833.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 2-Total | 62 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 2-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 1610.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 666.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-N at Month 0-Total | 183.9 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 2209.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 3945 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 5585.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 7941.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 898.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 3327.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 1840 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 0-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 2-Total | 293.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 442.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 2-Total | 158.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-N at Month 0-Total | 233.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-N at Month 0-Total | 377.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 2941.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | NL63-RBD-50-Y at Month 2-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-N at Month 0-Total | 12.1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-Y at Month 2-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 2-Total | 10.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 873.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 321.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 2-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50-Y at Month 0-Total | 354.4 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 1982.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HKU1-RBD-50-Y at Month 0-Total | 212.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 4187 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 6517.8 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 1797.5 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50-N at Month 0-Total | 464.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 2698.6 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-229E S1S2 ECD His-50-Y at Month 0-Total | 5.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 3074.2 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50-N at Month 0-Total | 1 MFI |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Comorbidity Group Among America Cohort | 229E-RBD-50-Y at Month 0-Total | 293 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point.SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 466.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2365.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 430.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3573.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 122.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 542.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 802.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 549 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 131 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 15.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 6799.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 4270.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 2.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 8.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 430.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 7.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 4162.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 102.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 32 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 2129 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 421.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 3858.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 61.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 388.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 326.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 562.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 2775.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 191.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 268.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 626.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 551 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 66.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 189.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 196.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 9.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 3914.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 10.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 611.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1235.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 1729.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 6037.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1596.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 1814.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 222.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 6125 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 234.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 5366.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 1394.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 111.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 2217.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 1472.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 235.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 3986.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 151.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 29.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 178.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 215.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 459.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 1699.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 7290.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 2566.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 3562.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 781.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 3141.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 5835.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 2597 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 143 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 7.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 328.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 142.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 424.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 132.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 206.6 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 122.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 1848.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 494.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 8722.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 726.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1634.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 241.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 1690.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 903 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 691.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 198 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 7721.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 13805.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 681.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 329 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2640.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 15804.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 2358.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 8685.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 1168.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 4180.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 275.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3720.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 485.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 997.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 3532.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 11878.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 97.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 5121.6 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 250.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 4453.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 518.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 383 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 1713 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 0-Total | 195.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 966.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 15218.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 0-Total | 154.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 229E-RBD-50 at Month 0-Total | 374 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3562 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 3818.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 10388.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 655.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 5454 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 4152.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 11790.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2402.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 1200.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 3132.5 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 7397.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 4158.9 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 131 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 8445.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 371.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 562.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and COVID-19 Severity Among America Cohort | HKU1-RBD-50 at Month 0-Total | 270.8 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 22.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3674 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 343 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 47 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 61.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 630.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 321 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 406.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 5275.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 679 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 577.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 217 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 204 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 215.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 152.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 218.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 50.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 1962.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 1393.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 6657.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1482.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1908.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 790 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 1233.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 1479.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 7638.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 2903.8 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 4576.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2345.2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 1529 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 1487.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 192.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 157.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1739.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 5373.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 414.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 2162.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 32.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 2412.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2048 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 8643.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 406.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 11.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 603.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 3675.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 182.6 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 5407.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 296.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 210.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 192.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 273.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 519.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 2815.5 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 2218.9 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 9566.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 7354.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 2504.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 7286.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 380.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 201.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 3503.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 200.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 145.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 4580.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 1581.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 171.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 7041 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 2270 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 1415.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1538 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 210.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 207.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 6335.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 1935.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 1769.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 242.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 15.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 290.5 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 302.8 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 63 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 0-Total | 555.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 662 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 6180.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4610 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | NL63-RBD-50 at Month 0-Total | 193.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3562 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-NL63 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 0-Total | 230.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 1702.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HKU1-RBD-50 at Month 0-Total | 195.9 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 2-Total | 306.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 229E-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 205.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 4309.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 2839.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 7569.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 1700 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-OC43 S1S2 ECD His-50 at Month 2-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1330.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His-50 at Month 0-Total | 557.2 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | OC43-RBD-50 at Month 0-Total | 124 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | HCoV-229E S1S2 ECD His-50 at Month 0-Total | 1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 1670.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 2385.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 844 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 8632.8 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 565 MFI |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and comorbidity group among Africa Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-non-RSA | 179.1 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-RSA | 191.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-Total | 66.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-non-RSA | 507.9 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-RSA | 361.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-non-RSA | 185.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-RSA | 310.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-Total | 1254.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-non-RSA | 2587.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-non-RSA | 31.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-Total | 259.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-RSA | 42 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-RSA | 147.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-Total | 147.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-RSA | 57.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-RSA | 90.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-non-RSA | 23.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-RSA | 320.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-RSA | 82.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-non-RSA | 310.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-Total | 36.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-non-RSA | 43.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-non-RSA | 66.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-RSA | 492.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-RSA | 378.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-Total | 139.5 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-RSA | 546.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-non-RSA | 144.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-RSA | 106.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-Total | 295.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-Total | 474.5 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-non-RSA | 63 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-non-RSA | 92 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-RSA | 1742.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-Total | 129.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-RSA | 161.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-Total | 79.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-non-RSA | 47.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-Total | 120.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-non-RSA | 9114.5 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-non-RSA | 636.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-Total | 39.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-Total | 2196 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-Total | 309.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-non-RSA | 232.5 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-Total | 394.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-RSA | 1246.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-Total | 694.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-non-RSA | 221.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-RSA | 271.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-Total | 34.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-Total | 971.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-Total | 57.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-non-RSA | 396.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-non-RSA | 43.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-non-RSA | 22.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-RSA | 267.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-RSA | 1425.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-Total | 309.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-non-RSA | 636.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-Total | 177.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-RSA | 148.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-Total | 848.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-Total | 116.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-RSA | 169.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-non-RSA | 56.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-RSA | 275.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-RSA | 83.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-Total | 235 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-non-RSA | 163 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-RSA | 424.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-Total | 1145.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-non-RSA | 205.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-Total | 142.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-RSA | 1106.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-non-RSA | 1632.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-RSA | 39.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-RSA | 6407.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-non-RSA | 146.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-non-RSA | 872 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-Total | 3743.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-Total | 253.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-non-RSA | 552.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-Total | 424.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-RSA | 142.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-RSA | 657.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-RSA | 2077.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-Total | 657.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-RSA | 62.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-non-RSA | 767.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-non-RSA | 45.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-Total | 58.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-non-RSA | 238.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-Total | 227.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-RSA | 345.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-non-RSA | 179.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-RSA | 198.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-Total | 98.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-RSA | 174.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-Total | 37.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-non-RSA | 103.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-non-RSA | 329.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-non-RSA | 10.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-non-RSA | 636.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-non-RSA | 484.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-RSA | 2629.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-Total | 34.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-RSA | 366.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-Total | 2598.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-Total | 224 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-RSA | 1582.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-non-RSA | 2567.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-Total | 361.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-RSA | 46.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-non-RSA | 52.9 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-RSA | 35.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-Total | 66 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-Total | 42.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-non-RSA | 25.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-RSA | 146.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-RSA | 576.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-RSA | 392.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-Total | 104.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-non-RSA | 50.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-RSA | 100.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-Total | 84.6 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-non-RSA | 28.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-RSA | 93.6 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-non-RSA | 25.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-non-RSA | 7.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-RSA | 337.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-non-RSA | 71.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-Total | 155.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-RSA | 41.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-Total | 830.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-Total | 530.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-Total | 280.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-non-RSA | 50.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-non-RSA | 214.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-Total | 29.9 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-non-RSA | 179.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-Total | 154.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-RSA | 102.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-RSA | 43.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-Total | 689.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-non-RSA | 173.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-non-RSA | 22.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-RSA | 689.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-Total | 830.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-Total | 55.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-Total | 528.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-non-RSA | 705.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-non-RSA | 43.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-non-RSA | 53 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-non-RSA | 602.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-non-RSA | 53.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-RSA | 308 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-Total | 55.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-RSA | 390.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-RSA | 5164.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-RSA | 81.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-RSA | 37.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-non-RSA | 153.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-RSA | 61.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-Total | 1022.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-RSA | 123.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-Total | 4233.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-RSA | 136.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-RSA | 1496.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-non-RSA | 163 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-non-RSA | 43.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-non-RSA | 3155.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-Total | 99.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-RSA | 109.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-RSA | 181.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-Total | 236.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-Total | 181.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-Total | 224 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-non-RSA | 445.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-non-RSA | 211.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-Total | 250.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-RSA | 278.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-non-RSA | 202.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-non-RSA | 728 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-Total | 307 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-RSA | 1076.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-non-RSA | 174.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-Total | 87.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-Total | 137.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-Total | 33.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-RSA | 292.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-RSA | 528.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-RSA | 165.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-RSA | 134.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-non-RSA | 25.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-RSA | 62.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-Total | 366.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-non-RSA | 329.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-RSA | 416.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-RSA | 2820.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-non-RSA | 702.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-RSA | 246.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-Total | 1755.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-Total | 155.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-RSA | 446.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-non-RSA | 80 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-Total | 299.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-non-RSA | 188.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-Total | 199.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-RSA | 227.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-non-RSA | 10 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-RSA | 284.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-Total | 247.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-non-RSA | 237.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-non-RSA | 48.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-Total | 120.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-Total | 165.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-RSA | 100.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-non-RSA | 145.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-non-RSA | 95.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-Total | 100.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-Total | 508.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-RSA | 794.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-RSA | 75.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-non-RSA | 190.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-Total | 38.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-RSA | 118.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-Total | 96.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-non-RSA | 48.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-Total | 47.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-RSA | 52.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-Total | 62.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-non-RSA | 10 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-non-RSA | 65.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-RSA | 34.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-non-RSA | 10 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-Total | 33.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-Total | 38.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-RSA | 38.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-non-RSA | 36.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-Total | 63.9 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-RSA | 694.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-Total | 407 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-non-RSA | 49.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-non-RSA | 64 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-Total | 93 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-non-RSA | 171.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-RSA | 31.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-non-RSA | 10 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 0-RSA | 98.2 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-non-RSA | 59.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-Total | 104.4 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 4-RSA | 104.4 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-Total | 72.9 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-non-RSA | 243.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-non-RSA | 10 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-Total | 351.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-RSA | 26.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-Total | 246.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 12-RSA | 396.8 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-RSA | 186.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-non-RSA | 174.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 12-RSA | 88.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 0-Total | 186.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-non-RSA | 188.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-Total | 276.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-non-RSA | 24.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-non-RSA | 43.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 2-Total | 26.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-non-RSA | 63 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 4-RSA | 356.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-Total | 150.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-Total | 1577.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 2-RSA | 208 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-non-RSA | 681.2 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 12-RSA | 2369.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-RSA | 362.2 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-Y at Month 2-RSA | 72.9 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 4-Total | 31.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-RSA | 49.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-Y at Month 0-Total | 49.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-non-RSA | 45.4 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-Total | 86.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-Total | 37.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 4-RSA | 113.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 2-RSA | 61.4 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID80-N at Month 12-non-RSA | 187.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-ID50-N at Month 0-non-RSA | 276 Titer |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3,4, overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-USA | 30.00 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Total | 126.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-Total | 73.50 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-USA | 49.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Peru | 209.0 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-USA | 54.00 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-USA | 263.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-USA | 157.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-USA | 88.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-Total | 322.1 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-Total | 104.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Peru | 822.9 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Total | 83.90 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-USA | 241.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-USA | 267.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Peru | 57.40 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Total | 38.40 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-Peru | 55.70 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Total | 493.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-Peru | 151.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-Total | 94.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Total | 38.60 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-USA | 92.50 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-Total | 30.60 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Peru | 968.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-USA | 197.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-Total | 232.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Total | 134.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-USA | 122.9 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Peru | 31.50 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-USA | 322.1 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-Total | 281.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-Peru | 104.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-USA | 94.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-USA | 96.10 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-Peru | 289.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Total | 133.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-USA | 56.00 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-USA | 30.60 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Peru | 214.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Peru | 196.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Total | 216.0 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Peru | 95.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-Total | 122.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Peru | 311.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-USA | 232.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-USA | 164.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-USA | 281.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Peru | 1087 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Total | 443.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-Peru | 55.70 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-Total | 281.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-USA | 318.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-USA | 58.80 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-USA | 73.50 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-USA | 71.70 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-USA | 48.00 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-USA | 111.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-Total | 318.0 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-Total | 73.50 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-Total | 62.60 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Total | 112.0 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Total | 222.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-USA | 88.30 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-USA | 190.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Peru | 739.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-Total | 116.0 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Total | 35.40 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Total | 1196 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Peru | 848.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-USA | 120.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Total | 367.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Peru | 39.80 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-USA | 346.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Peru | 152.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-USA | 30.00 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-Peru | 289.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-Peru | 104.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-Peru | 151.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-Total | 187.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-Total | 111.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-USA | 220.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Peru | 3196 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Total | 104.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Total | 105.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-USA | 608.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-Total | 232.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Peru | 183.0 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Peru | 152.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-USA | 55.70 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-Peru | 55.70 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Total | 105.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-USA | 30.00 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-Total | 281.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-USA | 55.20 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Total | 70.80 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-USA | 99.40 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-USA | 52.40 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-USA | 253.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-Peru | 289.6 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-Peru | 151.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Total | 126.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-USA | 157.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Peru | 222.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Peru | 447.6 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Peru | 522.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Peru | 994.9 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-USA | 169.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Peru | 127.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-USA | 80.70 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-Total | 68.10 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Total | 35.50 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-USA | 263.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Total | 475.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Peru | 147.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Peru | 39.80 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-Total | 209.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-USA | 238.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-USA | 88.30 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Total | 81.50 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Total | 201.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-Peru | 104.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-Total | 104.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Total | 347.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-USA | 52.60 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-USA | 462.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-USA | 22.80 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-Peru | 55.70 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-USA | 126.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-USA | 48.00 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-USA | 187.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-USA | 190.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-USA | 59.40 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-USA | 116.0 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Peru | 961.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-Total | 204.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Total | 410.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-USA | 117.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Peru | 186.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-Peru | 289.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-Total | 169.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Peru | 1141 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Total | 594.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-Total | 281.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-USA | 281.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Peru | 198.0 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Total | 176.0 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-USA | 167.0 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-Total | 314.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-USA | 314.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Peru | 211.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Total | 96.20 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Total | 107.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-Peru | 151.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-Peru | 104.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-Total | 75.50 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Peru | 54.60 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-USA | 44.10 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Total | 33.50 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Peru | 354.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Total | 143.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-Total | 59.20 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-Total | 111.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-USA | 62.60 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-USA | 111.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Peru | 58.60 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Total | 52.60 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-Total | 116.0 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Total | 104.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-USA | 30.00 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-USA | 226.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-USA | 253.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-Total | 45.10 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-USA | 80.70 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-Total | 239.0 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-Total | 80.40 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Peru | 65.00 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Total | 147.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-Peru | 259.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Peru | 983.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-USA | 89.00 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-Peru | 13.70 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-USA | 125.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-Total | 49.90 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-USA | 38.60 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-Peru | 92.70 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-Total | 120.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Peru | 26.60 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-USA | 25.80 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-USA | 116.0 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-Peru | 46.40 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-USA | 238.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-Peru | 60.30 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Total | 34.80 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Total | 96.20 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-USA | 100.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-Total | 134.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Total | 41.60 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-USA | 52.00 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Peru | 86.20 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-USA | 318.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-USA | 314.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-Peru | 239.0 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Peru | 143.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-Total | 346.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-Peru | 866.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-USA | 75.30 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Peru | 609.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Peru | 225.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-USA | 88.30 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Total | 336.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Total | 160.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-Peru | 80.40 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-Total | 91.50 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Peru | 213.0 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Total | 618.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-USA | 31.40 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Peru | 197.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-Total | 245.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-Total | 30.60 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Total | 134.2 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Total | 133.2 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-Peru | 196.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-Peru | 151.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-USA | 80.40 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-Peru | 289.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Peru | 15.50 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-Peru | 104.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-Total | 245.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Total | 522.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 12-Total | 87.30 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-Peru | 978.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Peru | 57.40 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 2-Total | 38.40 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-USA | 67.00 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-Total | 47.60 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Peru | 54.70 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 12-USA | 239.0 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 0-USA | 256.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-USA | 157.2 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-Total | 34.60 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-Peru | 55.70 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 4-USA | 30.60 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-USA | 94.30 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-Total | 80.70 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 2-USA | 91.20 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-N at Month 4-USA | 314.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 2-USA | 49.90 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-USA | 121.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-Total | 135.0 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 12-USA | 135.0 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-Y at Month 0-USA | 32.50 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Total | 122.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 4-Total | 94.30 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 2-Peru | 39.90 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-USA | 346.9 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 4-USA | 116.0 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 12-Total | 346.9 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID50-Y at Month 0-Total | 125.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-ID80-N at Month 0-Peru | 222.7 Titer |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and COVID-19 severity among Africa Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 148.5 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 203.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 51.90 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 1160 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 183.5 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 68.40 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 86.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 34.00 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 22.70 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 189.0 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 31.70 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 381.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 74.20 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 36.50 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 161.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 122.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 27.10 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 374.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 42.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 40.40 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 42.50 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 130.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 559.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 10.00 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 43.10 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 344.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 327.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 265.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 2543 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 997.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 478.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 165.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 125.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 52.40 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 356.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 276.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 174.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 88.50 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 80.40 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 45.70 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 634.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 240.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 161.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 36.10 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 22.30 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 102.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 85.60 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 46.10 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 1558 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 211.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 83.20 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 251.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 797.9 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 391.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 80.60 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 64.80 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 27.50 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 32.50 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 391.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 3521 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 224.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 31.50 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 53.00 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 95.10 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 382.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 422.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 130.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 101.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 100.9 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 1558 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 397.0 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 65.00 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 713.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 5130 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 169.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 657.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 1114 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 12337 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 1136 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 303.0 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 239.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 347.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 361.0 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 1328 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 179.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 3390 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 1914 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 413.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 1304 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 142.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 137.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 114.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 1522 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 540.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 490.0 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 427.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 399.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 100.0 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 1672 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 209.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 65.20 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 265.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 2065 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 1594 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 827.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 614.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 452.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 1672 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 193.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 659.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 421.0 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 157.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 738.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 203.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 328.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 580.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 494.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 146.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 177.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 2700 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 813.8 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 2231.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 1925.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 678.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 2658.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 643.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 643.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 1925.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 813.8 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 678.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 2658.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 2231.7 Titer |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3,4, overall and by region and COVID-19 severity among America Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 220.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 20.20 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 253.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 87.60 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 10.00 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 35.10 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 75.50 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-Peru | 113.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 75.50 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 80.70 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 38.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 27.90 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-Peru | 37.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 47.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 220.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 13.70 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 10.00 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 133.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 179.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 42.50 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 489.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 53.00 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 41.40 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 28.50 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-Peru | 104.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-Peru | 289.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 107.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 527.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 111.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 28.50 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 285.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 281.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 44.10 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 81.00 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 284.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 85.40 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-Peru | 13.70 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 89.90 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-Peru | 60.30 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 53.40 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 117.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 152.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 211.0 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 29.00 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 117.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 60.10 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 185.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 1034.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 334.0 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 246.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 334.0 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 227.0 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 1034.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 321.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 185.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 726.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 109.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 1778 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 459.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 890.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 2180 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 338.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 335.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 1121 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 103.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 726.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 357.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 2826 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 1497 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-Peru | 305.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 411.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 411.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 663.0 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 358.0 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 176.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-Peru | 245.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 198.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 120.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 601.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 262.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 127.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-Peru | 91.00 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 128.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 128.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 190.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 127.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 54.10 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-Peru | 73.50 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 64.60 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 46.60 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 627.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 120.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 675.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 281.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 281.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 1341 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 120.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 436.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 325.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 2599 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 281.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 232.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 232.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 111.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 73.50 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 111.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 124.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 73.50 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 169.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 293.9 Titer |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among Africa Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 244.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 341.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 252.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 7856.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 6035.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 964.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 341.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 201.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 100.9 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 279.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 222 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 86.5 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 100.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 98.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 63.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 2749.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 1076.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 361.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 55.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 40.1 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 19.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 71.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 54 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 23.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 40 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 117.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 1884.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 54.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 147.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 78.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 36 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 390.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 347.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 39.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 220.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 495.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 10 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 570.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 34.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 296.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 98.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 203.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 147.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 39.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 312.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 137.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 1436.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 133.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 324.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 156.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 133.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 26.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 335.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 16.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 34.9 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 312.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 68.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 60.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 120.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 24.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 410.6 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 119.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 182.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 119.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 119.9 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 269.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 240.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 36.6 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 57.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 1657.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 600.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 408.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 73.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 32.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 157.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 320.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 262.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 275.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 872 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 360.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 1194.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 124 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 41.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 416.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 86.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 106.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 60.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 351.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 50.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 81.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 223.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 250.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 77.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 205.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 1591.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 238.8 Titer |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 129.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 47.20 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 50.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 253.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 183.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 51.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 216.0 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Peru | 113.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 151.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 59.00 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 24.00 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 636.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 370.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 21.50 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 120.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 346.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 80.70 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 120.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 54.50 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 346.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Peru | 37.30 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 120.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 70.30 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 2322 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 1019 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 71.50 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Peru | 964.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 117.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 106.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 228.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 195.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 50.60 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Peru | 151.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 120.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 119.0 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 579.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 213.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 23.90 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Peru | 387.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 44.10 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 37.40 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 51.60 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 20.50 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Peru | 55.70 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 46.60 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 45.40 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 75.00 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 228.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 469.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Peru | 13.70 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 144.0 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 36.60 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Peru | 259.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 707.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 30.60 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 189.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 22.20 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 138.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Peru | 866.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 39.40 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 164.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 35.00 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 1264 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 103.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 26.90 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Peru | 29.40 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 61.90 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 152.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 682.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 94.30 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 120.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 411.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 120.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 311.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 137.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 220.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 77.40 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 37.50 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 105.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 267.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Peru | 80.40 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 111.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 90.40 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 574.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 281.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Peru | 46.60 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 41.70 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 374.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 151.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 88.90 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Peru | 120.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Peru | 239.0 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 346.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 128.3 Titer |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and enrollment group among Africa Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 34.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 50.9 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 169.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 135.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 183.5 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 68.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 42.1 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 163 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 312.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 36.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 40.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 451.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 103.4 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 31.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 135.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 82.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 20.9 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 38.7 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 211.1 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 1305.9 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 10 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 169 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 51.9 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 431.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 142.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 58.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 35.1 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 239.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 118.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 33.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 24.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 161.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 52.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 6268.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 59.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 945.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 71.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 358.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 2108.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 31.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 22.5 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 7946.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 23.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 130.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 32.9 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 82.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 156.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 612.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 303.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 796.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 36.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 66.6 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 426.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 43.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 121 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 137.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 99.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 217.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 95.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 36.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 100.9 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 62.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 34 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 605.6 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 10 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 323.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 31.9 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 288.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 155.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 252.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 78.3 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 2071.9 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 356.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 1237.1 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 356.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 396.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 458.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 147.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 190.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 274.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 125.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 122.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 101 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 122.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 478.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 4870.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 761.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 173.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 1149 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 181.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 18743.3 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 5616.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 763.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 116.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 520.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 377.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 543.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 121.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 437.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 124 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 163.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 92.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 89.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 501.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 74.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 698.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 971 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 2700 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 2443.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 1657.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 270.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 244.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 218.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 694.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 446.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 450.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 237.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 538 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 131.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 138.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 1698.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 852.9 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 783.2 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 3743.2 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 234.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 2671.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 11384.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 610.4 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 13387 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 3519.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 2610.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 190.4 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 572.9 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 1645.9 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 1570.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 188.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 184.8 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 717.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 351.7 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 3310.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 772.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 573.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 954.2 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 971.6 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-non-RSA | 144.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-non-RSA | 167.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-RSA | 62.8 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-Total | 190.8 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 12-non-RSA | 1389.2 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-RSA | 173.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-Total | 105 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-RSA | 1950.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-Total | 1141.3 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 0-non-RSA | 637.8 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-RSA | 296.8 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-Total | 600.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 12-non-RSA | 4857.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-RSA | 627.8 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-Total | 422 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 2-non-RSA | 122.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-RSA | 720.4 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-Total | 633.8 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID50 at Month 4-non-RSA | 537.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-RSA | 399.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 0-Total | 283.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 2-non-RSA | 31.3 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-RSA | 164.2 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G-ID80 at Month 4-Total | 164.2 Titer |
Primary
SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by neutralizing antibody assay (NAb) at Visit 1, 2,3,4, overall and by region and enrollment group among America Cohort (USA and Peru only)
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 10 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 10 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Peru | 37.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 179.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 30.6 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 10 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 29.1 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 42.5 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 10 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 38.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 81.8 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Peru | 113.2 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 37.3 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 35.1 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 40.1 Titer |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 113.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 103.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 26.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 253.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 253.3 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 80.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 62.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 684.8 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 21.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 346.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 22.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 346.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 80.7 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 84.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 167.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 120.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 48.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 120.4 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 48.6 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 83.2 Titer |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 22.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 44.1 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 56.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 76 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 235.6 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 182.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 239.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Peru | 13.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 450.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 70.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 328.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 220.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 80.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Peru | 259.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 138.2 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 737.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 25.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 315.9 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Peru | 29.4 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 608.8 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 89.9 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Peru | 866.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 25.5 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 56.7 Titer |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 26.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 51 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 1140.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 743.7 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 392.2 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 1034.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 1034.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 154.5 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 204 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 282.8 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 209 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 144.4 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 110 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 334 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 334 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 39.6 Titer |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 48.7 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 44.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 46.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 107.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 117.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 984.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 46.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 44.1 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 587.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 129.9 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 336.5 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 148.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 120.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 121.4 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 225.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 316.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 50.6 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 117.8 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 120.2 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 268.3 Titer |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 3636.2 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 622.4 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 690.4 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 554.4 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 358 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 2907.6 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 240.9 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 458.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 128.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 951.8 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 128.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 430.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 227.2 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 302.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 430.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 159.3 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 1232.5 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 82.1 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 1801.9 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 690.4 Titer |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 227.2 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Total | 73.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Peru | 232.2 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Total | 47.6 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-Peru | 75.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Peru | 204.9 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-USA | 130.2 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Total | 62.6 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Total | 139.8 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-Total | 187.1 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-USA | 22.9 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-USA | 36.6 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Total | 518.2 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-Peru | 73.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Peru | 215.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-USA | 232.2 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-USA | 61.2 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 0-Peru | 910.9 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 12-USA | 73.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 0-Total | 130.2 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 2-Peru | 124.2 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 2-Peru | 301.5 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 12-Total | 232.2 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID50 at Month 4-USA | 152.4 Titer |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614-ID80 at Month 4-USA | 53.4 Titer |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 27 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 126 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 131 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 140 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 14 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 138 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 124 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 127 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 26 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 104 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 39 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 114 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 140 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 140 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 12 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-Yes at Month 0-Total | 59 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-Yes at Month 0-Total | 58 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC-No at Month 0-Total | 95 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Comorbidity Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC-No at Month 0-Total | 93 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Time frame: Measured at Months 0
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 17 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 7 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 59 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 25 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 32 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 21 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 34 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 53 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 11 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 3 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 49 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 18 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 46 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 31 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 24 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 8 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and COVID-19 Severity Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 11 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort (USA and Peru)
Time frame: Measured at Months 0
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 12 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 38 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 39 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 33 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 38 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 60 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 69 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort
Antibody-dependent NK cell degranulation will be measured using ADCC assay at a dilution 1:500. Two readouts will be the background-subtracted % CD107A+ NK cells for the infected cells and the background-subtracted % CD107A+ NK cells for the transfected cells. The positive responses will be called if the values of background-subtracted % CD107A+ ≥ 4.07 and ≥5.27 for the infected and transfected cells, respectively. The cutoffs are determined by mean+2SD, respectively, from the SARS-CoV-2 negative controls. Percent CD107a+ NK Cells was the response magnitudes. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by antibody-dependent cellular cytotoxicity assay (ADCC) at Visit 1, overall and by region and enrollment group among America Cohort (USA and Peru only)
Time frame: Measured at Months 0
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 7 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 4 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 11 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 11 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 17 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 9 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 27 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 11 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 17 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 33 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 30 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 10 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 29 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 11 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-USA | 7 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-USA | 7 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Total | 13 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Peru | 5 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-T-ADCC at Month 0-Peru | 6 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (ADCC) by Region and Enrollment Group Among America Cohort | Bkg. Subtracted CD107A NK Cells-I-ADCC at Month 0-Total | 12 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and enrollment group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 23 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 38 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 27 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 39 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 23 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 39 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 23 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 36 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 36 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 12 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 9 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 12 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 4 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 5 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 7 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 15 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 20 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 11 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 47 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 24 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 49 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 50 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 27 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 44 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 11 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 38 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 48 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 47 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 45 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 1 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 24 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 3 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 46 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 48 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 10 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 24 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 40 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 17 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 24 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 45 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 15 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 32 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 41 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 38 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 0 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 5 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 3 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 21 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 5 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 17 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 20 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 3 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 20 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 33 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 45 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 13 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 10 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 90 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 80 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 27 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 11 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 71 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 17 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 15 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 16 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 48 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 5 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 16 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 39 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 16 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 47 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 15 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 48 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 92 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 44 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 35 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 94 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 82 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 89 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 41 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 43 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 50 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 33 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 43 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 41 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 9 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 44 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 13 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 13 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 15 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgA) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 8 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and enrollment group
Time frame: Measured at Months 0, 2, 4
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 34 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 31 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 38 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 19 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 36 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 34 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 31 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 23 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 30 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 30 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 30 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 31 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 30 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 19 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 31 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 16 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 14 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 16 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 4 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 5 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 7 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 31 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 36 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 33 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 35 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 24 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 27 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 51 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 35 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 51 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 24 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 52 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 35 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 25 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 32 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 34 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 27 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 27 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 24 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 51 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 27 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 36 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 51 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 32 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 35 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 27 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 10 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 18 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 45 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 45 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 38 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 10 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 26 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 45 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 38 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 24 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 11 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 24 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 38 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 33 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 43 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 47 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 38 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 32 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 16 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 25 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 30 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 15 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 34 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 15 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 30 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 43 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 29 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 29 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 17 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 11 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 29 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 36 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 40 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 11 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 30 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 16 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 11 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 31 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 32 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 33 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 41 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 25 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 30 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 42 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 23 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 24 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 36 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 11 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 27 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 24 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 14 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 36 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 34 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 48 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 38 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 27 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 37 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 10 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 11 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 14 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 35 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 11 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 39 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 36 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 48 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 11 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 35 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 27 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 17 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 27 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 27 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 23 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 27 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 27 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 26 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 33 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 17 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 11 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 11 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 17 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 11 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 49 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 14 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 23 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 17 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 35 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 42 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 48 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 92 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 35 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 22 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 43 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 42 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 44 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 36 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 82 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 17 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 47 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 34 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 71 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 36 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 35 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 36 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 36 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 20 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 42 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 71 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 36 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 70 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 23 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 37 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 37 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 23 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 35 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 92 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 72 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 43 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 71 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 17 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 24 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 22 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 36 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 34 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 48 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 36 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 41 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 82 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 86 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 44 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 91 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 37 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 73 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 24 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 68 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 36 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 39 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 43 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 43 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 43 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 36 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 92 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 93 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 24 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 32 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 38 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 74 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 35 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarizedSARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and enrollment group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 33 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 32 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 23 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 37 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 39 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 41 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 23 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 33 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 36 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 9 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 7 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 14 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 7 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 51 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 51 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 27 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 20 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 49 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 20 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 46 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 27 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 20 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 50 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 48 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 46 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 47 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 47 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 26 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 46 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 19 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 42 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 46 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 40 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 44 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 24 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 24 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 11 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 19 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 42 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 11 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 23 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 16 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 15 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 8 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 43 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 41 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 44 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 43 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 15 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 23 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 44 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 11 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 23 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 46 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 1 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 1 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 45 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 21 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 21 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 24 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 48 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 1 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 5 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 9 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 7 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 44 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 50 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 93 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 96 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 93 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 46 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 15 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 39 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 89 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 50 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 13 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 88 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 39 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 44 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 9 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 94 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 12 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 50 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 50 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 17 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 86 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 18 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 37 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 11 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 43 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 81 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 47 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 34 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 15 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG3) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 16 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 304 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 57 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 160 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 36 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 297 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 55 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 19 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 152 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 46 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 59 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 120 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 82 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 163 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 162 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 104 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 73 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 56 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 314 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 267 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 301 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 19 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 61 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 52 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 150 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 77 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 159 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 144 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 160 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 142 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 40 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 75 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 157 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 310 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 115 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 75 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 80 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 53 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 27 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 140 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 195 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 152 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 4 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 21 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 19 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 46 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 57 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 97 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 54 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 41 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 101 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 18 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 20 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 107 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 54 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 15 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 113 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 224 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 78 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 4 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 119 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 48 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 39 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 63 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 5 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 30 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 45 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 116 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 92 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 43 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 22 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 98 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 128 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 14 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 48 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 14 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 100 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 50 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 219 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 36 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 23 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 18 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 23 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 119 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 119 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 114 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 47 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 12 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 5 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 61 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 17 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 65 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 14 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 60 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 226 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 27 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 85 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 19 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 56 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 214 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 41 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 9 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 78 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 103 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 79 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 15 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 47 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 43 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 25 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 57 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 215 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 40 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 61 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 118 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 35 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 107 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 107 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 20 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 29 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 191 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 105 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 14 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 22 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 20 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 57 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 7 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 105 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 7 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 21 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 47 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 124 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 35 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 44 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 150 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 30 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 74 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 83 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 53 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 305 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 164 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 166 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 309 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 143 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 27 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 77 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 50 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 62 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 274 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 107 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 165 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 58 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 169 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 11 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 53 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 303 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 24 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 75 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 149 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 316 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 319 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 51 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 163 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 30 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 140 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 141 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 29 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 198 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 74 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 58 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 39 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 167 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 117 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 157 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 81 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 158 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 43 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 1 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 26 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 0 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 118 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 24 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 27 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 85 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 1 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 158 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 83 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 76 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 63 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 19 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 149 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 40 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 56 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 1 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 71 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 67 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 154 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 72 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 158 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 3 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 55 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 238 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 24 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 1 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 251 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 26 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 220 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 73 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 11 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 27 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 43 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 52 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 82 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 49 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 84 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 86 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 11 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 36 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 78 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 160 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 239 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 248 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 104 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 81 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 244 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 155 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 18 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 58 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 54 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 46 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 140 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 54 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 90 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 70 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 91 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 75 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 141 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 23 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 94 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 182 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 7 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 68 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 118 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 139 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 45 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 11 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 118 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 84 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 142 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 73 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 55 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 33 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 49 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 95 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 136 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 91 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 43 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 16 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 190 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 88 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 43 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 33 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 51 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 8 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 70 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 181 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 168 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 117 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 37 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 38 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 26 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 186 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 25 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 17 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 30 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 24 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 112 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 31 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 77 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 45 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 17 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 105 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 191 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 72 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 37 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 16 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 67 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 112 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 115 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 115 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 34 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 30 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 33 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 40 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 15 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 44 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 35 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 56 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 118 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 63 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 25 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 24 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 133 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 30 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 85 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 7 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 90 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 64 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 109 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 30 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 9 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 31 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 57 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 83 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 97 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 106 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 20 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 19 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 21 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 36 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 50 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 19 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 34 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 40 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 137 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 26 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 14 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 44 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 12 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 96 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 17 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 31 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 32 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 58 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 165 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 20 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 55 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 98 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 57 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 43 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 107 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 150 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 23 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 157 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 57 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 30 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 17 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 39 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 153 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 174 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 59 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 96 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 100 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 146 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 17 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 7 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 93 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 165 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 38 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 27 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 31 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 157 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 102 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 49 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 67 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 40 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 85 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 74 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 8 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 40 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 23 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 155 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 66 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 43 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 110 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 58 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 5 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 29 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 111 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 61 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 14 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 176 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 46 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 59 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 65 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 43 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 31 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 39 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 109 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 82 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 169 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 8 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 60 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 67 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 282 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 50 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 74 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 288 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 136 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 127 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 30 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 151 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 12 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 101 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 77 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 11 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 285 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 70 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 150 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 10 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 47 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 37 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 11 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 23 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 68 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 25 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 255 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 11 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 11 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 130 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 11 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 34 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 27 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 295 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 23 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 118 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 158 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 34 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 21 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 7 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 9 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 161 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 12 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 33 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 11 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 43 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 16 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 299 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 155 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 28 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 138 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 34 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 11 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 25 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 17 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 155 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 24 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 44 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 11 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 11 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 191 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 73 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 52 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 29 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 159 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 28 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 46 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 12 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 105 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 56 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 33 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 28 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 9 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 130 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 29 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 38 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 5 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 41 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 8 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 174 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 65 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 7 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 33 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 52 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 33 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 137 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 242 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 5 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 6 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 2 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 45 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 145 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 24 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 149 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 135 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 20 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 70 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 103 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 53 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 7 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 17 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 25 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 58 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 17 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 280 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 8 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 151 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 290 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 139 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 26 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 79 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 53 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 43 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 25 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 5 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 148 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 132 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 23 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 72 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 49 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 42 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 24 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 5 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 90 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 135 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 45 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 25 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 16 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 272 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 127 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 50 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 43 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 25 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 109 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 19 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 33 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 286 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 77 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 43 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 139 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 19 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 39 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 23 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 3 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 147 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 282 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 26 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 71 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 40 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 23 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 294 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 156 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 4 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 73 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 102 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 37 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 7 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 1 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 152 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 20 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 22 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 4 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 284 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 51 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 144 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 28 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 132 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 25 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 130 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 75 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 82 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 24 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 39 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 14 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 38 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 280 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 50 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 22 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 154 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 14 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 79 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 29 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 54 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 34 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 1 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 153 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 110 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 7 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 14 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 1 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 39 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 1 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 22 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 18 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 24 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 140 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 28 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 20 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 37 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 35 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 3 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 55 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 26 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 292 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 54 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 4 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 26 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 139 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 250 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 153 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 106 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 4 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 61 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 33 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 13 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 63 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 173 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 33 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 4 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 1 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 13 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 285 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 74 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 23 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 132 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 150 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 10 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 44 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 3 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 12 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 11 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 23 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 53 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 85 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 13 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 22 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 33 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 249 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 48 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 51 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 11 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 107 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 40 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 24 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 16 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 157 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 222 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 142 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 59 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 44 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 25 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 48 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 146 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 47 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 114 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 17 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 9 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 9 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 69 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 107 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 17 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 68 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 148 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 260 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 38 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 105 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 247 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 65 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 2 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 27 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 11 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 16 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 69 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 34 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 124 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 90 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 73 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 137 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 46 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 66 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 36 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 28 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 60 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 24 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 61 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 110 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 256 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 146 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 41 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 17 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 14 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 48 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 142 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 40 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 4 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 26 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 67 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 27 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 116 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 59 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 264 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 50 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 17 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 33 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 44 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 50 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 8 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 61 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 140 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 12 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 268 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 3 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 104 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 3 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 49 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 43 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 22 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 7 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 42 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 1 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 26 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 16 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 65 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 28 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 22 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 18 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 20 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 145 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 146 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 1 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 49 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 9 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 5 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 76 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 2 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 51 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 73 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 28 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 9 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 22 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 45 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 254 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 64 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 22 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 64 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 27 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 35 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 70 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 1 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 42 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 25 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 112 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 2 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 114 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 122 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 57 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 29 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 136 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 258 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 46 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 11 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 144 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 266 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 12 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 9 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 54 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 36 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 13 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 9 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 97 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 67 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 226 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 21 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 69 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 90 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 258 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 19 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 25 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 8 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 113 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 142 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 41 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 4 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 63 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 145 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 48 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 39 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 1 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 21 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 158 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 29 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 45 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 57 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 40 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 121 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 54 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 31 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 51 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 17 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 41 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 53 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 56 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 51 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 30 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 26 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 47 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 48 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 140 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 57 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 73 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 82 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 66 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 38 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 42 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 37 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 7 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 55 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 74 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 55 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 32 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 132 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 29 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 77 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 52 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 26 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 37 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 22 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 12 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 41 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 33 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 39 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 29 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 54 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 51 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 53 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 16 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 54 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 35 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 109 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 58 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 47 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 127 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 80 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 58 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 137 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 127 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 24 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 1 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 35 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 68 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 33 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 39 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 51 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 5 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 70 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 68 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 18 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 27 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 66 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 5 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 70 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 70 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 57 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 7 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 17 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 39 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 45 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 3 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 25 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 1 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 3 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 25 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 37 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 19 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgA) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 0 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 20 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 71 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 15 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 53 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 17 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 66 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 42 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 75 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 74 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 15 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 18 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 70 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 19 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 16 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 74 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 20 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 77 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 81 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 76 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 49 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 40 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 80 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 24 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 78 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 69 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 19 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 42 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 124 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 146 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 149 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 138 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 43 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 142 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 40 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 39 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 74 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 91 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 146 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgA) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 17 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3 , overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0, 2, 4
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total | 154 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 238 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA | 69 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA | 67 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 156 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Peru | 100 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 135 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total | 170 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA | 70 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 121 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-USA | 67 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-USA | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA | 61 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 225 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 232 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru | 102 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Total | 167 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Total | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 97 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 236 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 157 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 156 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru | 101 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 124 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 154 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 313 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Peru | 100 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 146 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 111 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 236 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 235 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Total | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 109 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-USA | 70 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total | 171 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 112 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 300 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 313 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 233 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 123 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 105 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 122 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 19 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total | 163 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 150 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 233 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total | 172 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 306 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru | 96 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru | 103 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 113 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 100 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 125 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 159 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 228 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 17 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 143 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 248 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 136 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA | 68 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-USA | 68 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 105 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru | 93 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Total | 168 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 126 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 110 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 104 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 150 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 235 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 125 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 109 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Total | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 154 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Peru | 102 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Total | 172 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 306 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 156 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 124 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 105 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 80 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru | 28 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 38 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA | 49 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 71 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 103 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Total | 51 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 219 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 116 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 91 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 89 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 104 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 166 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 74 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru | 74 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 220 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total | 122 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 47 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Peru | 28 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 108 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 43 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 47 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 82 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 83 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 106 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 43 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 80 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Total | 130 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Peru | 79 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 114 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 102 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 36 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 75 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 91 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 168 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 77 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Peru | 78 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 93 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Total | 127 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 77 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-USA | 49 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 181 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 46 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 104 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 81 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA | 24 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 119 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 92 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 74 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total | 128 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 79 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru | 79 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total | 130 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru | 27 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 161 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 47 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA | 23 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 105 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total | 52 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 58 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru | 29 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 38 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 40 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 82 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 107 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru | 72 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 79 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 227 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-USA | 24 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 72 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 171 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru | 79 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 80 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru | 26 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 89 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 40 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 35 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total | 129 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 59 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Peru | 27 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 74 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 39 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 108 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA | 50 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 39 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 99 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 42 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA | 25 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total | 53 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 38 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 58 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru | 79 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 216 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 39 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total | 116 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA | 51 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-USA | 48 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Total | 126 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru | 26 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 116 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 38 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Peru | 78 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 41 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total | 48 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 173 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 75 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 168 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total | 50 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 166 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA | 22 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 159 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-USA | 24 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Peru | 27 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 116 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 98 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA | 48 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 101 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 77 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 223 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-USA | 25 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Total | 53 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 170 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 41 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 61 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total | 52 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 39 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 72 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 55 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 40 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 47 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 90 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 40 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Total | 51 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 41 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA | 25 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 43 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 88 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 169 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 80 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 81 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-USA | 51 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 230 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 109 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 126 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA | 63 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA | 57 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 149 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-USA | 63 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Total | 168 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Peru | 105 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 107 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 236 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 163 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 136 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Total | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 232 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 96 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 129 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-USA | 66 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 240 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total | 171 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 111 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 242 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru | 106 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 11 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total | 171 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA | 65 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 138 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA | 66 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total | 155 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru | 107 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 151 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 153 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 239 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 302 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 163 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 316 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Peru | 105 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru | 108 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 132 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 112 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Total | 173 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 236 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 11 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Total | 169 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 98 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 105 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru | 98 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 166 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total | 163 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA | 63 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-USA | 64 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 252 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 130 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 146 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 317 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 237 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 129 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 11 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 11 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 147 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 103 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Peru | 107 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 163 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 160 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 309 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 109 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru | 100 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 142 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 232 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 129 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 312 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total | 173 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 241 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 11 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 131 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 128 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 11 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 104 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 108 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 72 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 59 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 85 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 91 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 77 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Total | 145 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 155 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 62 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA | 32 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 66 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Peru | 101 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 83 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 153 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 62 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 83 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 187 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 244 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 125 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 61 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 61 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Peru | 99 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 56 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 60 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 65 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Total | 141 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 206 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 75 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-USA | 42 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru | 92 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA | 42 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 141 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total | 38 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 77 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA | 32 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total | 143 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru | 101 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 74 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 187 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 59 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 5 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 123 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 54 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 180 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 249 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total | 38 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 158 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 66 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 60 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 59 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 91 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 193 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 64 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total | 145 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 241 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 184 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 53 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru | 93 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total | 135 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 86 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 56 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 56 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 85 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 120 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 63 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 58 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 185 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-USA | 44 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 89 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 60 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 121 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 52 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA | 39 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-USA | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 57 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 188 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA | 42 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 57 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 179 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Total | 38 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 81 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 131 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-USA | 32 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 184 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 155 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 122 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 246 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 119 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 54 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 64 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-USA | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA | 27 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 181 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total | 33 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 123 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 59 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 236 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Peru | 99 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru | 101 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA | 44 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 51 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 80 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 155 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Total | 140 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 5 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA | 43 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 53 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 133 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total | 143 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 49 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru | 100 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-USA | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 64 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total | 131 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 64 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 121 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 65 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru | 7 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 94 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total | 104 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 106 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 67 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total | 60 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA | 33 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 98 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 147 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 49 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 89 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 140 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 51 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru | 78 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total | 115 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA | 37 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 38 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 59 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 40 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 109 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 70 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-USA | 37 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 115 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 188 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 51 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA | 36 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total | 63 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA | 33 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 139 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 40 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 67 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 181 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 90 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 138 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 136 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 111 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA | 36 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 192 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 74 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru | 78 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA | 38 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total | 67 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 39 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 99 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru | 78 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Total | 116 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-USA | 38 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 44 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 107 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 63 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 40 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Total | 67 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-USA | 38 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 115 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 90 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 136 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 46 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Peru | 77 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Total | 112 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-USA | 35 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 70 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 87 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 133 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Total | 65 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 109 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 150 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 88 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 46 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 111 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru | 29 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 39 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 54 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 51 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-USA | 37 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Peru | 77 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total | 66 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 92 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 185 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 51 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 58 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total | 66 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 141 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 91 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total | 116 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 66 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 41 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 134 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 139 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 67 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 184 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 143 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 95 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 142 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 140 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru | 71 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru | 73 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 49 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA | 38 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 114 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 107 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Total | 65 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total | 114 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Peru | 78 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Peru | 29 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 46 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 39 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 90 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru | 30 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 142 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA | 38 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 72 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 41 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 72 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 111 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 46 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 91 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 88 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total | 109 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 73 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA | 36 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 115 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 107 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 103 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA | 36 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 92 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-USA | 36 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 157 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 118 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 39 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 69 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 97 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Total | 113 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 69 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 97 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 69 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 51 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 123 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 76 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total | 84 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Total | 81 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 66 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 81 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 123 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru | 67 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 55 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 55 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 98 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 44 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 102 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 123 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru | 33 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA | 49 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 105 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 62 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Peru | 71 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Total | 97 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-USA | 26 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 55 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 95 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 123 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 109 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 66 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru | 72 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total | 98 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 57 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 157 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 100 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 46 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 124 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 78 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru | 35 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA | 26 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 122 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 70 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 119 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 72 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru | 36 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total | 82 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA | 46 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 39 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 129 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 125 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 82 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 84 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 40 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru | 72 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total | 98 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 95 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 136 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 41 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 84 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 124 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 40 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Peru | 72 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 55 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 153 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 126 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 78 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Peru | 35 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 173 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 65 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 108 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 171 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 40 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 46 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 122 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 76 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-USA | 46 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru | 68 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA | 50 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total | 85 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 72 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA | 26 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 45 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Total | 97 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 175 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 150 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 123 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 75 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA | 49 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 48 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru | 35 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 153 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Peru | 71 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru | 30 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 42 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total | 73 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 125 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Total | 80 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total | 90 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 174 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA | 23 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 76 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total | 82 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 83 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA | 43 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 108 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-USA | 50 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 98 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 85 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Total | 85 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 121 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 86 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 48 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 76 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA | 23 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 108 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 36 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 128 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total | 91 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 167 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 157 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 52 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 82 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-USA | 26 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-USA | 26 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 126 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Total | 98 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Peru | 34 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 83 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 82 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 44 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 122 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru | 71 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total | 97 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 117 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-USA | 47 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Peru | 34 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 52 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 122 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 126 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 42 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 63 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 43 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 73 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 99 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 221 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 297 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total | 148 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 156 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 283 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 125 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 223 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 213 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 98 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 20 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru | 5 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 298 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 140 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 103 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total | 164 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 15 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA | 62 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA | 61 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total | 162 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA | 59 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru | 95 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total | 162 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru | 101 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA | 13 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 217 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 100 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 123 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 94 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 130 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Peru | 4 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Total | 164 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 223 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-USA | 62 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-USA | 58 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 123 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 23 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 93 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 16 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 221 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 27 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Total | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 128 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA | 13 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 123 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 221 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total | 16 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Total | 18 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 98 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru | 3 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Peru | 101 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Total | 159 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 20 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 135 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 120 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 34 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA | 58 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total | 17 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA | 53 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total | 155 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 34 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 20 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 101 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Total | 160 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 241 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 158 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 20 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-USA | 59 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 140 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 124 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 24 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru | 103 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru | 5 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 34 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 15 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Peru | 4 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 290 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Total | 18 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 155 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 141 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 136 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 18 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total | 18 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 20 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 122 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 291 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 23 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 34 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru | 97 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 155 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Peru | 5 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 23 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 7 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 20 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru | 5 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 35 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 94 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 7 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 27 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru | 102 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 25 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru | 3 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 227 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 93 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 224 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Peru | 102 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 98 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 152 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 131 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 224 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 126 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Peru | 101 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 23 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 19 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 24 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total | 22 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 41 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total | 22 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 17 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 213 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA | 65 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru | 95 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 142 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 149 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 114 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 115 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA | 10 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 93 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru | 96 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 38 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 19 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 132 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-USA | 63 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 228 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Total | 156 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 96 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Peru | 93 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 117 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 215 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 216 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 134 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 145 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 99 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA | 10 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 33 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Peru | 95 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 34 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 38 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 25 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 34 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 19 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 35 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 148 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru | 88 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 288 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 113 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 140 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-USA | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 143 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 148 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Total | 22 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 284 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 34 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 95 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 14 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 34 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 19 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 34 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 34 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 40 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-USA | 10 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 291 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Total | 160 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total | 158 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 148 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 23 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total | 160 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 209 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 21 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-USA | 65 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 88 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 206 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 36 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 279 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 33 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 114 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA | 62 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-USA | 63 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 34 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA | 62 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru | 86 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Total | 156 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 136 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 99 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total | 144 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total | 159 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 40 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Peru | 93 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA | 58 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Total | 21 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 212 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 20 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total | 23 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 100 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru | 94 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 111 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA | 10 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total | 22 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 214 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 291 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA | 65 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total | 20 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 20 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 207 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 114 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 104 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 25 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 19 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA | 11 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 101 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 124 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 116 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 89 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 19 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA | 8 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-USA | 11 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total | 150 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 99 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 121 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Total | 23 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 219 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 215 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA | 62 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 104 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total | 164 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total | 162 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru | 100 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 22 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 117 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA | 10 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 121 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA | 61 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 218 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 106 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 87 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 39 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 225 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 39 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Total | 164 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-USA | 11 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-USA | 63 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 119 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-USA | 61 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 278 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Peru | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 24 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 40 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 83 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 25 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 204 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 10 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 121 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 148 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Total | 19 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total | 155 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-USA | 13 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA | 11 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 123 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 13 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 119 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total | 17 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 292 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 223 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 223 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 104 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 105 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 23 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Peru | 99 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 14 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Total | 17 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Total | 160 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 23 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 24 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total | 147 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 10 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 24 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 14 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA | 11 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 151 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 10 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 228 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 108 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 14 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 137 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total | 164 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 25 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru | 92 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru | 101 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 92 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Peru | 99 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 99 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 122 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 225 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 133 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 141 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 224 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 292 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 145 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA | 62 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 102 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA | 13 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA | 13 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 210 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Peru | 101 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 10 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 24 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 9 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total | 19 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 41 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 24 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA | 63 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 13 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 26 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA | 55 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 40 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 37 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 16 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 26 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total | 19 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Peru | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 148 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru | 94 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 285 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 118 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total | 16 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 40 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 10 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 137 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 144 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 23 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-USA | 11 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 10 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Total | 17 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 148 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Peru | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 285 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 216 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total | 17 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 99 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 39 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru | 102 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 120 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 14 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 10 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 24 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 25 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 132 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-USA | 62 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 25 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 119 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 224 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Total | 161 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Total | 42 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 77 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 81 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 17 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 43 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total | 43 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 143 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 190 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 51 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 118 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 73 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 114 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Peru | 90 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 75 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 112 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 143 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA | 47 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 146 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 75 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total | 43 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 190 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total | 42 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA | 29 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Total | 136 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 48 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 259 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 264 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 42 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 111 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Peru | 15 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 129 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 76 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 109 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 47 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA | 28 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 17 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 47 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 197 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru | 16 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 65 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 60 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Peru | 92 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 59 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 193 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 210 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 116 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 19 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 257 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 55 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru | 85 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 60 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 117 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 182 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru | 92 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-USA | 46 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru | 92 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 17 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-USA | 26 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total | 44 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 41 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 58 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA | 43 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 113 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 68 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 37 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA | 28 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 67 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 17 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-USA | 47 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 190 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 41 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Total | 44 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 120 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total | 138 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 142 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 51 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-USA | 29 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA | 23 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total | 129 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 109 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 43 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA | 44 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 186 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 79 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 112 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total | 35 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 113 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 189 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA | 26 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru | 12 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 62 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 77 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 32 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 114 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru | 91 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 80 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Peru | 90 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 40 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 50 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA | 47 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 77 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Total | 136 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 184 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 259 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 57 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Total | 41 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 45 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru | 15 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru | 86 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru | 15 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 41 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total | 138 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 59 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-USA | 46 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 252 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 67 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA | 46 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 74 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Peru | 15 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-USA | 27 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total | 129 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total | 139 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 54 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 111 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 36 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 193 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 72 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 140 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru | 15 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Peru | 15 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Total | 139 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 119 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 34 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 115 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 28 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 66 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Total | 151 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Total | 148 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Total | 32 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 202 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 60 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 41 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-USA | 18 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 140 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 28 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Peru | 11 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 203 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Total | 29 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 68 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-USA | 21 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 251 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-USA | 19 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-USA | 53 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 45 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 17 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 37 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-Peru | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 137 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 198 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Total | 151 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 114 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Peru | 11 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-USA | 54 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 112 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Total | 28 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Total | 151 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 29 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 91 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 113 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 263 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 66 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 46 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Total | 149 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 18 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 201 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 118 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 44 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 4-Peru | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 37 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 111 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-USA | 53 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 90 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 34 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Total | 136 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 185 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 89 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 43 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Peru | 9 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-Peru | 88 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 143 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-Total | 28 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 4-Peru | 95 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 113 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 57 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-USA | 55 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 71 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 4-Peru | 95 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 26 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 112 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 93 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Total | 144 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 4-Peru | 11 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 258 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 4-USA | 19 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Total | 149 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 46 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-USA | 55 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 17 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 49 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 4-USA | 48 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-USA | 18 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 86 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 31 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 198 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 30 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 29 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 4-Peru | 91 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 112 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-Peru | 97 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 46 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 140 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 17 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 90 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Total | 29 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 43 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 258 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 112 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 22 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 59 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 118 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 123 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-USA | 54 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 204 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 4-USA | 19 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Total | 29 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 80 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 68 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 121 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 203 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 114 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 45 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 87 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 114 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 140 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-USA | 21 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 17 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 201 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 4-Peru | 11 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 4-Peru | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-Total | 32 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 264 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 190 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 87 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 4-USA | 21 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 4-USA | 54 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 47 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 4-Total | 32 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 124 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 4-Peru | 96 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 26 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 206 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 16 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 68 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 45 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 75 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 15 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 4-Peru | 95 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 4-Peru | 96 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 18 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 43 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3 , overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Time frame: Measured at Months 0, 2, 4
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 33 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 50 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 46 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 31 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 40 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 38 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 32 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 39 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 39 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 35 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 32 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 40 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 32 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 53 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 34 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 36 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 30 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 49 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 54 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 32 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 32 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 39 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 40 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 38 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 17 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 23 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 30 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 46 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 103 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 57 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 43 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 106 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 63 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 33 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 73 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 40 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 55 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 138 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 83 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 41 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 106 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 65 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 31 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 107 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 70 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 65 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 33 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 39 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 73 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 40 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 56 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 55 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 136 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 80 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 137 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 82 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 40 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 43 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 103 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 107 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 63 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 64 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 31 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 70 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 39 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 65 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 55 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 138 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 83 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 43 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 108 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 65 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 29 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 66 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 37 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 58 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 141 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 83 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 42 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 108 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 66 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 33 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 73 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 40 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 96 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 52 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 42 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 103 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 61 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 34 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 72 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 38 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 35 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 43 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 95 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 52 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 42 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 19 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 19 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 51 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 48 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 51 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 19 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 70 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 70 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 50 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 34 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 38 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 60 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 18 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 69 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 52 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 38 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 38 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 52 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 39 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 57 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 18 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 51 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 36 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 56 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 50 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 40 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 68 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 69 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 26 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 26 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 43 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 41 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 23 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 31 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 15 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 32 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 23 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 33 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Peru | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 23 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 11 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 46 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 24 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 26 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 16 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-USA | 8 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-USA | 8 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 24 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 34 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Peru | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 16 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 32 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 4-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 34 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 24 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 34 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 32 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 20 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG1) at Visit 1, 2, 3, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Time frame: Measured at Months 0, 2, 4
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 19 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 19 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 21 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 45 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 72 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 72 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 54 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 60 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 57 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 38 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 55 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 45 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 72 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 45 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 58 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 56 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 57 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 54 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 56 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 71 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 60 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 74 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 56 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 43 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 59 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 78 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 55 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 37 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 61 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 42 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 59 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 42 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 77 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 58 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 59 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 41 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 82 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 42 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 57 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 37 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 56 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 63 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 57 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 82 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 42 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 78 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 55 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 40 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 110 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 4-Total | 75 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 112 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 110 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 121 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 112 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 4-Total | 72 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 115 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 114 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 4-Total | 69 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 116 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 4-Total | 75 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 114 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 4-Total | 72 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 147 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 149 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 4-Total | 72 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 112 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 147 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 115 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 144 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 4-Total | 74 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 148 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG1) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 4-Total | 73 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 297 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 279 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 43 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 131 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 155 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 156 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 36 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 56 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 54 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 38 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 135 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 78 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 287 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 153 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 19 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 159 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 54 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 160 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 19 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 49 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 52 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 72 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 73 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 156 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 312 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 316 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 160 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 75 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 312 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 152 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 52 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 148 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 151 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 161 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 57 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 83 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 19 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 314 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 152 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 292 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 141 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 6 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 139 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 23 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 20 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 16 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 96 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 14 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 98 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 16 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 22 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 58 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 105 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 114 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 47 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 19 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 211 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 106 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 120 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 66 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 14 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 21 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 5 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 51 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 231 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 58 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 16 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 104 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 52 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 215 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 226 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 119 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 199 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 37 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 120 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 45 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 51 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 22 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 9 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 33 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 105 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 12 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 90 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 46 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 39 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 23 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 117 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 27 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 41 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 109 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 22 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 41 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 57 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 96 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 30 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 97 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 93 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 45 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 207 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 59 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 109 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 58 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 48 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 15 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 45 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 16 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 96 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 16 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 61 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 106 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 20 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 111 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 226 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 56 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 19 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 225 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 12 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 41 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 114 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 107 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 14 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 59 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 51 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 95 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 19 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 117 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 4 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 46 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 51 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 159 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 135 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 37 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 77 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 48 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 73 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 25 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 154 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 316 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 297 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 283 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 129 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 161 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 42 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 165 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 49 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 74 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 151 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 166 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 317 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 319 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 153 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 71 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 49 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 54 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 290 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 83 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 54 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 152 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 36 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 317 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 165 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 150 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 158 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 132 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 294 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 56 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 29 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 167 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 25 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 136 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 3 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 18 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 84 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 58 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 38 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 233 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 152 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 27 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 83 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 67 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 73 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 81 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 151 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 157 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 26 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 91 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 84 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 81 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 159 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 27 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 91 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 250 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 64 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 248 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 66 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 26 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 251 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 249 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 237 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 71 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 157 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 46 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 50 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 74 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 93 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 79 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 12 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 154 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 81 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 92 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 226 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 26 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 49 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 24 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 232 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 74 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 51 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 69 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 32 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 147 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 73 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 27 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 76 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 76 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 62 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 82 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 158 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 24 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 17 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 126 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 125 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 108 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 79 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 83 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 182 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 35 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 39 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 192 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 119 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 29 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 81 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 194 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 73 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 7 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 75 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 34 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 15 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 118 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 92 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 40 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 190 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 37 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 43 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 9 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 139 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 65 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 94 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 128 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 39 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 41 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 32 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 129 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 177 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 16 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 74 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 83 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 29 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 191 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 62 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 116 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 16 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 23 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 7 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 170 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 46 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 91 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 94 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 143 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 116 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 139 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 49 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 119 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 46 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 26 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 31 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 23 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 29 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 113 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 178 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 45 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 73 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 36 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 46 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 13 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 113 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 22 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 18 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 66 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 7 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 34 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 7 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 45 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 25 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 41 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 141 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 64 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 56 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 157 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 55 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 7 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 28 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 58 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 32 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 107 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 13 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 20 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 29 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 58 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 162 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 104 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 40 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 55 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 64 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 103 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 59 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 35 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 159 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 100 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 38 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 29 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 164 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 8 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 59 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 23 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 90 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 159 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 23 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 101 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 58 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 64 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 107 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 20 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 145 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 56 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 42 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 109 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 29 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 46 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 89 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 92 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 37 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 5 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 146 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 150 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 27 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 52 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 29 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 65 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 31 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 28 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 171 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 7 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 100 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 9 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 67 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 98 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 14 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 11 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 150 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 9 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 12 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 90 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 28 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 172 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 28 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 108 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 172 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 41 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 57 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 158 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 5 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 176 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 41 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 56 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 8 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 145 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 27 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 49 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 20 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 102 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 9 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 105 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 158 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 35 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 21 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 126 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 66 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 29 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 39 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 25 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 295 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 157 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 296 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 48 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 153 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 74 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 19 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 26 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 9 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 33 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 25 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 274 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 31 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 296 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 139 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 29 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 30 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 266 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 22 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 31 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 120 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 9 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 143 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 27 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 22 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 146 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 22 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 138 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 29 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 9 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 68 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 159 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 71 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 301 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 10 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 46 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 35 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 46 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 158 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 35 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 151 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 7 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 157 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 34 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 50 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 25 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 79 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 23 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 10 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 37 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 123 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 29 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 41 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 151 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 126 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 277 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 279 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 18 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 9 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 52 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 137 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 10 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 27 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 10 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 24 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 123 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 5 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 289 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 147 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 140 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 34 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 7 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 21 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 42 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 25 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 16 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 272 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 266 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 128 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 46 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 51 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 141 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 21 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 80 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 55 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 42 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 5 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 147 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 288 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 141 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 22 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 74 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 52 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 42 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 24 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 5 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 137 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 255 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 118 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 39 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 27 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 17 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 40 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 23 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 2 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 6 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 149 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 293 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 144 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 18 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 67 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 49 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 17 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 25 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 9 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 5 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 142 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 265 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 16 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 50 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 38 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 22 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 2 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 125 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 36 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 41 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 23 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 5 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 291 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 144 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 42 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 24 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 149 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 71 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 50 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 4 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 5 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 144 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 21 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 67 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 17 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 38 Participants |
| Group 8 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 119 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 20 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 12 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 52 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 144 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 3 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 140 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 152 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 16 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 295 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 290 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 3 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 151 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 40 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 143 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 3 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 17 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 28 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 25 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 50 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 37 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 73 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 82 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 22 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 21 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 71 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 265 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 40 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 35 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 25 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 23 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 143 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 23 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 37 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 4 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 150 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 24 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 40 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 144 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 7 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 293 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 25 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 129 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 139 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 127 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 146 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 76 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 38 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 50 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 258 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 52 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 70 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 40 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 4 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 139 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 25 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 55 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 150 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 7 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 271 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 275 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 36 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 291 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 48 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 54 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 122 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 27 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 20 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 36 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 6 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 5 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 23 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 40 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 15 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 7 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 68 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 248 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 117 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 27 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 15 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 242 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 35 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 43 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 68 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 19 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 263 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 101 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 25 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 37 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 22 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 50 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 145 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 23 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 65 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 17 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 19 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 4 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 70 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 14 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 12 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 44 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 63 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 62 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 263 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 42 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 15 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 118 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 240 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 66 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 41 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 139 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 20 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 139 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 49 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 19 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 36 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 118 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 55 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 19 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 120 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 19 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 267 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 146 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 147 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 10 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 13 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 58 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 44 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 63 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 19 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 262 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 47 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 32 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 4 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 11 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 97 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 232 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 144 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 142 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 135 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 18 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 106 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 22 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 47 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 68 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 57 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 21 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 19 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 39 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 62 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 27 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 43 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 16 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 23 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 45 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 103 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 16 Participants |
| Group 10 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 3 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Total | 65 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Total | 70 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-USA | 46 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Total | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Peru | 139 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Peru | 131 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Total | 263 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-USA | 47 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-USA | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-USA | 32 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-USA | 120 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-USA | 108 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-USA | 110 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Total | 13 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Total | 66 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-USA | 45 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 2-Peru | 3 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Total | 49 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Peru | 3 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-Total | 11 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-USA | 45 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Peru | 136 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-USA | 50 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Total | 67 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 2-Peru | 17 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Peru | 135 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-Y at Month 0-Peru | 22 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-USA | 8 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Total | 76 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Total | 67 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Total | 64 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-USA | 9 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Total | 263 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-Total | 66 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Peru | 2 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 0-USA | 41 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Peru | 2 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-Total | 237 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-USA | 45 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-Total | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-USA | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 2-USA | 47 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-Peru | 22 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Total | 35 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Total | 61 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-Y at Month 2-USA | 8 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Peru | 143 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Peru | 144 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Peru | 16 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Peru | 3 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 2-Peru | 12 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-USA | 43 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | 2019-nCoV S/293F-50-N at Month 0-Peru | 143 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-Total | 267 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-Peru | 22 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-USA | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 0-USA | 124 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-USA | 100 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-USA | 8 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-N at Month 2-Peru | 19 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 DB His-50-N at Month 0-Total | 231 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-Total | 47 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 2-USA | 8 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-Total | 263 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 2-Total | 11 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 0-Total | 249 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 2-Peru | 26 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-USA | 121 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Peru | 2 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Peru | 3 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-N at Month 2-USA | 43 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50-Y at Month 0-Total | 68 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 2-Total | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-USA | 10 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 0-Total | 70 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 0-USA | 119 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-N at Month 0-Total | 244 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-Y at Month 2-Total | 13 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Total | 68 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 2-USA | 31 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50-Y at Month 0-USA | 39 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-USA | 40 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-N at Month 0-USA | 102 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 2-Peru | 2 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50-Y at Month 0-Peru | 23 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-Y at Month 2-Total | 13 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50-N at Month 2-USA | 45 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1 C His-50-Y at Month 0-Total | 63 Participants |
| Group 11 | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Comorbidity Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50-N at Month 0-Peru | 142 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 52 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 27 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 24 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 42 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 56 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 30 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 23 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 39 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 45 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 55 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 51 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 25 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 45 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 4 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 126 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 39 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 34 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 50 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 75 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 55 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 73 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 123 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 50 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 4 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 127 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 23 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 29 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 9 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 138 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 46 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 82 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 136 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 37 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 83 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 54 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 82 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 138 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 69 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 8 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 117 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 56 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 43 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 55 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 46 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 19 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 12 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 82 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 38 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 23 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 136 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 54 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 25 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 51 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 48 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 76 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 31 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 51 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 7 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 4 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 40 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 72 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 71 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 4 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 71 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 71 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 70 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 8 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 40 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 69 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 69 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 68 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 45 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-USA | 3 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-USA | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-USA | 19 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | 2019-nCoV S/293F-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Peru | 26 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 48 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and COVID-19 Severity Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Peru | 2 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by binding antibody multiplex assay (BAMA IgG3) at Visit 1, 2, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Time frame: Measured at Months 0, 2
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 28 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 31 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 26 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 27 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 75 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 17 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 19 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 73 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 65 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 17 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 65 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 73 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 10 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 74 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 19 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 66 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 63 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 72 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 74 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 73 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 78 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 77 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 78 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 70 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 79 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 24 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 0-Total | 150 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 2-Total | 43 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 0-Total | 150 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis)-50 at Month 2-Total | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 0-Total | 143 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin-50 at Month 2-Total | 39 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 0-Total | 151 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | 2019-nCoV S/293F-50 at Month 2-Total | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 0-Total | 136 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 DB His-50 at Month 2-Total | 20 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1S2 ECD His-50 at Month 0-Total | 154 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 Nucleoprotein His-50 at Month 2-Total | 33 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 0-Total | 140 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S Hexapro_293F_PPF-50 at Month 2-Total | 32 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 0-Total | 141 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (IgG3) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | SARS-CoV-2 S1 C His-50 at Month 2-Total | 32 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and comorbidity group among Africa Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 4-Total | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 2-Total | 10 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 0-Total | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 12-Total | 169 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 0-Total | 277 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 12-Total | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 4-Total | 200 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 2-Total | 202 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 0-Total | 248 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 0-Total | 44 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 12-Total | 21 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 4-Total | 30 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 2-Total | 29 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 12-Total | 155 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 2-Total | 183 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 4-Total | 178 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 2-Total | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 0-Total | 255 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 4-Total | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 12-Total | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 2-Total | 184 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 0-Total | 37 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 4-Total | 182 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 12-Total | 153 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 0-Total | 218 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 0-Total | 74 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 2-Total | 54 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 12-Total | 141 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 2-Total | 158 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 4-Total | 158 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 4-Total | 50 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 12-Total | 35 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 4-Total | 40 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 12-Total | 142 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 4-Total | 168 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 0-Total | 239 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 2-Total | 44 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 12-Total | 34 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 0-Total | 53 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 2-Total | 168 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 2-Total | 190 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 0-Total | 28 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 12-Total | 16 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 12-Total | 160 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 4-Total | 186 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-N at Month 0-Total | 264 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 4-Total | 22 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among Africa Cohort | SARS-Cov-2 D614G-Y at Month 2-Total | 22 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 0-Total | 34 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 4-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 2-Total | 171 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 12-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 4-Total | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 12-Total | 18 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 2-Total | 20 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 0-Total | 301 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 4-Total | 19 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 2-Total | 20 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 0-Total | 43 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 12-Total | 20 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 4-Total | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 0-Total | 292 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 12-Total | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 2-Total | 171 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 0-Total | 296 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 2-Total | 26 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 12-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 0-Total | 39 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 2-Total | 165 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 4-Total | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 4-Total | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 12-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 4-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 12-Total | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 2-Total | 149 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 0-Total | 70 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 2-Total | 42 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 0-Total | 265 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 4-Total | 12 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 12-Total | 16 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 0-Total | 144 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 4-Total | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 2-Total | 106 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 0-Total | 191 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 12-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 2-Total | 85 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 4-Total | 5 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 4-Total | 17 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 12-Total | 7 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 0-Total | 32 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 0-Total | 303 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-Y at Month 2-Total | 23 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 12-Total | 15 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Comorbidity Group Among America Cohort | VRC7480_G614-N at Month 2-Total | 168 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and COVID-19 severity
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 36 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 73 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 59 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 52 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 37 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 33 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 50 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 49 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 26 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 72 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 30 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 107 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 32 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 96 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 25 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 137 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 97 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 78 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 70 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 46 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 22 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 14 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 15 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 3 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 35 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 27 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 18 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 31 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 44 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 28 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 17 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 8 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 7 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 4 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 15 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 5 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 3 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 8 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 1 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 1 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 1 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 1 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 1 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 1 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and COVID-19 severity
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-Peru | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-USA | 14 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-USA | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-Total | 54 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-Peru | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-Peru | 25 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-Peru | 30 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-USA | 54 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-Peru | 56 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-Total | 84 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-Total | 139 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-Total | 9 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-USA | 83 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-Total | 9 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-Total | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-Total | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-Total | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-Peru | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-Total | 16 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-Peru | 30 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-Total | 70 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-USA | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-Peru | 4 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-Total | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-USA | 3 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-Total | 45 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-Peru | 5 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-Total | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-USA | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-Total | 49 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-Total | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-Peru | 6 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-USA | 3 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 12-Total | 3 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 4-USA | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 0-USA | 21 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-USA | 11 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and COVID-19 Severity Among America Cohort | VRC7480_G614 at Month 2-Total | 17 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among Africa Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 7 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 17 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 16 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 20 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 61 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 27 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 36 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 22 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 9 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 33 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 29 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 48 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 13 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 37 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 8 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 24 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 46 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 50 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 36 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 12 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 52 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 13 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 37 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 60 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 10 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 40 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 43 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 146 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 45 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 56 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 96 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 40 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 63 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 106 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 43 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 65 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 108 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 101 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-Peru | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 12-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 12-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-Peru | 21 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-Peru | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-USA | 8 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-Total | 18 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-Total | 75 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-Peru | 48 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-USA | 27 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 12-Peru | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 12-Total | 4 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 12-USA | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-Peru | 31 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-Total | 48 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-USA | 17 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-Peru | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-Total | 5 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-Total | 80 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-Total | 43 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-Peru | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-Total | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-USA | 32 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-Peru | 48 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 12-Total | 3 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-USA | 18 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 12-Peru | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 12-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-Peru | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 12-USA | 9 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-Peru | 23 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-Total | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-Total | 82 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-Total | 151 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 2-USA | 59 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-USA | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 4-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 12-Peru | 5 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-Peru | 50 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 12-Total | 14 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | VRC7480_G614 at Month 0-USA | 101 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and enrollment group among Africa Cohort
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in South Africa population, regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 12 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 43 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 32 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 59 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 48 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 11 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 46 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 31 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 34 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 44 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 11 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 4 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 7 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 14 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 5 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 21 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 68 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 58 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 41 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 79 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 27 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 80 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 20 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 60 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 110 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 87 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 17 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 5 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 4 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 7 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 3 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 10 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 13 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 3 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 10 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 3 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 16 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 37 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 14 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 23 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 43 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 27 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 40 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 33 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 51 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 13 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 8 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 9 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 12 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 4 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 5 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 5 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 6 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 18 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 11 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 13 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 3 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-RSA | 7 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-RSA | 3 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-Total | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-non-RSA | 7 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-Total | 13 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-RSA | 9 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-Total | 10 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-non-RSA | 9 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 12-non-RSA | 7 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 4-RSA | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 2-non-RSA | 7 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among Africa Cohort | SARS-Cov-2 D614G at Month 0-Total | 18 Participants |
Primary
SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort
Neutralizing antibodies against SARS coronaviruses are measured in 293T/ACE2 cells for all HIV negative samples. MPI (maximum percent inhibition) is also measured. Positivity calls are an ID50/ID80 (50% and 80% inhibitory dose) value either \>20 (the lower limit of detection (LLOD) of the assay) or MPI is between 10%-50%. The neutralizing antibody ID50/ID80 of all HIV positive samples are measured by a different assay, VSV pseudovirus neutralization assay. Positivity calls are based on whether or not any neutralization is observed through entire titration (starting dilution 1:20) with MPI between 10%-50%. For the positive calls but the neutralization does not reach 50% or 80%, ID50/ID80 titer is first estimated by Prism. The table summarized SARS-CoV-2-specific Antibody Binding Response Rate by neutralizing antibody assay (NAb) at Visit 1, 2, 3, 4, overall and by region and enrollment group among America Cohort (USA and Peru only)
Time frame: Measured at Months 0, 2, 4, 12
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Peru | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-USA | 15 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-Peru | 1 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Total | 22 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Peru | 13 Participants |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Total | 37 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Total | 15 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-USA | 12 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Total | 6 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-USA | 4 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Total | 51 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-Peru | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-Total | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-Total | 2 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-USA | 28 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-Peru | 1 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-USA | 16 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Total | 33 Participants |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-USA | 1 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-Total | 1 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-USA | 1 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Peru | 11 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Total | 29 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-USA | 18 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Peru | 22 Participants |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Total | 47 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Peru | 23 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-USA | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-Total | 2 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Total | 43 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-Total | 1 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Total | 30 Participants |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-USA | 1 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-USA | 13 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Peru | 17 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Total | 30 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-Total | 3 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-USA | 24 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-Total | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-USA | 2 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Total | 49 Participants |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-USA | 3 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-Peru | 7 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-USA | 8 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 12-Total | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-Total | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 4-USA | 7 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Total | 41 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-Total | 93 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-USA | 27 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 2-Peru | 14 Participants |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Rate (Nab) by Region and Enrollment Group Among America Cohort | VRC7480_G614 at Month 0-USA | 44 Participants |
Primary
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and Comorbidity Group among America Cohort
Time frame: Measured at Months 0
Population: American Population with positive responders (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 0 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 0 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 0 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 0 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 1.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 0.8 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 0.8 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 1.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 1.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 0.8 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 0 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 0.8 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 0.8 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
Primary
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and COVID-19 severity among America Cohort
Time frame: Measured at Months 0
Population: American Population with positive responders (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Total | 0 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Peru | 0 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 1.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Total | 1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.8 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Total | 1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 1.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
Primary
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Time frame: Measured at Months 0
Population: American Population with positive responders (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-USA | 0 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.8 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.8 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
Primary
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and enrollment group among America Cohort positive responders (USA and Peru)
Time frame: Measured at Months 0
Population: American Population among positive responders (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 2.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 0 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 0 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 2.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.8 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.6 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 0.4 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 0.9 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 0.3 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Peru | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 0.7 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0.1 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 0.5 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 0.2 % T cells expressing IFN-g/IL-2 |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Magnitude (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 0.3 % T cells expressing IFN-g/IL-2 |
Primary
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1, overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0
Population: American Population with positive responders (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 6 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 65 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 102 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 113 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 218 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 139 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 49 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 101 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 214 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 16 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 47 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 14 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 113 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 131 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 84 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 124 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 7 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 188 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 59 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 244 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 100 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 6 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 46 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 114 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 18 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 225 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 213 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 82 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 9 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 42 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 30 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 35 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 8 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 101 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 113 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 117 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 67 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 86 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 7 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 71 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 7 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 29 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 12 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 13 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 29 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 123 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 27 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 54 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 85 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 124 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 263 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 200 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 12 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 73 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 103 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 18 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 138 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 144 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 18 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 36 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 189 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 26 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 31 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 11 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 93 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 76 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 87 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 6 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 57 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 4 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 25 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 14 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 21 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 59 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 24 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 39 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 16 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 19 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 23 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 38 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 57 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 4 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 92 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 87 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 50 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 10 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 30 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 52 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 45 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 38 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 24 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 11 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 84 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 31 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 77 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 61 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 69 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 34 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 35 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 33 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 37 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 67 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 32 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 162 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 6 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 33 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 33 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 85 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 52 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 69 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 67 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 22 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 83 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 35 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 105 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 13 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 9 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 16 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 98 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 28 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 174 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 24 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 76 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 19 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 16 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 37 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 24 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 49 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 10 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 78 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 49 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 38 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 143 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 41 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 28 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 69 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 12 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 82 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 14 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 34 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 68 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 150 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 67 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 88 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 69 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 152 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 165 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 34 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 62 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 69 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 98 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 10 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 86 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 42 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 47 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 33 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 99 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 116 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 122 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 96 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 95 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 115 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 11 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 211 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 28 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 18 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 242 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 120 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 135 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 116 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 222 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 107 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 11 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 8 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 191 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 214 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 50 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 65 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 11 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 221 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 15 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 51 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 4 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 197 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 138 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 55 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 9 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 71 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 13 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 80 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 7 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 11 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 83 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 52 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 108 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 261 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 77 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 27 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 7 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 30 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 126 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 27 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 12 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 20 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 82 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 118 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 143 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 31 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 103 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 20 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 20 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 169 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 48 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 0 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 51 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 9 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 33 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 10 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 31 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 161 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 111 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 58 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 26 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 5 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 1 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 71 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 209 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 30 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 138 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 63 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 124 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 59 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 50 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 48 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 14 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 13 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 61 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 48 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 3 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 42 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 11 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 15 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 52 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 3 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 49 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 19 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 111 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 16 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 48 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 113 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 5 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 54 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 40 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 49 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 130 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 30 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 193 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 93 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 63 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 2 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 63 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 5 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 49 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 59 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 52 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 54 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 3 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 43 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 56 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 47 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 117 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 176 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 165 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 113 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 59 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 5 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 47 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 56 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 3 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 181 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 57 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 3 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 27 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 18 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 85 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 62 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 54 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 19 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 0 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 19 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 12 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 24 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 0 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 11 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 0 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 42 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 6 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 6 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 9 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 152 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 5 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 20 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 33 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 23 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 43 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 84 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 20 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 14 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 60 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 19 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 17 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 106 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 61 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 95 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 51 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 50 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 43 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 124 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 37 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 35 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 36 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 29 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 14 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 33 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 42 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 81 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 38 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 34 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 97 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 34 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 87 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 10 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 138 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 33 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 27 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 3 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 68 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 11 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 136 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 94 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 48 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 94 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 95 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 80 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 7 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 35 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 37 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 86 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 8 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 44 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 49 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 71 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 29 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 51 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 123 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 146 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 117 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 63 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 10 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 56 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 44 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 25 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 31 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 83 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 62 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 18 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 73 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 79 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 17 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 39 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 38 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 127 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 75 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 59 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 55 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 9 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 23 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 32 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 51 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 11 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 44 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 92 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 112 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 21 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 38 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 104 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 160 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 17 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 61 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 4 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 43 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 68 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 9 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 89 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 64 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 39 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 51 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 70 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 19 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 35 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 72 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 37 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 81 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 71 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 103 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 50 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 15 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 12 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 32 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 20 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 75 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 17 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 38 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 134 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 91 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 47 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 52 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 42 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 11 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 8 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 3 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 111 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 62 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 15 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 82 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 16 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 131 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 89 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 33 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 112 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 37 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 56 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 67 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 32 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 42 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 74 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 10 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 100 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 18 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 110 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 121 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 68 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 34 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 112 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 29 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 47 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 37 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 17 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 33 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 37 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 40 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 43 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 11 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 131 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 17 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 111 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 74 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 44 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 66 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 107 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 8 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 33 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 56 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 31 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 75 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 41 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 4 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 138 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 45 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 36 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 13 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 20 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 119 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 101 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 33 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 7 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 35 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 38 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 42 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 9 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 23 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 88 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 1 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 110 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 199 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 89 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 128 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 7 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 20 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 227 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 99 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 7 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 25 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 18 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 48 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 118 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 211 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 93 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 4 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 208 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 89 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 23 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 74 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 21 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 7 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 5 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 26 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 4 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 3 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 182 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 27 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 2 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 5 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 3 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 49 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 78 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 3 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 40 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 2 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 8 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 6 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 18 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 2 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 2 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 45 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 19 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 86 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 6 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 25 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 19 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 61 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 113 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 52 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 110 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 7 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 23 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 8 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 9 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 110 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 17 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 5 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 127 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 46 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 196 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 4 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 0 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 12 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 2 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 28 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 18 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 66 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 182 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 10 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 21 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 75 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 4 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 16 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 28 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 119 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 108 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 9 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 27 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 81 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 17 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 10 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 13 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 104 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 135 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 2 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 63 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 15 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 245 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 73 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 9 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 24 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 68 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 60 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 74 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 4 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 19 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 7 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 18 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 29 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 108 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 97 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 49 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 16 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 12 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 118 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 16 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 100 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 44 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 24 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 3 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 63 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 12 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 11 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 0 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 12 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 70 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 29 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 18 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 236 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 7 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 3 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 73 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 26 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 11 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 24 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 170 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 128 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 36 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 33 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 44 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 5 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 19 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 103 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 16 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 111 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 28 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 19 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 2 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 28 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 29 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 186 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 89 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 121 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 77 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 14 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 6 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 89 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 18 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 174 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 84 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 1 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 192 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 11 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 14 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 203 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 15 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 1 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 15 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 114 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 107 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 1 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 6 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 44 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 219 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 33 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 8 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 16 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 11 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 33 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 39 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 58 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 44 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 13 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 6 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 102 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 1 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 92 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 98 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 203 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 21 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 29 Participants |
| Group 8 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 12 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 82 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 100 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 210 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 108 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 9 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 14 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 115 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 12 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 45 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 111 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 10 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 93 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 11 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 17 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 8 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 5 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 20 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 26 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 26 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 3 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 6 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 12 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 5 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 24 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 3 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 6 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 3 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 19 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 32 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 183 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 3 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 11 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 7 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 24 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 9 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 89 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 14 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 46 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 9 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 30 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 9 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 90 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 0 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 1 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 207 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 117 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 0 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 226 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 126 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 7 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 63 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 44 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 39 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 95 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 200 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 19 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 79 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 101 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 59 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 76 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 16 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 13 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 5 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 187 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 69 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 15 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 6 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 30 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 15 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 132 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 9 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 242 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 3 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 110 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 50 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 133 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 108 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 83 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 7 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 115 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 65 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 11 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 26 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 18 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 2 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 52 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 12 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 17 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 0 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 7 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 22 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 201 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 6 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 12 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 4 Participants |
| Group 9 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 5 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 63 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 36 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 10 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 124 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 60 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 28 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 20 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 60 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 15 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 13 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 95 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 53 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 35 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 26 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 38 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 9 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 66 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 41 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 154 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 11 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 36 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 46 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 56 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 3 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 13 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 41 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 13 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 107 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 168 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 98 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 36 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 71 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 88 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 15 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 212 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 11 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 35 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 196 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 19 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 7 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 7 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 2 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 38 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 10 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 25 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 21 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 4 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 11 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 5 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 8 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 30 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 72 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 68 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 4 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 23 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 18 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 178 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 4 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 108 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 1 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 13 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 82 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 42 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 191 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 99 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 109 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 23 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 69 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 38 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 17 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 56 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 99 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 53 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 18 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 36 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 79 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 52 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 20 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 90 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 164 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 35 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 32 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 49 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 52 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 17 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 17 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 70 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 117 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 10 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 167 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 47 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 14 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 4 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 69 Participants |
| Group 10 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 4 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Total | 14 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Peru | 11 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-USA | 2 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Peru | 13 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-Total | 39 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Peru | 5 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Total | 103 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Peru | 119 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-USA | 12 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-USA | 29 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Peru | 110 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Peru | 1 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-Total | 185 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Total | 28 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Peru | 18 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-USA | 20 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Peru | 16 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-USA | 17 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-Total | 46 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-USA | 8 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-USA | 44 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Peru | 46 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-Y at Month 0-Total | 33 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Total | 40 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-USA | 92 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Total | 12 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-USA | 74 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-Y at Month 0-Peru | 11 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-USA | 9 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-USA | 71 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-USA | 8 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-Y at Month 0-Peru | 4 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-N at Month 0-USA | 75 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-Peru | 6 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Total | 49 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-USA | 22 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Total | 40 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Peru | 105 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-Peru | 16 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-Y at Month 0-USA | 8 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-USA | 21 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-Y at Month 0-USA | 33 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Total | 181 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Peru | 97 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-USA | 27 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-Peru | 103 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Peru | 111 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-USA | 84 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-Y at Month 0-Total | 14 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-USA | 37 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-Total | 193 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Peru | 43 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S2-N at Month 0-Total | 179 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-N at Month 0-USA | 82 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Total | 24 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-N at Month 0-Peru | 59 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Spike-N at Month 0-Total | 203 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Peru | 44 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Peru | 102 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-Total | 170 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Total | 59 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Total | 23 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-Y at Month 0-Peru | 13 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-N at Month 0-Peru | 12 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-Total | 57 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Total | 22 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-Y at Month 0-Total | 55 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-USA | 43 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Peru | 0 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-USA | 27 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-USA | 21 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF3a6-Y at Month 0-Peru | 6 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Peru | 11 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Any COV2-Y at Month 0-USA | 28 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Peru | 77 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Peru | 4 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-Peru | 18 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-Y at Month 0-Total | 2 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S1-N at Month 0-Peru | 38 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-USA | 13 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-E M-N at Month 0-USA | 68 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF7a7b8-N at Month 0-USA | 11 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-N at Month 0-Total | 168 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-USA | 5 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-N-N at Month 0-USA | 78 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-ORF3a6-N at Month 0-Total | 66 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-N at Month 0-Total | 120 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Total | 217 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-S1-Y at Month 0-USA | 30 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-Y at Month 0-Total | 12 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-E M-Y at Month 0-Total | 6 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-Any COV2-N at Month 0-Peru | 125 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-S2-N at Month 0-USA | 10 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-N-Y at Month 0-Total | 32 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD4+-ORF7a7b8-Y at Month 0-Peru | 9 Participants |
| Group 11 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Comorbidity Group Among America Cohort | CD8+-Spike-N at Month 0-Total | 70 Participants |
Primary
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Time frame: Measured at Months 0
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Total | 33 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-USA | 18 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Peru | 7 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Total | 16 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Peru | 11 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Total | 20 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 8 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 15 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 9 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Peru | 10 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Total | 20 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-USA | 10 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Peru | 12 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Total | 21 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Peru | 13 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Total | 25 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-USA | 12 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 14 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Total | 33 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-USA | 19 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Peru | 11 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Total | 27 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-USA | 16 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 8 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 6 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Peru | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Total | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Total | 78 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-USA | 37 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-USA | 23 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Peru | 1 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Total | 72 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-USA | 46 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 23 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-USA | 52 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Total | 93 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 41 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Peru | 40 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 22 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Total | 11 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-USA | 56 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Total | 96 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Peru | 14 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Peru | 35 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Total | 38 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 45 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Total | 33 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-USA | 61 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Total | 107 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-USA | 19 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 22 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 46 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 23 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-USA | 50 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Peru | 37 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Total | 87 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 17 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 13 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 29 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Total | 84 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 20 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Peru | 15 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 16 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-USA | 45 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-USA | 47 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 42 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Total | 84 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Peru | 39 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-USA | 7 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Peru | 32 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Peru | 37 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-USA | 7 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Total | 8 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Peru | 4 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 7 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 10 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-USA | 5 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Peru | 11 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Peru | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-USA | 5 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-USA | 5 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 10 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Total | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Total | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Peru | 8 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Total | 13 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-USA | 5 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Peru | 5 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 5 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 14 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-USA | 5 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Peru | 12 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Total | 14 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Peru | 5 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Peru | 12 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Total | 16 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 5 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Total | 10 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Peru | 34 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Total | 58 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-USA | 3 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Peru | 30 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-USA | 1 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-USA | 26 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Total | 46 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-USA | 16 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-USA | 24 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 18 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Total | 64 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-USA | 3 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Peru | 12 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 25 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 22 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 7 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Peru | 12 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Peru | 38 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Peru | 31 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 17 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 22 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-USA | 3 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 16 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 40 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 5 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Total | 67 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 46 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Total | 56 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-USA | 27 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Total | 66 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-USA | 26 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Peru | 40 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Peru | 4 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 34 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Peru | 34 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Total | 54 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Total | 5 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-USA | 25 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 30 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-USA | 20 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Peru | 7 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Total | 59 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Peru | 10 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Total | 7 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Total | 16 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Total | 42 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-USA | 13 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-USA | 2 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Total | 43 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-USA | 17 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 26 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 23 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 32 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 11 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-USA | 17 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-Total | 30 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-USA | 2 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 15 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Total | 7 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-N at Month 0-USA | 10 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-Total | 46 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Total | 44 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-USA | 16 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 9 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-USA | 18 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-E M at Month 0-Peru | 27 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Total | 45 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Any COV2 at Month 0-USA | 18 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 12 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S2 at Month 0-Peru | 5 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S1 at Month 0-Peru | 27 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Any COV2 at Month 0-Total | 36 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-S1 at Month 0-Total | 14 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 3 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Total | 46 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-Peru | 28 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 21 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 11 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-Spike at Month 0-Peru | 11 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 11 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-N at Month 0-Peru | 25 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-S2 at Month 0-Peru | 27 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 15 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD4+-Spike at Month 0-USA | 18 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and COVID-19 Severity Among America Cohort | CD8+-E M at Month 0-Peru | 5 Participants |
Primary
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1, overall and by region and days since SARS-CoV-2 diagnosis group among America Cohort
Time frame: Measured at Months 0
Population: American Population with positive responders (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 8 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 22 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Peru | 10 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Total | 12 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Peru | 14 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Total | 16 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 17 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 9 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Peru | 12 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Total | 16 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Peru | 13 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Total | 17 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Peru | 15 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Total | 20 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 12 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 17 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Peru | 11 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Total | 16 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Total | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Peru | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Total | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 29 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Total | 53 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 34 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 4 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 13 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 53 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Total | 49 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-USA | 3 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 9 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 19 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Peru | 37 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Total | 11 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Total | 23 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Total | 20 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-USA | 14 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-USA | 14 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Total | 4 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 26 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Total | 45 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-USA | 7 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-USA | 13 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Peru | 31 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 5 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Peru | 37 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 5 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 16 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Total | 50 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Total | 48 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Peru | 15 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Peru | 37 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Peru | 8 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-USA | 11 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 21 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 18 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-USA | 5 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Peru | 40 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 4 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 58 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Peru | 39 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Total | 54 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 34 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 12 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Peru | 16 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-USA | 14 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-USA | 12 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 40 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Total | 53 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 26 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 35 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Peru | 11 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 9 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Peru | 34 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Total | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-USA | 19 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Total | 17 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Peru | 34 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Total | 54 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-USA | 20 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Peru | 38 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Peru | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Total | 61 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-USA | 23 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 42 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Peru | 12 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 64 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 22 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Peru | 7 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Total | 18 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-USA | 1 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Peru | 41 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Total | 61 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-USA | 20 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 30 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-USA | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 7 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 41 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 66 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 23 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 25 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Peru | 32 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Total | 47 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-USA | 15 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 25 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Peru | 30 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Total | 51 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-USA | 21 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 22 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 32 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 10 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-USA | 9 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-USA | 75 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 45 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 45 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Total | 117 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Spike at Month 0-Peru | 42 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Peru | 41 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 126 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 63 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-USA | 68 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-USA | 70 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 81 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 14 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Total | 100 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Peru | 14 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Peru | 36 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-Total | 32 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 41 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-Total | 94 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S2 at Month 0-Peru | 32 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-USA | 68 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 14 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-E M at Month 0-USA | 58 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-USA | 22 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-USA | 14 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 18 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Peru | 25 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Total | 38 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Total | 17 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-S1 at Month 0-Total | 109 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-Total | 78 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 23 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-E M at Month 0-Peru | 3 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Peru | 35 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-N at Month 0-USA | 53 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 64 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S2 at Month 0-Peru | 6 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 28 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 14 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 98 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Spike at Month 0-Peru | 16 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-S1 at Month 0-USA | 18 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 32 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 64 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 34 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD4+-N at Month 0-Total | 105 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 18 Participants |
Primary
SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort
Flow cytometry was used to examine SARS-CoV-2 specific CD4+ and CD8+ T-cell responses using an intracellular cytokine staining (ICS). Positive calls will be made using Fisher's exact positivity test for all the markers. The magnitudes are % T cells expressing IFN-g/IL-2. The table summarized SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate by flow cytometry at Visit 1 , overall and by region and enrollment group among America Cohort (USA and Peru only)
Time frame: Measured at Months 0
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 16 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 11 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Peru | 0 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 8 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 14 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 23 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 19 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 12 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 9 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 10 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 4 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 10 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 21 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 10 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 9 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 12 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 10 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 2 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 13 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 1 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 13 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 5 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 3 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 6 Participants |
| Group 1A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 7 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 8 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 8 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 1 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 3 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 11 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 5 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 3 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 6 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 3 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Peru | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 7 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 7 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 5 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 3 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 1 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 5 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 8 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 0 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 1 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 2 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 3 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 8 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 1 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 5 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 5 Participants |
| Group 1B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 11 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 8 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 1 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 4 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 10 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 5 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 15 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 4 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 11 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 12 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 25 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 13 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 14 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 7 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 20 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 19 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 12 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 12 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 10 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 27 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 15 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 9 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 17 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 33 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 16 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Peru | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 18 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 3 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 15 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 26 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 7 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 31 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 8 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 24 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 2 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 6 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 0 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 4 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 13 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 5 Participants |
| Group 1C | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 13 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 19 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Peru | 1 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 23 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 5 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 5 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 23 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 18 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 15 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 4 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 40 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 21 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 18 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 41 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 36 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 3 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 21 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 13 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 18 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 29 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 46 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 8 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 30 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 20 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 14 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 12 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 17 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 6 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 17 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 9 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 44 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 9 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 2 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 14 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 23 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 5 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 18 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 23 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 43 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 8 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 37 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 17 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 20 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 19 Participants |
| Group 1D | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 7 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 17 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 7 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Peru | 2 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 14 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 35 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 32 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 15 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 9 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 30 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 3 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 12 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 16 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 17 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 5 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 19 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 1 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 16 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 12 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 32 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 11 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 17 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 35 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 7 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 19 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 17 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 4 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 37 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 31 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 15 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 37 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 11 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 9 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 2 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 20 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 14 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 16 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 6 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 16 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 21 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 13 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 4 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 11 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 22 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 16 Participants |
| Group 2A | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 15 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 8 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 43 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 12 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 29 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 17 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 19 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 32 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 13 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 24 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 45 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 21 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 24 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 45 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 21 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 46 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 21 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 19 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 33 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 14 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Peru | 3 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 7 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 16 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 26 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 10 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 7 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 13 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 6 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 21 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 11 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 3 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 6 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 10 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 2 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 3 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 1 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 6 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 10 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 4 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 25 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 47 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 22 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 22 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 39 Participants |
| Group 2B | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 17 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-USA | 7 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Total | 21 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-Peru | 15 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-USA | 6 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Total | 20 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF7a7b8 at Month 0-Peru | 14 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-USA | 17 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Peru | 47 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-USA | 8 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Total | 22 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-ORF3a6 at Month 0-Peru | 14 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-USA | 24 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Total | 55 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Total | 31 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-Total | 79 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-N at Month 0-Peru | 31 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-USA | 3 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Total | 10 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-E M at Month 0-Peru | 7 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-USA | 28 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-Peru | 21 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Any COV2 at Month 0-USA | 32 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Total | 63 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Any COV2 at Month 0-Peru | 35 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-USA | 30 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Total | 75 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-Spike at Month 0-Peru | 45 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-USA | 24 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Peru | 40 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-USA | 26 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Total | 65 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S2 at Month 0-Peru | 39 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-USA | 25 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Total | 66 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Total | 61 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-E M at Month 0-Total | 57 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-S1 at Month 0-Peru | 41 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-USA | 14 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Total | 43 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF7a7b8 at Month 0-Peru | 29 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-ORF3a6 at Month 0-USA | 10 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Total | 23 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-Spike at Month 0-Peru | 16 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-USA | 3 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Total | 8 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S2 at Month 0-Peru | 5 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD8+-S1 at Month 0-USA | 6 Participants |
| Group 3 | SARS-CoV-2-specific CD4+ and CD8+ T Cell Response Rate (ICS) by Region and Enrollment Group Among America Cohort | CD4+-N at Month 0-Peru | 37 Participants |
Primary
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , overall and by region
Time frame: Measured at Months 0
Population: african Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | COPD/emphysema/ asthma | 0 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Currently smoke cigarettes or marijua0 | 12 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders | 6 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Prolonged viral shedding | 1 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders, non HIV | 0 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Chronic kidney disease | 1 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | HIV | 6 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes with complications | 1 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Any targeted conditions at enrollment | 14 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Hypertension | 7 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes | 4 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Myocarditis/ pericarditis | 0 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Congestive heart failure | 0 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Ever smoked cigarettes or marijua0 | 20 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Prolonged viral shedding | 0 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes | 3 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes with complications | 0 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Any targeted conditions at enrollment | 12 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders, non HIV | 0 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | COPD/emphysema/ asthma | 2 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders | 2 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Chronic kidney disease | 0 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Hypertension | 8 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Congestive heart failure | 0 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | HIV | 2 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Currently smoke cigarettes or marijua0 | 1 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Myocarditis/ pericarditis | 0 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Ever smoked cigarettes or marijua0 | 2 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders, non HIV | 1 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Currently smoke cigarettes or marijua0 | 12 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Congestive heart failure | 0 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Myocarditis/ pericarditis | 0 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Any targeted conditions at enrollment | 44 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | HIV | 14 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Ever smoked cigarettes or marijua0 | 27 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders | 15 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes with complications | 0 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Chronic kidney disease | 0 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Prolonged viral shedding | 2 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | COPD/emphysema/ asthma | 9 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Hypertension | 15 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes | 11 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Hypertension | 15 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Prolonged viral shedding | 0 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Any targeted conditions at enrollment | 17 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | COPD/emphysema/ asthma | 0 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Chronic kidney disease | 1 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Congestive heart failure | 1 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Currently smoke cigarettes or marijua0 | 3 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes | 6 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes with complications | 1 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Ever smoked cigarettes or marijua0 | 6 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | HIV | 0 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders | 0 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders, non HIV | 0 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Myocarditis/ pericarditis | 0 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Congestive heart failure | 0 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders | 18 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes | 15 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Hypertension | 18 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Chronic kidney disease | 2 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Prolonged viral shedding | 1 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Myocarditis/ pericarditis | 0 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Currently smoke cigarettes or marijua0 | 4 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Any targeted conditions at enrollment | 38 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes with complications | 2 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders, non HIV | 0 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | HIV | 18 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Ever smoked cigarettes or marijua0 | 10 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | COPD/emphysema/ asthma | 2 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Ever smoked cigarettes or marijua0 | 4 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Currently smoke cigarettes or marijua0 | 2 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Myocarditis/ pericarditis | 0 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Congestive heart failure | 2 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | HIV | 2 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Chronic kidney disease | 2 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | COPD/emphysema/ asthma | 1 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders | 3 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Any targeted conditions at enrollment | 20 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders, non HIV | 1 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Prolonged viral shedding | 0 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Hypertension | 18 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes | 10 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes with complications | 2 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Hypertension | 8 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Myocarditis/ pericarditis | 1 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes with complications | 1 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders, non HIV | 1 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Congestive heart failure | 1 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Prolonged viral shedding | 1 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Ever smoked cigarettes or marijua0 | 6 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | COPD/emphysema/ asthma | 3 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Chronic kidney disease | 0 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Currently smoke cigarettes or marijua0 | 2 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Immune system disorders | 3 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | HIV | 2 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Any targeted conditions at enrollment | 13 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among Africa Cohort | Diabetes | 4 Participants |
Primary
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort
SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , overall and by region
Time frame: Measured at Months 0
Population: American Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Currently smoke cigarettes or marijua0 | 8 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - ever | 11 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | COPD/emphysema/ asthma | 2 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - current | 5 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Myocarditis/ pericarditis | 0 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Chronic kidney disease | 0 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | HIV | 4 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes | 3 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Congestive heart failure | 0 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders, non HIV | 1 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes with complications | 1 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders | 5 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Ever smoked cigarettes or marijua0 | 18 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - current | 4 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Any targeted conditions at enrollment | 14 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Hypertension | 6 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - ever | 11 Participants |
| Group 1A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Prolonged viral shedding | 1 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes | 26 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Hypertension | 22 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Prolonged viral shedding | 0 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders | 30 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Ever smoked cigarettes or marijua0 | 16 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Any targeted conditions at enrollment | 21 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Chronic kidney disease | 28 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | COPD/emphysema/ asthma | 23 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Myocarditis/ pericarditis | 25 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - current | 18 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - ever | 17 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - ever | 19 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Congestive heart failure | 24 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Currently smoke cigarettes or marijua0 | 5 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - current | 20 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes with complications | 27 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders, non HIV | 31 Participants |
| Group 1B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | HIV | 29 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - ever | 17 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders, non HIV | 5 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - ever | 15 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | COPD/emphysema/ asthma | 6 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Ever smoked cigarettes or marijua0 | 23 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Any targeted conditions at enrollment | 18 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Congestive heart failure | 0 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - current | 4 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Hypertension | 2 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | HIV | 6 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes | 3 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Currently smoke cigarettes or marijua0 | 8 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders | 11 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Chronic kidney disease | 0 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes with complications | 0 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Myocarditis/ pericarditis | 0 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - current | 4 Participants |
| Group 1C | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Prolonged viral shedding | 3 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes with complications | 1 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | COPD/emphysema/ asthma | 6 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes | 8 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - current | 1 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - ever | 19 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Myocarditis/ pericarditis | 0 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders, non HIV | 4 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders | 6 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Hypertension | 20 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Ever smoked cigarettes or marijua0 | 25 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Prolonged viral shedding | 2 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Congestive heart failure | 0 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Currently smoke cigarettes or marijua0 | 2 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - current | 1 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Any targeted conditions at enrollment | 32 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | HIV | 2 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Chronic kidney disease | 0 Participants |
| Group 1D | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - ever | 14 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes with complications | 1 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Any targeted conditions at enrollment | 20 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Currently smoke cigarettes or marijua0 | 3 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | COPD/emphysema/ asthma | 4 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Chronic kidney disease | 0 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - current | 2 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - ever | 11 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Congestive heart failure | 1 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes | 7 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Ever smoked cigarettes or marijua0 | 15 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | HIV | 4 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Hypertension | 12 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders | 6 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders, non HIV | 2 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - current | 2 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - ever | 7 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Myocarditis/ pericarditis | 0 Participants |
| Group 2A | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Prolonged viral shedding | 0 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders | 14 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Ever smoked cigarettes or marijua0 | 24 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes with complications | 0 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders, non HIV | 10 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes | 9 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Currently smoke cigarettes or marijua0 | 2 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Congestive heart failure | 3 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - current | 2 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - ever | 18 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - current | 0 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - ever | 17 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Chronic kidney disease | 1 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | COPD/emphysema/ asthma | 8 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Prolonged viral shedding | 0 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Myocarditis/ pericarditis | 0 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Any targeted conditions at enrollment | 33 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Hypertension | 17 Participants |
| Group 2B | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | HIV | 4 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | HIV | 21 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Ever smoked cigarettes or marijua0 | 47 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Prolonged viral shedding | 30 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Myocarditis/ pericarditis | 1 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes | 12 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Congestive heart failure | 3 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - ever | 26 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders, non HIV | 8 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Chronic kidney disease | 2 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Currently smoke cigarettes or marijua0 | 12 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Immune system disorders | 29 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | COPD/emphysema/ asthma | 11 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Any targeted conditions at enrollment | 53 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Hypertension | 22 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Marijua0 smoking - current | 6 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - ever | 37 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Diabetes with complications | 3 Participants |
| Group 3 | SARS-CoV-2-specific Infection Presentation, Including Clinical Course, Along With Demographics and Corresponding Medical History of Participants , Overall and by Region Among America Cohort | Cigarette smoking - current | 9 Participants |
Primary
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort
SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). The sample will be included in the analysis only if the number of IgD- B cells is equal or greater than 1000 for that sample. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and comorbidity group among America Cohort
Time frame: Measured at Months 0
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Total | 0.00 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Peru | 0.40 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Total | 0.05 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-USA | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Total | 0.66 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Peru | 0.39 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Total | 0.07 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-USA | 0.05 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-USA | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Total | 0.15 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Peru | 0.07 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Peru | 0.12 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Peru | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Peru | 0.79 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Peru | 0.08 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-USA | 0.26 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Peru | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Total | 0.69 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Peru | 0.02 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Total | 0.07 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Peru | 0.04 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Peru | 0.02 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Peru | 0.00 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Peru | 0.10 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Peru | 0.18 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Peru | 0.02 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Total | 0.10 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-USA | 0.10 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Peru | 0.19 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Total | 0.13 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Peru | 0.13 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Total | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-USA | 0.56 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Total | 0.11 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Peru | 0.10 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Total | 0.00 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Peru | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-USA | 0.09 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Peru | 0.00 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Total | 0.34 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-USA | 0.04 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Total | 0.32 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Peru | 0.04 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-USA | 0.04 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Peru | 0.07 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Total | 0.15 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-USA | 0.12 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-USA | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Total | 0.15 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Peru | 0.64 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-USA | 0.28 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-USA | 0.12 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Total | 0.04 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Peru | 0.16 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-USA | 0.10 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Total | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-USA | 0.16 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-USA | 0.68 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Total | 0.15 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Total | 0.12 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Total | 0.20 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Peru | 0.40 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Peru | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Total | 0.10 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Total | 0.33 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Peru | 0.65 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-USA | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-USA | 0.28 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Peru | 0.11 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Total | 0.00 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Peru | 0.38 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Total | 0.07 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-USA | 0.67 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-USA | 0.15 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Total | 0.04 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Peru | 0.08 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Total | 0.00 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Peru | 1.20 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Total | 0.07 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Total | 0.10 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-USA | 0.02 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Peru | 0.15 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Peru | 0.14 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Total | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Peru | 0.05 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Peru | 0.02 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Peru | 0.03 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Total | 0.02 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Peru | 0.18 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Total | 0.02 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Peru | 0.00 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Peru | 0.05 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Peru | 0.71 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Total | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Peru | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Peru | 0.07 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Total | 0.68 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Total | 0.14 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-USA | 0.04 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-USA | 0.17 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Total | 0.04 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Total | 0.72 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-USA | 0.53 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-USA | 0.11 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Peru | 0.00 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-USA | 0.11 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Peru | 0.04 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-USA | 0.05 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-USA | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-USA | 0.09 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Peru | 0.19 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Peru | 0.24 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Peru | 0.16 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Total | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-USA | 0.27 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Total | 0.29 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-USA | 0.05 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-USA | 0.04 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-USA | 0.09 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Peru | 0.02 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-USA | 0.00 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-USA | 0.05 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Total | 0.10 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Total | 0.29 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Total | 0.72 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-USA | 0.12 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-USA | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-USA | 0.16 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Total | 0.07 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Peru | 0.47 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-USA | 0.14 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Peru | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Peru | 0.08 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Total | 0.33 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Total | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-USA | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-USA | 0.05 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-USA | 0.09 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-USA | 0.15 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-USA | 0.10 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Total | 0.00 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-USA | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-USA | 0.06 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Peru | 0.15 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-USA | 0.69 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Peru | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Peru | 0.05 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Total | 0.08 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Peru | 0.12 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-USA | 0.06 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Peru | 0.40 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Peru | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-USA | 0.15 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Total | 0.06 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Peru | 0.11 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Total | 0.15 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Peru | 0.20 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Peru | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-USA | 0.28 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Peru | 0.07 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Peru | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Peru | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Total | 0.07 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Total | 0.03 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Peru | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Peru | 0.37 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Total | 0.12 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Peru | 0.10 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Peru | 0.07 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Peru | 0.73 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Peru | 0.16 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Peru | 0.10 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-USA | 0.05 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Peru | 0.00 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-USA | 0.12 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Total | 0.10 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Total | 0.06 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Total | 0.15 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Peru | 0.00 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Total | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Total | 0.26 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Total | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Peru | 0.15 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Peru | 0.64 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Total | 0.06 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-USA | 0.06 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-USA | 0.06 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Total | 0.04 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Peru | 0.08 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Total | 0.06 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Peru | 0.04 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Peru | 0.08 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Total | 0.07 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Peru | 0.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Peru | 0.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Total | 0.15 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Peru | 0.07 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-USA | 0.06 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Peru | 0.81 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Total | 0.81 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-USA | 0.05 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Peru | 0.13 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Peru | 0.08 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Total | 0.07 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-USA | 0.09 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Peru | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Peru | 0.00 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-USA | 0.00 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Total | 0.00 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Total | 0.10 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Total | 0.33 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Peru | 0.11 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-USA | 0.05 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-USA | 0.11 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Peru | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Total | 0.13 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Peru | 0.40 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-USA | 0.28 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Peru | 0.41 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Total | 0.33 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Total | 0.10 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Peru | 0.19 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-USA | 0.28 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-USA | 0.09 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-USA | 0.11 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Peru | 0.04 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Total | 0.04 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Total | 0.14 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Peru | 0.00 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Peru | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Peru | 0.19 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Peru | 0.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Total | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-USA | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-USA | 0.75 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-USA | 0.04 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-USA | 0.58 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-USA | 0.14 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Peru | 0.18 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Total | 0.20 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Total | 0.63 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-USA | 0.22 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Total | 0.00 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Total | 0.04 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-USA | 0.21 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-USA | 0.00 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-USA | 0.33 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Peru | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-USA | 0.09 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Total | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Total | 0.39 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Peru | 0.27 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Total | 0.08 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Peru | 0.10 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Peru | 0.10 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-USA | 0.08 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-USA | 0.05 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-USA | 0.10 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Total | 0.00 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Peru | 0.04 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Total | 1.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Total | 0.04 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Total | 0.13 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Total | 0.06 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Peru | 1.05 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-USA | 0.06 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Total | 0.15 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Peru | 0.68 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Peru | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Peru | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Peru | 0.18 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-USA | 0.04 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Total | 0.02 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Peru | 0.03 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Peru | 0.04 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Total | 0.02 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Peru | 0.05 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-USA | 0.97 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Peru | 0.07 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-USA | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Total | 0.06 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Peru | 0.07 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Peru | 0.15 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-USA | 0.57 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Peru | 0.00 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-USA | 0.14 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Peru | 0.02 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Total | 0.08 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Peru | 0.27 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-USA | 0.06 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Total | 0.63 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Total | 0.22 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-USA | 0.26 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Peru | 0.12 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Total | 0.09 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Peru | 0.51 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-USA | 0.02 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-USA | 0.16 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-USA | 0.07 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Total | 0.32 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Total | 0.00 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Peru | 0.14 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Peru | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Total | 0.18 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Peru | 0.39 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Total | 0.10 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Total | 0.16 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Total | 0.07 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Total | 0.34 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Total | 0.04 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Total | 0.72 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Peru | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Peru | 0.52 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Peru | 0.08 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-USA | 0.06 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Peru | 0.04 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Peru | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Total | 0.12 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Peru | 0.20 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-USA | 0.06 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Peru | 0.00 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-USA | 0.04 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Peru | 0.81 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Peru | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Total | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Peru | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-USA | 0.28 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Total | 0.00 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-USA | 0.06 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-USA | 0.36 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Peru | 0.12 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Total | 0.09 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-USA | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Total | 0.07 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Total | 0.00 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Peru | 0.29 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Peru | 0.02 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Peru | 0.16 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Peru | 0.08 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-USA | 0.26 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-USA | 0.67 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Total | 0.10 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-USA | 0.15 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-USA | 0.08 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-USA | 0.00 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Peru | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-USA | 0.09 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-USA | 0.15 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Total | 0.28 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Peru | 0.09 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Peru | 0.42 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Total | 0.03 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Total | 0.06 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Total | 0.09 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Peru | 0.05 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Total | 0.06 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Peru | 0.10 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-USA | 0.03 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-USA | 0.12 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-USA | 0.05 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Peru | 0.00 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Peru | 0.02 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-USA | 0.09 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Total | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Total | 0.00 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Peru | 0.08 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Peru | 0.04 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Total | 0.50 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Total | 0.15 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Total | 0.14 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Total | 0.07 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Total | 0.04 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Peru | 0.62 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Total | 0.68 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-USA | 0.12 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Peru | 0.02 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Total | 0.06 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-USA | 0.56 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-USA | 0.08 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-USA | 0.06 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Total | 0.68 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-USA | 0.06 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Peru | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Total | 0.11 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Peru | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Total | 0.07 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Peru | 0.18 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Peru | 0.12 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Total | 0.15 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Peru | 0.10 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Total | 0.07 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Total | 0.15 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-USA | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-USA | 0.06 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Total | 0.04 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-USA | 0.15 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Total | 0.00 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Peru | 0.00 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-USA | 0.26 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Peru | 0.02 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Total | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Peru | 0.00 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-USA | 0.05 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Peru | 0.02 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Peru | 0.19 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Peru | 0.04 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Total | 0.09 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Peru | 0.75 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Peru | 0.12 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Total | 0.14 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-USA | 0.10 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-USA | 0.76 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Peru | 0.14 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Total | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Peru | 0.08 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Peru | 0.40 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Total | 0.33 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Total | 0.00 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-USA | 0.15 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-USA | 0.04 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-USA | 0.29 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Peru | 0.05 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Total | 0.33 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Peru | 0.04 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Peru | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-USA | 0.10 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Peru | 0.15 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Peru | 0.07 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-USA | 0.03 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Peru | 0.37 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Total | 0.08 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Peru | 0.16 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Total | 0.15 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Peru | 0.00 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Total | 0.00 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Peru | 0.08 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-USA | 0.06 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Peru | 0.02 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Peru | 0.62 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-USA | 0.11 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-USA | 0.05 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Peru | 0.07 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Total | 0.06 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Peru | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-USA | 0.00 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Peru | 0.40 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Total | 0.35 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-USA | 0.28 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-USA | 0.03 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Peru | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Peru | 0.37 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-USA | 0.25 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Total | 0.28 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-USA | 0.08 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Peru | 0.04 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Total | 0.05 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Peru | 0.10 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Peru | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-USA | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Peru | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Total | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-USA | 0.14 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Peru | 0.11 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Total | 0.15 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-USA | 0.19 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Peru | 0.00 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Total | 0.00 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Total | 0.07 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Total | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Peru | 0.08 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Total | 0.07 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-USA | 0.06 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Total | 0.06 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Peru | 0.02 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Peru | 0.05 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Peru | 0.79 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Total | 0.69 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-USA | 0.63 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-USA | 0.63 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Peru | 0.19 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Total | 0.15 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Peru | 0.14 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Total | 0.11 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-USA | 0.11 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Peru | 0.12 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Total | 0.11 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-USA | 0.10 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Total | 0.00 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Total | 0.63 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-USA | 0.06 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-USA | 0.05 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Peru | 0.03 percentage of cells |
| Group 8 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Total | 0.03 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Total | 0.03 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Total | 0.29 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Total | 0.04 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-USA | 0.12 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Total | 0.07 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Total | 0.71 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Peru | 0.08 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-USA | 0.69 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Total | 0.19 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-USA | 0.19 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Peru | 0.19 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-USA | 0.06 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Total | 0.07 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-USA | 0.16 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Total | 0.00 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Total | 0.00 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Total | 0.15 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Peru | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Total | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Total | 0.04 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-USA | 0.03 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Peru | 0.02 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-USA | 0.09 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-USA | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-USA | 0.06 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Total | 0.00 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Total | 0.06 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-USA | 0.04 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-USA | 0.04 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Peru | 0.04 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-USA | 0.06 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-USA | 0.28 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Peru | 0.15 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Total | 0.04 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Total | 0.34 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Total | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Peru | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Peru | 0.12 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Total | 0.07 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Peru | 0.40 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-USA | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-USA | 0.00 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Peru | 0.07 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-USA | 0.07 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Total | 0.00 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Total | 0.10 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Total | 0.16 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Peru | 0.00 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-USA | 0.29 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Peru | 0.72 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 9 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-USA | 0.05 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-USA | 0.30 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Total | 0.38 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-USA | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Peru | 0.11 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Peru | 0.40 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Peru | 0.00 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Total | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Peru | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Total | 0.11 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-USA | 0.19 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Total | 0.05 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Peru | 0.00 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-USA | 0.10 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-USA | 0.13 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Peru | 0.07 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Peru | 0.03 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-USA | 0.06 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Total | 0.07 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Total | 0.00 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Peru | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Total | 0.52 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Peru | 0.51 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Total | 0.00 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Total | 0.73 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Peru | 0.19 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-USA | 0.05 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Total | 0.13 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Peru | 0.12 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Peru | 0.02 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-USA | 0.05 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Total | 0.04 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Peru | 0.10 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-USA | 0.06 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Peru | 0.04 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Peru | 0.08 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Peru | 0.16 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Peru | 0.02 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Total | 0.16 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Total | 0.07 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-USA | 0.05 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Total | 0.06 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Peru | 0.04 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Peru | 0.77 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Peru | 0.07 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Total | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Peru | 0.10 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Total | 0.09 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-USA | 0.12 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Total | 0.27 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-USA | 0.55 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Peru | 0.15 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Peru | 0.33 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Peru | 0.01 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Total | 0.10 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Total | 0.16 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-USA | 0.04 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-USA | 0.08 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-USA | 0.26 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Total | 0.04 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-USA | 0.10 percentage of cells |
| Group 10 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-USA | 0.68 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Peru | 0.04 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Peru | 0.67 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Peru | 0.00 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-USA | 0.15 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Total | 0.15 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-USA | 0.00 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Y-Peru | 0.17 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-USA | 0.16 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Total | 0.15 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-N-Peru | 0.15 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-USA | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Total | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Total | 0.00 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-USA | 0.63 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Y-Peru | 0.02 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Peru | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Peru | 0.19 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Peru | 0.13 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Total | 0.04 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-Peru | 0.04 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-Total | 0.16 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-USA | 0.09 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Y-Total | 0.10 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-N-USA | 0.11 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-USA | 0.28 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Total | 0.30 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-Y-Peru | 0.41 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Peru | 0.18 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Total | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-Peru | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-Total | 0.13 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-USA | 0.04 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Total B Cells-Y-USA | 0.11 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-USA | 0.28 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Total | 0.36 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ of Total B Cells-N-Peru | 0.40 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-Y-Total | 0.04 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Peru | 0.11 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Y-Peru | 0.00 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-Total | 0.10 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Total | 0.06 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-N-USA | 0.09 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-Peru | 0.08 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-USA | 0.04 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Total B Cells-Y-Peru | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Total | 0.07 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-USA | 0.00 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Total | 0.69 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-Y-Peru | 0.81 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-USA | 0.61 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgG+ of Memory B Cells-N-Total | 0.64 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-N-Total | 0.00 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-Y-USA | 0.06 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-USA | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Total | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-Y-Peru | 0.02 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgM+ of Memory B Cells-N-USA | 0.05 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-USA | 0.01 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-USA | 0.06 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ of Total B Cells-N-Peru | 0.08 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Peru | 0.08 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Total | 0.06 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Total B Cells-N-Peru | 0.02 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-USA | 0.06 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-Y-Total | 0.07 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %S+ IgA+ of Memory B Cells-N-Peru | 0.07 percentage of cells |
| Group 11 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Comorbidity Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-N-Total | 0.01 percentage of cells |
Primary
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort
SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). The sample will be included in the analysis only if the number of IgD- B cells is equal or greater than 1000 for that sample. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and COVID-19 severity among America Cohort (USA and Peru)
Time frame: Measured at Months 0
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.39 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.03 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.09 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-USA | 0.21 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-Total | 0.22 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.03 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-Peru | 0.05 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.03 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.28 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-Total | 0.05 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.1 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.07 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.08 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-USA | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.08 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.33 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.11 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.04 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-Peru | 0.29 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.05 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.04 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.08 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.07 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.17 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.02 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.14 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.63 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.63 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.63 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.14 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.13 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-Total | 0.31 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.05 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.04 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-Peru | 0.08 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.09 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-Total | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.11 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-USA | 0.04 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-USA | 0.26 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.14 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.08 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-Peru | 0.43 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.1 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.08 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.11 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.13 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.15 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.24 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0.03 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-Peru | 0.08 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-Total | 0.08 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-USA | 0.08 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.09 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.07 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.78 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.95 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.98 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.2 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.2 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.17 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.11 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.1 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.1 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.07 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-Peru | 0.43 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-Total | 0.36 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-USA | 0.34 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.07 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.2 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.07 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-Peru | 0.43 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.2 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.07 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.09 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-USA | 0.07 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.1 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-Total | 0.08 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.11 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-Peru | 0.1 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-USA | 0.37 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.04 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-Total | 0.42 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.04 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.04 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.27 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.25 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.23 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 1.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 1.07 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 1.13 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.2 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.03 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.24 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.06 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-USA | 0.3 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.21 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-Total | 0.4 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.08 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 1.07 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.02 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.16 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.02 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-USA | 0.05 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ of Total B Cells-Peru | 0.43 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.23 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.11 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-Total | 0.07 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 1.09 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.1 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ of Total B Cells-Peru | 0.09 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.23 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.1 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.04 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.23 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.04 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and COVID-19 Severity Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 1.08 percentage of cells |
Primary
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort
SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). The sample will be included in the analysis only if the number of IgD- B cells is equal or greater than 1000 for that sample. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group among America Cohort
Time frame: Measured at Months 0
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-Peru | 0.05 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.09 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.15 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-Total | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.11 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-Peru | 0.33 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.13 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-USA | 0.07 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.1 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.09 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.77 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-USA | 0.32 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.52 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.08 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.05 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.05 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.11 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-Total | 0.32 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0.02 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.02 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.48 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.05 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.02 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.14 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.13 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.22 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.13 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.77 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-Peru | 0.43 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.1 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.5 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.34 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.12 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.11 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.18 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.11 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.13 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.07 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0.02 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-Peru | 0.08 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-USA | 0.24 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-Total | 0.07 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-Total | 0.32 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-USA | 0.05 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.08 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.15 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.08 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.08 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.02 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.15 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.13 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.13 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.14 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-Peru | 0.07 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-Total | 0.06 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-USA | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.07 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.06 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.05 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.62 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.62 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.6 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.17 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.08 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.1 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.09 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.09 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.05 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-Peru | 0.4 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-Total | 0.32 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-USA | 0.25 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-Peru | 0.42 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.06 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.29 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.03 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.06 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.06 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.03 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-USA | 0.05 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-Total | 0.07 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-USA | 0.3 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ of Total B Cells-Peru | 0.11 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ of Total B Cells-Total | 0.33 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.13 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.16 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.16 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.11 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.21 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.86 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.2 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.1 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.95 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 1 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Days Since SARS-CoV-2 Diagnosis Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.09 percentage of cells |
Primary
SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort
SARS-CoV-2-specific B cell responses and B cell phenotypic data was identified and characterized using fluorescently-labelled recombinant Env proteins (S6P and RBD) in combination with a flow cytometry antibody panel on all available samples from the enrollment visit (V1). There is no positivity call for B cell phenotypic data. The magnitude is B cell subset frequency. The table summarized SARS-CoV-2-specific Memory B Cell Response Magnitude by flow cytometry at Visit 1, overall and by region and enrollment group among America Cohort (USA and Peru only)
Time frame: Measured at Months 0.
Population: The 'Overall Number of Participants Analyzed' summarized the participants number in American Population (USA and Peru only), regardless the assay availability. The 'Number Analyzed' for each antigen summarized the participants number at each time point with available assay data. The 'Number Analyzed' may be smaller than 'Overall Number of Participants Analyzed' due to assay data unavailable.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.04 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.08 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-USA | 0.21 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Total | 0.05 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.03 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Peru | 0.05 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.03 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.32 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.04 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.4 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.09 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Peru | 0.3 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.08 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.18 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.12 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Total | 0.21 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.06 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.04 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.07 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.1 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.01 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-USA | 0.04 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.02 percentage of cells |
| Group 1A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.33 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.35 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.38 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Peru | 0.17 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.23 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.09 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-USA | 0.24 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.09 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.01 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.03 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Peru | 0.05 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.07 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Total | 0.07 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.07 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-USA | 0.07 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Total | 0.23 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.06 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.05 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.11 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.04 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.05 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.04 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.04 percentage of cells |
| Group 1B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Total | 0.05 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Total | 0.28 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.15 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.12 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.1 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.1 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-USA | 0.05 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.49 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.12 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.13 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.02 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.08 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-USA | 0.26 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.1 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.1 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.05 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.69 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.43 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.05 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.04 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.06 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Peru | 0.06 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.1 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Peru | 0.33 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1C | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.04 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.25 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.24 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.21 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Peru | 0.14 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Total | 0.1 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-USA | 0.07 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.08 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.07 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.06 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.02 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.81 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.93 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.99 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.23 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.22 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.18 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.14 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.13 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.08 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.06 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.05 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.04 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Peru | 0.51 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Total | 0.43 percentage of cells |
| Group 1D | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-USA | 0.34 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.16 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Total | 0.07 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.21 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.19 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.02 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.12 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-USA | 0.42 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Peru | 0.06 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.06 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.04 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.02 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.18 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.04 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.22 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.05 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.14 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.88 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.07 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.11 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Peru | 0.37 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 1.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-USA | 0.09 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.94 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Total | 0.39 percentage of cells |
| Group 2A | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.11 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.28 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 1.25 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.04 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.26 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.07 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.19 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.11 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.18 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-USA | 0.06 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-USA | 0.3 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.09 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Total | 0.07 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.09 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Peru | 0.11 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Total | 0.4 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.09 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.05 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.05 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0.03 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.04 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.25 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.28 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 1.21 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Peru | 0.47 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 1.21 percentage of cells |
| Group 2B | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.04 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Peru | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Peru | 0.1 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Total | 0.16 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Total | 0.1 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-Total | 0.07 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-USA | 0.58 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-Total | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-Peru | 0.18 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-Peru | 0.1 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ of Total B Cells-USA | 0.04 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-USA | 0.25 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-USA | 0.1 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-Peru | 0.02 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-USA | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-USA | 0.08 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Peru | 0.07 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Total | 0.16 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Total B Cells-USA | 0.01 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Peru | 0.43 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Total | 0.04 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Total | 0 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-Peru | 0 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgA+ of Memory B Cells-Total | 0.08 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Total B Cells-Peru | 0.22 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-Peru | 0.04 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Total | 0.7 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ of Memory B Cells-USA | 0.05 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ of Total B Cells-Total | 0.35 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgG+ of Memory B Cells-USA | 0.12 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgG+ of Memory B Cells-Peru | 0.83 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgM+ of Memory B Cells-USA | 0 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %S+ IgM+ IgD+ of Total B Cells-USA | 0.09 percentage of cells |
| Group 3 | SARS-CoV-2-specific Memory B Cell Response Magnitude (B Cell) by Region and Enrollment Group Among America Cohort | %RBD+ IgA+ of Memory B Cells-Total | 0.01 percentage of cells |
Secondary
Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR
This outcome measures the detection rate of viral RNA in nasopharyngeal or nasal swab samples collected at Visits 1, 2, 3, 4 using RT-PCR. Participation was optional, and not all participants provided samples. Results presented in this table include only participants from the Africa cohort (South Africa and other African countries), whose samples were tested using the RT-RNA Fisher TaqPath assay and Americas cohort (Peru and the United States), samples were tested using the RT-RNA Panther assay.
Time frame: Measured at Months 0, Month 2, Month 4, Month 12
Population: Nasopharyngeal or nasal swab samples were collected at enrollment from 155 participants in the Americas cohort (Peru and USA) using the RT-RNA Panther assay, and from 320 participants in the Africa cohort (South Africa and other African countries) using the RT-RNA Fisher TaqPath assay.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 0 Africa | 5 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 0 Africa | 5 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 0 America | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 12 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 4 America | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 0 Africa | 5 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 12 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 4 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 4 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 12 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 12 America | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 4 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 4 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 2 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 2 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 12 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 2 America | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 2 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 2 Africa | 0 Participants |
| Group 1A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 0 Africa | 5 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 12 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 12 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 12 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 0 America | 1 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 0 Africa | 6 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 0 Africa | 6 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 0 Africa | 6 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 2 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 2 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 2 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 2 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 4 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 4 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 4 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 4 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 12 Africa | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 0 Africa | 6 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 4 America | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 2 America | 0 Participants |
| Group 1B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 12 America | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 12 America | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 4 Africa | 1 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 2 Africa | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 4 Africa | 1 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 4 Africa | 1 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 0 Africa | 17 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 12 Africa | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 2 Africa | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 0 Africa | 17 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 12 Africa | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 0 Africa | 17 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 2 Africa | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 2 America | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 0 America | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 2 Africa | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 0 Africa | 17 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 4 Africa | 1 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 4 America | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 12 Africa | 0 Participants |
| Group 1C | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 12 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 2 America | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 0 Africa | 3 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 4 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 4 America | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 4 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 12 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 12 America | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 4 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 0 America | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 2 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 0 Africa | 3 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 0 Africa | 3 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 2 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 12 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 0 Africa | 3 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 12 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 2 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 2 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 4 Africa | 0 Participants |
| Group 1D | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 12 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 0 America | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 0 Africa | 11 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 2 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 2 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 0 Africa | 11 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 2 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 12 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 4 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 4 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 4 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 4 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 12 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 12 America | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 12 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 2 Africa | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 2 America | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 0 Africa | 11 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 0 Africa | 11 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 4 America | 0 Participants |
| Group 2A | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 12 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 12 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 2 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 2 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 12 America | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 12 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 2 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 0 Africa | 3 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 0 America | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 4 America | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 2 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 0 Africa | 3 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 4 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 4 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 12 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 12 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 2 America | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 4 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 0 Africa | 3 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 4 Africa | 0 Participants |
| Group 2B | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 0 Africa | 3 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 4 Africa | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 0 Africa | 5 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 4 Africa | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 0 Africa | 5 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 2 Africa | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 0 America | 1 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 2 Africa | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 12 Africa | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 0 Africa | 5 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 2 Africa | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 2 America | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 12 Africa | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 2 Africa | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 IC at Month 0 Africa | 5 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 S-GENE at Month 12 Africa | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 4 America | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | ORF at Month 12 America | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 ORF1ab at Month 4 Africa | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 12 Africa | 0 Participants |
| Group 3 | Detection of Viral RNA in Nasopharyngeal or Nasal Swab Samples Via RT-PCR | SARS-COV-2 N-GENE at Month 4 Africa | 0 Participants |
Secondary
SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort
BAMA assays was performed for samples from participants at Visit 1 (Month 0, baseline) and available samples at follow-up visits (Month 2, 4). Serum SARS-CoV-2-specific IgA, IgG1, IgG3 responses (dilution 1:50) to SARS-CoV-2 antigens were measured on a Bio-Plex instrument (Bio-Rad). The Bioplex software provides 2 readouts: a background-subtracted mean fluorescence intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate), and a concentration based on a standard curve. Positive responses at each visit will be called if the MFI minus blank values are ≥ isotype, antigen, and dilution-specific cutoff (will be provided by the lab). MFIs minus blank (or net MFI) are used to summarize the magnitude at a given time-point. The table summarized SARS-CoV-2-specific Antibody Binding Response Magnitude by binding antibody multiplex assay (BAMA IgA nasal sample) at Visit 1, 2, 3, overall and by region and enrollment group among America Cohort
Time frame: Measured at Months 0, 2, 5
Population: American Population (USA and Peru only), all available data at each visit
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Total | 2.07 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Peru | 1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-USA | 4.43 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Peru | 1.7 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-USA | 4.66 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Total | 1.19 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-USA | 4.49 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-Total | 4.66 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Peru | 0.09 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Peru | 1.19 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Total | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Total | 0.09 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-USA | 0.23 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Total | 0.19 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Total | 0.36 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Peru | 0.16 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-USA | 0.14 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Peru | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-Total | 2.26 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-USA | 1.16 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-Total | 0.14 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Peru | 0.36 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-USA | 1.66 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Total | 0.77 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Peru | 0.72 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-USA | 2.26 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Peru | 0.16 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-USA | 0.06 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Total | 0.12 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Peru | 0.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-USA | 0.61 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-Total | 0.61 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Total | 0.04 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Peru | 0.04 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Total | 0.46 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-USA | 0.65 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Total | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Total | 0.21 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Peru | 0.16 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-USA | 0.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-Total | 0.6 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Total | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Peru | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Total | 0.16 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-USA | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-USA | 0.41 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-USA | 2.67 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-Total | 0.97 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-Total | 2.67 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Total | 0.07 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Peru | 0.06 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-USA | 0.34 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-Total | 0.34 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Total | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Peru | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-USA | 0.18 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-USA | 0.97 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Peru | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Total | 0.03 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Peru | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-USA | 0.08 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-Total | 0.08 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Total | 0.09 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Peru | 0.09 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Peru | 0.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-USA | 4.96 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-Total | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Total | 0.3 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Peru | 0.19 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-USA | 4.73 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-Total | 4.73 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Total | 0.02 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Peru | 0.02 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-USA | 2.38 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Total | 0.15 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Peru | 0.1 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Total | 0.5 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Total | 0.33 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-USA | 0.23 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-Total | 0.23 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Peru | 0.48 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Peru | 0.33 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Total | 0.03 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Peru | 0.03 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-USA | 0.36 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Total | 0.03 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Peru | 0.03 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-USA | 0.77 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-Total | 0.77 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-USA | 1.64 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-USA | 3.85 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Total | 0.02 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Peru | 0.02 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-USA | 2 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Total | 0.06 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Peru | 0.02 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-USA | 1.58 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-Total | 1.58 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Total | 0.48 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Total | 0.88 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Peru | 0.06 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Total | 0.06 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-USA | 1.51 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Peru | 0.19 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Total | 0.19 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-USA | 1.55 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-Total | 1.55 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-USA | 0.93 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Total | 0.12 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Peru | 0.62 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-USA | 1.04 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Peru | 0.12 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Total | 0.4 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-USA | 0.86 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Peru | 0.18 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-Total | 0.86 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Peru | 0.87 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Total | 0.87 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Peru | 1.36 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Peru | 0.32 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Total | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-Total | 0.93 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-USA | 2.25 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-USA | 1.66 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Total | 0.68 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Peru | 0.67 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-USA | 1.65 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-Total | 1.65 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Total | 0.23 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Peru | 0.23 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Total | 1.63 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Peru | 0.01 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-USA | 1.9 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-Total | 4.49 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Total | 0.24 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-USA | 0.16 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Peru | 0.28 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-Total | 0.85 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-USA | 0.85 MFI |
| Group 1A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Total | 1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-Peru | 1.88 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-Total | 1.36 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-USA | 0.72 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Peru | 0.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-USA | 0.09 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Peru | 0.09 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Total | 0.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Total | 0.09 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-Peru | 0.3 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-Total | 0.3 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-USA | 0.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Peru | 2.75 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Total | 1.72 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Peru | 2.63 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-USA | 0.7 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Total | 2.63 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-USA | 0.77 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Peru | 2.8 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-Peru | 0.7 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-Total | 0.7 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Total | 1.7 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-USA | 0.61 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Total | 2.79 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Peru | 2.79 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-Peru | 0.28 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-Total | 0.28 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-USA | 0.37 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Peru | 0.37 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Total | 0.23 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-USA | 0.09 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Peru | 0.26 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-Peru | 0.05 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-Total | 0.05 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-USA | 0.03 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Peru | 0.11 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Total | 0.26 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-USA | 0.05 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Total | 0.08 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Total | 0.08 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Peru | 0.08 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-Peru | 0.95 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-Total | 0.74 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-USA | 0.53 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Total | 1.34 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-USA | 0.45 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Peru | 2.23 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Peru | 1.46 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Total | 1.46 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-USA | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-Peru | 0.2 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-Total | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Peru | 0.24 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-USA | 0.03 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Total | 0.13 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Peru | 0.21 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Total | 0.21 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-Peru | 0.4 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-Total | 0.53 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-USA | 0.7 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Peru | 1.78 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Total | 1.36 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-USA | 0.93 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Total | 2.11 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Peru | 2.11 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-Peru | 0.36 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-Total | 0.17 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Peru | 1.27 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-USA | 0.08 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Total | 0.7 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Peru | 1.09 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-USA | 0.13 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Total | 1.09 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-Peru | 1.64 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-Total | 0.64 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-USA | 0.35 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Peru | 0.08 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-USA | 0.06 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Total | 0.07 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Peru | 0.06 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-Peru | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-Total | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-USA | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Peru | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Total | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-USA | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Peru | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Total | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-Peru | 0.83 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-Total | 0.03 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-USA | 0.03 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Peru | 0.03 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Total | 0.03 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-USA | 0.03 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Peru | 0.03 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Total | 0.03 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-Peru | 0.81 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-Total | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-USA | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Peru | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Total | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-USA | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Peru | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Total | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-Peru | 1.15 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-Total | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-USA | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Peru | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Total | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-USA | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Peru | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Total | 0.02 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-Peru | 1.47 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-Total | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-USA | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Peru | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Total | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-USA | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Peru | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Total | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-Peru | 1.34 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-Total | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-USA | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Peru | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Total | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-USA | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Peru | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Total | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-Peru | 1.43 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-Total | 0.04 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-USA | 0.04 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Total | 0.06 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Peru | 0.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Total | 0.07 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-USA | 0.04 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Peru | 0.04 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Total | 0.04 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-Peru | 1.08 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-Total | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-USA | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Peru | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Total | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-USA | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Peru | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Total | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-Peru | 3.34 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-USA | 1.28 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-Total | 2.39 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Peru | 0.18 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-USA | 0.17 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Total | 0.18 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Peru | 0.17 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Total | 0.17 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-Peru | 0.1 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-Total | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Peru | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-USA | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-USA | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Total | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Peru | 0.01 MFI |
| Group 1B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-USA | 0.12 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Total | 0.06 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-USA | 0.28 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Peru | 0.25 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Peru | 0.06 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Total | 1.48 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Peru | 0.03 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-USA | 0.69 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-USA | 0.51 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-USA | 0.09 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-Total | 0.07 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-USA | 0.05 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Total | 0.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Peru | 0.17 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Peru | 0.18 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-USA | 0.03 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-USA | 0.37 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-Total | 0.03 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Total | 0.07 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-USA | 0.13 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Total | 0.04 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-USA | 0.09 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-USA | 0.49 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Peru | 0.02 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-USA | 0.25 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Total | 0.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Peru | 0.31 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-Total | 0.06 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-Total | 0.51 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Peru | 0.08 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Peru | 0.11 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-USA | 0.02 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-Total | 0.02 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Total | 0.99 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-USA | 0.25 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Peru | 0.06 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-USA | 0.06 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Peru | 0.24 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-USA | 0.02 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Total | 0.25 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Total | 0.23 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-USA | 1.09 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-USA | 0.19 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-USA | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-USA | 0.12 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Total | 0.05 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-USA | 0.42 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Peru | 0.09 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-USA | 0.11 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Peru | 0.11 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Peru | 0.08 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-USA | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Total | 0.11 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Total | 0.98 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-USA | 0.57 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Total | 0.07 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Peru | 0.04 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-USA | 0.35 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Total | 0.18 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Total | 0.1 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Peru | 0.03 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Total | 0.56 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Peru | 0.16 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Total | 0.07 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Peru | 0.76 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Total | 0.05 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-USA | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-USA | 0.04 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Total | 0.76 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-Total | 0.04 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Peru | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-Total | 0.47 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Peru | 1.08 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-USA | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-USA | 0.54 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Peru | 2.28 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-USA | 0.36 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-USA | 0.47 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Total | 0.09 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Peru | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-USA | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Peru | 1.51 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-USA | 0.58 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Peru | 0.76 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-USA | 0.08 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-Total | 0.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Peru | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Peru | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Total | 0.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-USA | 1.23 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Total | 0.62 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Total | 1.06 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-USA | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-Total | 0.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Total | 0.12 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-USA | 0.04 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-USA | 0.14 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Peru | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-USA | 0.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-Total | 0.69 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-Total | 0.36 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-USA | 0.42 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Peru | 0.13 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Peru | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-USA | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-USA | 0.4 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Peru | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-USA | 0.03 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Total | 0.46 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-USA | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Peru | 0.89 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Peru | 0.52 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-Total | 0.03 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-USA | 0.9 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-Total | 0.12 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Total | 0.12 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-Total | 0.01 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Peru | 0.06 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-USA | 0.31 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-USA | 0.07 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-USA | 0.26 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Total | 0.25 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Peru | 0.24 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-USA | 1.02 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-USA | 0.46 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-USA | 0.02 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-Total | 0.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Peru | 0.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-USA | 0.39 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-Total | 0.02 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-USA | 0.16 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Total | 0.02 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-USA | 0.29 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-USA | 0.76 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Peru | 0.69 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Peru | 0.02 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-USA | 0.19 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Peru | 0.13 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Total | 0.3 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Total | 0.17 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Peru | 0.15 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Total | 0.19 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-USA | 0.02 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-USA | 0.04 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-USA | 0.2 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Total | 0.59 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Total | 0.11 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-USA | 0.04 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-Total | 0.02 MFI |
| Group 1C | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Peru | 0.51 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-USA | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Peru | 0.59 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Peru | 1.63 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Total | 3.35 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Total | 0.77 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-USA | 1.18 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-USA | 0.29 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-USA | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-Total | 0.29 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-USA | 3.37 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Peru | 0.09 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-USA | 0.46 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Total | 0.27 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Total | 0.16 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Peru | 0.14 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-USA | 2.32 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-Total | 1.27 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Peru | 3.32 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-USA | 1.27 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Peru | 2.11 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-Total | 1.88 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Peru | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Total | 1.99 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-USA | 0.32 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-USA | 1.87 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-Total | 2.16 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Peru | 2.24 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Total | 2.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-USA | 1.43 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-USA | 2.16 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-Total | 0.19 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-USA | 0.19 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-USA | 1.88 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Peru | 0.97 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Total | 0.7 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-USA | 1.92 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Peru | 0.25 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Peru | 0.39 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-USA | 0.44 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Total | 0.38 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-USA | 0.42 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-Total | 0.15 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-USA | 0.15 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Peru | 0.09 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-USA | 0.62 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Total | 0.35 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Total | 1.92 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-USA | 2.76 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Peru | 0.66 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-USA | 0.16 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-Total | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Total | 1.53 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-USA | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Peru | 0.1 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Total | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-USA | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-USA | 1.66 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Peru | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Total | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-USA | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Peru | 0.09 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-Total | 0.03 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-USA | 0.03 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Peru | 0.03 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Peru | 1.08 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Total | 0.03 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Peru | 1.84 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-USA | 0.03 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Total | 1.66 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Peru | 0.28 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Total | 0.03 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-USA | 0.03 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-Total | 0.23 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-USA | 0.23 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Peru | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Total | 1.94 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Total | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-USA | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Peru | 1.16 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Peru | 0.12 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Total | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-USA | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-USA | 1.94 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-Total | 0.42 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-USA | 0.89 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-USA | 0.42 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Peru | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-USA | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Total | 0.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-USA | 0.41 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-USA | 0.25 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Peru | 0.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Total | 0.09 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-USA | 0.09 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-Total | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-Total | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-USA | 1.17 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-USA | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-USA | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Peru | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Total | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-USA | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Peru | 0.15 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Total | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-USA | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Total | 0.89 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-Total | 0.22 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-USA | 0.22 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-Total | 1.17 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Peru | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Peru | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Total | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-USA | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Peru | 0.07 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Total | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-USA | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-Total | 0.45 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-USA | 0.45 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Total | 0.75 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Peru | 0.04 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Total | 0.46 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Total | 0.24 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Total | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-USA | 1.4 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Peru | 0.26 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Total | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Total | 0.41 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-USA | 0.41 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-Total | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-USA | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Peru | 0.62 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Peru | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Total | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-USA | 0.66 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Peru | 0.48 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-USA | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Total | 2.04 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-USA | 1.86 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-USA | 2.34 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-Total | 0.66 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-USA | 0.51 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Peru | 0.47 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-Total | 0.06 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-USA | 0.06 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Peru | 0.14 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Total | 1.86 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Total | 0.5 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Peru | 1.3 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Peru | 0.35 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-USA | 0.27 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Total | 0.22 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Total | 0.16 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-USA | 0.16 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Peru | 0.18 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-Total | 0.41 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-Total | 1.55 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-USA | 1.55 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Total | 0.01 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Total | 3.02 MFI |
| Group 1D | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-USA | 3.96 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-USA | 0.56 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Total | 0.15 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-Total | 0.09 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Peru | 0.24 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Peru | 0.72 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-USA | 0.33 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-USA | 0.09 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-USA | 0.38 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-USA | 0.12 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-USA | 0.15 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Peru | 0.34 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-Total | 2.12 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-USA | 1.05 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Total | 0.32 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-USA | 0.44 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Peru | 0.41 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Peru | 0.31 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Peru | 2.16 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Peru | 0.72 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-USA | 0.42 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-USA | 0.95 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-Total | 0.03 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Total | 1.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-USA | 1.13 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Total | 0.01 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Peru | 0.57 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Total | 0.41 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-USA | 0.42 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-USA | 0.18 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-Total | 1.05 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Total | 0.42 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Peru | 1.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Total | 1.42 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Peru | 0.59 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Peru | 0.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Total | 0.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Total | 0.08 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Total | 0.29 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-Total | 0.02 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-USA | 0.07 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-Total | 0.18 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-Total | 0.44 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-USA | 0.02 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Peru | 1.08 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Total | 0.99 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-USA | 0.32 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Peru | 0.27 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-Total | 0.29 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Total | 0.4 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-USA | 0.28 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Peru | 0.19 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-Total | 0.06 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Total | 0.56 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-USA | 0.96 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-USA | 0.29 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-USA | 0.12 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-USA | 0.57 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Peru | 0.02 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Total | 0.72 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Total | 0.01 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Total | 0.02 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Total | 2.84 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Peru | 0.62 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Total | 0.45 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Peru | 3.18 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-Total | 0.03 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Peru | 0.58 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-USA | 0.01 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-USA | 0.03 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Total | 0.54 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Total | 0.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Peru | 0.24 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Total | 0.53 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Peru | 0.29 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Total | 0.19 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-USA | 0.39 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-USA | 0.09 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-USA | 0.31 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-USA | 1.8 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Peru | 1.73 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Peru | 0.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-USA | 0.33 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-Total | 0.07 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-USA | 0.15 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Total | 0.2 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Total | 1.73 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Peru | 0.1 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Peru | 0.15 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Peru | 0.01 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Total | 0.11 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Total | 1.08 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-Total | 0.27 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Peru | 0.45 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Total | 2.05 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-USA | 0.27 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Total | 0.25 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Peru | 0.7 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Total | 0.15 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Peru | 2.22 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Total | 0.26 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Total | 0.67 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Peru | 0.08 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Peru | 0.01 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-USA | 0.13 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-Total | 0.84 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Peru | 0.25 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-USA | 0.52 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-USA | 0.06 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-Total | 2.86 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-Total | 0.39 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Total | 0.25 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-Total | 0.56 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Peru | 1.55 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-Total | 0.94 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-Total | 0.01 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Total | 0.67 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-Total | 1.13 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-USA | 2.12 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-USA | 0.94 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-USA | 2.86 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Total | 0.64 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Peru | 0.11 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Peru | 3.22 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Peru | 2.11 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-USA | 0.03 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Peru | 0.01 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Total | 0.45 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Total | 0.62 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Peru | 1.27 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Total | 0.24 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-USA | 0.22 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-USA | 0.84 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-Total | 0.52 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Total | 0.51 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Peru | 0.89 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-USA | 0.16 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Total | 0.89 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Peru | 0.45 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Total | 0.01 MFI |
| Group 2A | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Peru | 1.98 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Total | 2.72 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Peru | 1.17 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Peru | 1.49 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Peru | 0.65 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-USA | 0.08 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Total | 3.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-USA | 2.92 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Peru | 0.65 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-USA | 0.45 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-USA | 0.33 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Peru | 1.19 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Peru | 5.91 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Peru | 10.13 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Total | 0.62 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Peru | 7.58 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-USA | 1.16 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-USA | 1.38 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Total | 1.42 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Total | 4.2 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Total | 0.53 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Total | 0.51 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-USA | 2.12 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-Total | 0.23 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-USA | 0.22 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-Total | 0.18 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-USA | 1.14 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-Total | 0.33 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-USA | 0.75 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Total | 1.17 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-USA | 0.75 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-Total | 0.53 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-USA | 0.18 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-USA | 0.39 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-USA | 0.26 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-Total | 1.18 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-USA | 0.1 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-Total | 0.54 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-USA | 1.86 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-USA | 0.29 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Peru | 7 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Peru | 3.44 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Peru | 1.7 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-USA | 0.11 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Total | 1.22 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-USA | 0.35 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-Total | 0.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Peru | 0.13 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Peru | 6.99 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-USA | 2.05 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Peru | 0.76 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-USA | 0.81 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-Total | 0.55 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Peru | 1.48 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Total | 4.8 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Total | 1.28 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-USA | 0.84 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Total | 1.71 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-USA | 0.51 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Peru | 7.26 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-USA | 1.09 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-Total | 0.81 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-USA | 0.54 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Total | 0.69 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Total | 1.46 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Total | 0.31 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-USA | 0.38 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Total | 1.3 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-USA | 0.23 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Total | 0.64 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Total | 0.75 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-USA | 0.26 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-USA | 0.27 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Peru | 8.95 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-Total | 0.91 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Peru | 1.53 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Peru | 9.18 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Peru | 1.57 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-USA | 3.35 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Total | 0.17 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Total | 6.59 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Total | 0.99 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Peru | 1.64 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Peru | 7.46 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-Total | 1.91 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-USA | 0.92 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-Total | 0.34 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Total | 2.24 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-USA | 0.55 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Peru | 0.55 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Peru | 3.65 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-Total | 0.46 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Total | 1.64 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-USA | 0.67 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-Total | 0.74 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-Total | 1.47 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-USA | 1.57 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Total | 1.04 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Total | 0.11 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-USA | 0.22 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Peru | 5.04 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-Total | 0.38 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-USA | 1.04 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-USA | 1.91 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-Total | 0.3 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-USA | 0.91 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-Total | 0.22 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-USA | 0.74 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-USA | 0.34 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Total | 1.71 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Peru | 0.99 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-USA | 0.3 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-USA | 2.47 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Peru | 6.17 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Peru | 2.67 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-USA | 0.33 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Total | 0.47 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-USA | 0.79 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Peru | 0.7 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Peru | 4.17 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-USA | 0.82 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Total | 7.53 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-Total | 0.08 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Peru | 0.75 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Total | 0.98 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Total | 0.7 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-USA | 3.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-USA | 0.4 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Total | 0.6 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-USA | 0.53 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-USA | 0.46 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-USA | 1.15 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-USA | 1.18 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Total | 0.42 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Peru | 0.51 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-USA | 0.31 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Peru | 13.71 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-USA | 1.26 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Peru | 3.57 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Peru | 0.02 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-USA | 0.08 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Total | 0.5 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-USA | 3.87 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-USA | 1.18 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Peru | 0.17 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Peru | 2.29 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Total | 0.57 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Total | 0.99 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Total | 0.52 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Total | 3.66 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-USA | 2.35 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-USA | 0.23 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Peru | 4.34 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Peru | 3.08 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-USA | 1.47 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Peru | 2.7 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Total | 0.75 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Total | 0.19 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-Total | 0.08 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-USA | 1.42 MFI |
| Group 2B | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Total | 0.26 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-USA | 0.33 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-USA | 1.33 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Peru | 0.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-USA | 0.16 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-Total | 0.13 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Total | 0.19 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-USA | 0.14 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 4-USA | 0.08 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Peru | 5.76 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-USA | 0.59 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-USA | 0.08 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-Total | 0.44 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-USA | 0.88 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-USA | 1.75 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 0-USA | 0.44 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Peru | 0.24 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 2-Peru | 0.25 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Peru | 0.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-Total | 0.38 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-USA | 0.72 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 2-USA | 0.15 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-Total | 0.21 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-Total | 1.28 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-Total | 0.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-USA | 1.34 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Peru | 2.89 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 0-USA | 0.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-Total | 0.46 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-Total | 0.17 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S Hexapro-293F-PPF at Month 4-USA | 0.06 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-Total | 0.74 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 0-USA | 0.21 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 0-USA | 0.74 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 4-USA | 0.81 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-USA | 2.28 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Peru | 1.01 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Total | 0.74 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-USA | 0.01 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Peru | 2.09 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-Total | 0.75 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 2-USA | 0.68 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-USA | 0.44 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Total | 1.57 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Peru | 4.35 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-Total | 0.74 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.1.7-AB at Month 4-USA | 0.3 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Peru | 0.07 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-Total | 0.14 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-Total | 0.01 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-USA | 1.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Total | 3.53 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 0-USA | 0.14 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-USA | 1.09 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Peru | 0.12 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 4-Peru | 1.49 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-Total | 0.13 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 0-Total | 0.44 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 2-USA | 0.14 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 0-USA | 0.01 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Total | 2.99 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Peru | 0.18 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Total | 0.51 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-Total | 0.09 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.351-AB at Month 4-USA | 0.05 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Peru | 0.01 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 0-Total | 0.88 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-Total | 0.32 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Total | 0.95 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-USA | 2.05 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 0-USA | 0.32 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 2-Peru | 0.31 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Peru | 1.3 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-Total | 0.2 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-USA | 1.11 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 2-USA | 0.21 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-Total | 0.24 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-USA | 0.52 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 2-USA | 0.18 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 4-Peru | 4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Peru | 0.15 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Peru | 2.91 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Total | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Peru | 0.01 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | NL63-RBD at Month 0-Total | 1.11 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-Total | 0.24 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-B.1.617-AB at Month 4-USA | 0.12 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Total | 0.27 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-Total | 0.53 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-USA | 0.27 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 0-USA | 0.53 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-USA | 0.01 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 0-Total | 1.75 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 4-Peru | 1.28 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Peru | 0.17 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-USA | 4.51 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 4-Peru | 0.7 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-Peru | 4.38 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-Total | 0.37 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 2-USA | 0.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-Total | 0.15 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-Peru | 1.78 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Peru | 0.67 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-USA | 0.27 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Peru | 0.19 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-Total | 1.27 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Total | 0.27 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-USA | 0.28 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S-P.1-AB at Month 4-Total | 0.27 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Total | 0.22 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-Total | 0.32 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-NL63 S1S2 ECD His at Month 4-USA | 0.19 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 2-Total | 0.01 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 0-USA | 0.32 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 2-USA | 1.87 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 S1 C His at Month 2-Peru | 0.35 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 2-Peru | 0.51 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 2019-nCoV S/293F at Month 2-USA | 1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 2-Peru | 2.61 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-USA | 0.87 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 0-Total | 0.87 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Peru | 1.17 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Total | 0.85 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-USA | 0.62 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Total | 0.55 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Peru | 0.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 4-USA | 2.24 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-Total | 0.44 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Peru | 1.97 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 2-USA | 0.26 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-Total | 1.69 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-Total | 1.27 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 4-USA | 0.46 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 DB His at Month 0-Total | 0.62 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-Total | 0.08 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 4-Peru | 0.55 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 2-USA | 1.72 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 0-USA | 0.08 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Peru | 0.06 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Peru | 2.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HKU1-RBD at Month 0-USA | 0.17 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-Total | 0.44 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-Total | 1.6 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 0-Total | 1.09 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-OC43 S1S2 ECD His at Month 0-Total | 2.05 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 2-USA | 0.51 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Peru | 0.1 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-USA | 0.15 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Total | 0.38 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-229E S1S2 ECD His at Month 4-Peru | 0.85 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-Total | 0.27 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 Nucleoprotein His at Month 4-USA | 0.4 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 spike (PreS Nexelis) at Month 2-USA | 1.54 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | 229E-RBD at Month 2-Total | 0.31 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-Total | 0.3 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2-NTD-AVI Biotin at Month 4-Total | 0.01 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | OC43-RBD at Month 4-Peru | 0.44 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | HCoV-HKU1 N5 S1S2 ECD His at Month 4-Total | 1.95 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 0-USA | 0.3 MFI |
| Group 3 | SARS-CoV-2-specific Antibody Binding Response Magnitude (IgA Nasal Sample) by Region and Enrollment Group Among America Cohort | SARS-CoV-2 RBD-B.1.427/429-AB at Month 2-Peru | 0.18 MFI |